Cutis is a peer-reviewed clinical journal for the dermatologist, allergist, and general practitioner published monthly since 1965. Concise clinical articles present the practical side of dermatology, helping physicians to improve patient care. Cutis is referenced in Index Medicus/MEDLINE and is written and edited by industry leaders.

Top Sections
Coding
Dermpath Diagnosis
For Residents
Photo Challenge
Tips
ct
Main menu
CUTIS Main Menu
Explore menu
CUTIS Explore Menu
Proclivity ID
18823001
Unpublish
Negative Keywords
ammunition
ass lick
assault rifle
balls
ballsac
black jack
bleach
Boko Haram
bondage
causas
cheap
child abuse
cocaine
compulsive behaviors
cost of miracles
cunt
Daech
display network stats
drug paraphernalia
explosion
fart
fda and death
fda AND warn
fda AND warning
fda AND warns
feom
fuck
gambling
gfc
gun
human trafficking
humira AND expensive
illegal
ISIL
ISIS
Islamic caliphate
Islamic state
madvocate
masturbation
mixed martial arts
MMA
molestation
national rifle association
NRA
nsfw
nuccitelli
pedophile
pedophilia
poker
porn
porn
pornography
psychedelic drug
recreational drug
sex slave rings
shit
slot machine
snort
substance abuse
terrorism
terrorist
texarkana
Texas hold 'em
UFC
Negative Keywords Excluded Elements
div[contains(@class, 'alert ad-blocker')]
section[contains(@class, 'nav-hidden')]
section[contains(@class, 'nav-hidden active')
Altmetric
DSM Affiliated
Display in offset block
Disqus Exclude
Best Practices
CE/CME
Education Center
Medical Education Library
Enable Disqus
Display Author and Disclosure Link
Publication Type
Clinical
Slot System
Featured Buckets
Disable Sticky Ads
Disable Ad Block Mitigation
Featured Buckets Admin
Show Ads on this Publication's Homepage
Consolidated Pub
Show Article Page Numbers on TOC
Expire Announcement Bar
Wed, 01/29/2025 - 13:41
Use larger logo size
Off
publication_blueconic_enabled
Off
Show More Destinations Menu
Disable Adhesion on Publication
Off
Restore Menu Label on Mobile Navigation
Disable Facebook Pixel from Publication
Exclude this publication from publication selection on articles and quiz
Challenge Center
Disable Inline Native ads
survey writer start date
Wed, 01/29/2025 - 13:41
Current Issue
Title
Cutis
Description

A peer-reviewed, indexed journal for dermatologists with original research, image quizzes, cases and reviews, and columns.

Current Issue Reference

Navigating the Evolving Landscape of the Dermatologic Workforce

Article Type
Changed
Wed, 01/05/2022 - 15:23
Display Headline
Navigating the Evolving Landscape of the Dermatologic Workforce

As of 2018, the mean dermatologist to population ratio in the United States was 1.10 per 100,000 people, highlighting a shortage of dermatologists that is only predicted to increase in coming years.1-4 This undersupply is fueled by both an increasing burden of dermatologic disease and population growth.4 Without readily available access to dermatologic care, many patients are left waiting for weeks to see a dermatologist, depending on geographic region.5-7 It is not simply patients who perceive wait times to be prolonged; approximately half of dermatologists surveyed by the American Academy of Dermatology (AAD) reported an undersupply of dermatologists in their communities, a finding that strongly correlated with patient wait times.2 Ensuring the dermatologic workforce is sufficient to fulfill patient needs requires innovation of current practice models. To address this unmet demand, many practices have begun incorporating physician extenders, a term that encompasses physicians not board certified in dermatology, physician assistants, and nurse practitioners.7 The evolving landscape of the dermatologic workforce raises questions about future practice models and patient outcomes.

Scope of Practice for Physician Extenders

In practice, the role of physician extenders is highly variable. Legislation involving the scope of practice for physician extenders constantly is changing and varies by state. As of November 2021, 24 states and the District of Columbia permit nurse practitioners “full practice” authority to triage patients, interpret diagnostic tests, and prescribe treatments without physician oversight, including controlled substances.8,9 Even in states with “reduced practice” and “restricted practice” paradigms, which necessitate physician oversight, there remains ambiguity. Across the country, state regulatory bodies differ in statues governing licensing requirements, accessibility of the supervising physician, and ultimately culpability in the case of patient harm. Lack of consensus guidelines that clearly define roles and responsibilities has kindled controversy regarding extent of autonomy and liability for adverse outcomes.10,11

With respect to procedures, the AAD has explicitly recommended that “only active and properly licensed doctors of medicine and osteopathy shall engage in the practice of medicine” but that “under appropriate circumstances, a physician may delegate certain procedures and services to appropriately trained nonphysician office personnel.”12 This statement does not refer to or explicitly list the procedures that are appropriate for delegation to nonphysician personnel, and there is wide variability in how this recommendation is applied in daily practice. As it was originally intended, the AAD’s “Ethics in Medical Practice” position statement indicated that dermatologists must directly oversee physician extenders, a responsibility that is defined as being “present on-site, immediately available and able to respond promptly” to issues arising during the provision of health care services.12

Adverse Events From Cosmetic Procedures

The American Society for Dermatologic Surgery has documented a steady growth in the demand for cosmetic, medical, and surgical services,13 a trend that has heralded an increase in the number of procedures performed by physician extenders.14,15 One study contrasted the risk for adverse events following minimally invasive cosmetic procedures performed by physicians or nonphysicians. Of 2116 patients surveyed, 50 adverse events were documented.14 The cohort treated by nonphysicians experienced a higher incidence of laser burns and dyspigmentation, and the use of improper technique was the most frequently implicated cause of developing an adverse event. Approximately 24.6% of American Society for Dermatologic Surgery members reported treating 10 or more complications of cosmetic procedures performed by nonphysicians.14 Beyond laser burns and dyspigmentation, this wide range of complications included inappropriately placed filler product, facial drooping, and scarring. These studies highlight the need for further investigation into the outcomes of procedures performed by physician extenders.

Training of Physician Extenders

Even with medical management, emphasis on proper training of personnel is key and remains a legitimate concern. The training of physician extenders in dermatology differs greatly by location; while some physician extenders operate under meticulous guidance and thus can expand their skill set, other physician extenders shadow dermatologists for an arbitrary amount of time before being thrust into practice.10 It would be a disservice to both patients and nonphysician providers alike to conflate the latter regimen with the 4 years of medical school, 1 year of internship, and 3 years of rigorous specialized dermatologic training that physicians undergo.

This stark discrepancy between the training of physicians and physician extenders raises difficult questions about the patient’s right to make an informed decision regarding how they receive health care. Indeed, the casually regulated autonomous practice of some nonphysician providers has ignited public shock and ire.11

Reducing Health Care Expenditures

As legislatures deliberate over expanding scope of practice, policies should be based on evidence that prioritizes patient safety. In the appropriate setting, physician extenders can be instrumental to mitigating health care disparities; the use of physician extenders can diminish wait times for patients with routine visits for stable dermatologic disease.16 Moreover, reducing health care expenditures often is cited as a major benefit of increased utilization of physician extenders.14 It stands to reason that compensation of nonphysician providers is less expensive for a practice compared with physicians. Physician extenders participating in the management of stable chronic conditions or mild acute conditions may be cost-efficient in these circumstances; however, evidence suggests that physician extenders may incur greater costs than physicians with respect to the utilization of diagnostic tests or prescribing medications. For example, several studies have documented a substantial difference in the number of biopsies needed per malignant neoplasm by physicians compared to physician extenders.17-19 Particularly in patients younger than 65 years and in patients without history of skin cancer, physician extenders had to perform a greater number of biopsies to diagnose malignant neoplasms vs physicians.18 In addition to increased utilization of diagnostic tests, nonphysician providers more frequently prescribe medications of varying classes.20-22 Whether in outpatient offices, emergency departments, or hospital clinics, physician extenders more frequently prescribe antibiotics, which has concerning implications for antibiotic stewardship.20,21 In states with independent prescription authority, physician extenders are more than 20 times more likely to overprescribeopioids compared to physician extenders in states requiring physician supervision.23 These findings warrant additional investigation into how prescription patterns vary by provider type and how these differences impact patient outcomes.

Final Thoughts

Improving patient care is inherently a team endeavor, and the contributions of all members of the health care team are critical to success. Engaging physician extenders may help mitigate disparities in dermatologic care, with respect to surveillance of stable chronic conditions or the diagnosis of mild acute diseases. However, the exact scope of practice of physician extenders remains ambiguous, and their training regimens can vary drastically. Therefore, in the interest of patient safety, new patients or medically complex patients (ie, cutaneous lymphomas, nonstable autoimmune connective tissue disease) should be examined and managed by physicians. In either scenario, the patient should be informed of which providers are available and should be integrated into the decision-making process for their care. Through mutual respect, close collaboration, and candid assessments of patient complexity, different parties within the medical team can unite behind the mission to improve patient outcomes and champion equitable access to health care.

References
  1. Vaidya T, Zubritsky L, Alikhan A, et al. Socioeconomic and geographic barriers to dermatology care in urban and rural US populations. J Am Acad Dermatol. 2018;78:406-408.
  2. Resneck J Jr, Kimball AB. The dermatology workforce shortage. J Am Acad Dermatol. 2004;50:50-54.
  3. American Medical Association. Physician Characteristics and Distribution in the US. American Medical Association; 2002.
  4. Kimball AB, Resneck JS Jr. The US dermatology workforce: a specialty remains in shortage. J Am Acad Dermatol. 2008;59:741-755.
  5. Tsang MW, Resneck JS Jr. Even patients with changing moles face long dermatology appointment wait-times: a study of simulated patient calls to dermatologists. J Am Acad Dermatol. 2006;55:54-58.
  6. Suneja T, Smith ED, Chen GJ, et al. Waiting times to see a dermatologist are perceived as too long by dermatologists: implications for the dermatology workforce. Arch Dermatol. 2001;137:1303-1307.
  7. Zurfley F Jr, Mostow EN. Association between the use of a physician extender and dermatology appointment wait times in Ohio. JAMA Dermatol. 2017;153:1323-1324.
  8. Bean M. NP practice authority by state. Becker’s Hospital Review website. Published April 8, 2021. Accessed December 4, 2021. https://www.beckershospitalreview.com/nursing/np-practice-authority-by-state.html
  9. States with full practice authority for nurse practitioners. Maryville University website. Accessed December 15, 2021. https://online.maryville.edu/nursing-degrees/np/resources/states-granting-np-full-practice-authority/
  10. Slade K, Lazenby M, Grant-Kels JM. Ethics of utilizing nurse practitioners and physician’s assistants in the dermatology setting. Clin Dermatol. 2012;30:516-521
  11. Hafner K, Palmer G. Skin cancers rise, along with questionable treatments. New York Times. November 20, 2017. Accessed December 4, 2021. https://www.nytimes.com/2017/11/20/health/dermatology-skin-cancer.html
  12. American Academy of Dermatology. Policy #P-61.500. the use of non-physician office personnel. Published February 22, 2002. Updated July 31, 2004. http://www.aad.org/Forms/Policies/Uploads/AR/COE%20-%20Ethics%20in%20Medical%20Practice%20Booklet.pdf
  13. 2016 ASDS Survey on Dermatologic Procedures. American Society for Dermatologic Surgery website. Published May 30, 2017. Accessed December 15, 2021. https://www.asds.net/skin-experts/news-room/press-releases/asds-survey-nearly-105-million-treatments-performed-in-2016
  14. Rossi AM, Wilson B, Hibler BP, et al. Nonphysician practice of cosmetic dermatology: a patient and physician perspective of outcomes and adverse events. Dermatol Surg. 2019;45:588-597. 
  15. Anderson AM, Matsumoto M, Saul MI, et al. Accuracy of skin cancer diagnosis by physician assistants compared with dermatologists in a large health care system. JAMA Dermatol. 2018;154:569-573.
  16. O’Brien JC, Chong BF. Reducing outpatient dermatology clinic wait times in a safety net health system in Dallas, Texas. J Am Acad Dermatol. 2016;75:631-632.
  17. Aldredge LM, Young MS. Providing guidance for patients with moderate-to-severe psoriasis who are candidates for biologic therapy: role of the nurse practitioner and physician assistant. J Dermatol Nurses Assoc. 2016;8:14-26.
  18. Roblin DW, Howard DH, Becker ER, et al. Use of midlevel practitioners to achieve labor cost savings in the primary care practice of an MCO. Health Serv Res. 2004;39:607-626.
  19. Nault A, Zhang C, Kim K, et al. Biopsy use in skin cancer diagnosis: comparing dermatology physicians and advanced practice professionals. JAMA Dermatol. 2015;151:899-902.
  20. Privalle A, Havighurst T, Kim K, et al. Number of skin biopsies needed per malignancy: comparing the use of skin biopsies among dermatologists and nondermatologist clinicians [published online August 10, 2019]. J Am Acad Dermatol. 2020;82:110-116.
  21. Roumie CL, Halasa NB, Edwards KM, et al. Differences in antibiotic prescribing among physicians, residents, and nonphysician clinicians. Am J Med. 2005;118:641-648.
  22. Sanchez GV, Hersh AL, Shapiro DJ, et al. Outpatient antibiotic prescribing among United States nurse practitioners and physician assistants [published online August 10, 2016]. Open Forum Infect Dis. 2016;3:ofw168.
  23. Lozada MJ, Raji MA, Goodwin JS, et al. Opioid prescribing by primary care providers: a cross-sectional analysis of nurse practitioner, physician assistant, and physician prescribing patterns [published online April 24, 2020]. J Gen Intern Med. 2020;35:2584-2592.
Article PDF
Author and Disclosure Information

From the Department of Dermatology, University of Miami/Jackson Memorial Hospital, Florida.

The author reports no conflict of interest.

Correspondence: Soraya Azzawi, MD (swazzawi@gmail.com).

Issue
Cutis - 108(6)
Publications
Topics
Page Number
E17-E19
Sections
Author and Disclosure Information

From the Department of Dermatology, University of Miami/Jackson Memorial Hospital, Florida.

The author reports no conflict of interest.

Correspondence: Soraya Azzawi, MD (swazzawi@gmail.com).

Author and Disclosure Information

From the Department of Dermatology, University of Miami/Jackson Memorial Hospital, Florida.

The author reports no conflict of interest.

Correspondence: Soraya Azzawi, MD (swazzawi@gmail.com).

Article PDF
Article PDF

As of 2018, the mean dermatologist to population ratio in the United States was 1.10 per 100,000 people, highlighting a shortage of dermatologists that is only predicted to increase in coming years.1-4 This undersupply is fueled by both an increasing burden of dermatologic disease and population growth.4 Without readily available access to dermatologic care, many patients are left waiting for weeks to see a dermatologist, depending on geographic region.5-7 It is not simply patients who perceive wait times to be prolonged; approximately half of dermatologists surveyed by the American Academy of Dermatology (AAD) reported an undersupply of dermatologists in their communities, a finding that strongly correlated with patient wait times.2 Ensuring the dermatologic workforce is sufficient to fulfill patient needs requires innovation of current practice models. To address this unmet demand, many practices have begun incorporating physician extenders, a term that encompasses physicians not board certified in dermatology, physician assistants, and nurse practitioners.7 The evolving landscape of the dermatologic workforce raises questions about future practice models and patient outcomes.

Scope of Practice for Physician Extenders

In practice, the role of physician extenders is highly variable. Legislation involving the scope of practice for physician extenders constantly is changing and varies by state. As of November 2021, 24 states and the District of Columbia permit nurse practitioners “full practice” authority to triage patients, interpret diagnostic tests, and prescribe treatments without physician oversight, including controlled substances.8,9 Even in states with “reduced practice” and “restricted practice” paradigms, which necessitate physician oversight, there remains ambiguity. Across the country, state regulatory bodies differ in statues governing licensing requirements, accessibility of the supervising physician, and ultimately culpability in the case of patient harm. Lack of consensus guidelines that clearly define roles and responsibilities has kindled controversy regarding extent of autonomy and liability for adverse outcomes.10,11

With respect to procedures, the AAD has explicitly recommended that “only active and properly licensed doctors of medicine and osteopathy shall engage in the practice of medicine” but that “under appropriate circumstances, a physician may delegate certain procedures and services to appropriately trained nonphysician office personnel.”12 This statement does not refer to or explicitly list the procedures that are appropriate for delegation to nonphysician personnel, and there is wide variability in how this recommendation is applied in daily practice. As it was originally intended, the AAD’s “Ethics in Medical Practice” position statement indicated that dermatologists must directly oversee physician extenders, a responsibility that is defined as being “present on-site, immediately available and able to respond promptly” to issues arising during the provision of health care services.12

Adverse Events From Cosmetic Procedures

The American Society for Dermatologic Surgery has documented a steady growth in the demand for cosmetic, medical, and surgical services,13 a trend that has heralded an increase in the number of procedures performed by physician extenders.14,15 One study contrasted the risk for adverse events following minimally invasive cosmetic procedures performed by physicians or nonphysicians. Of 2116 patients surveyed, 50 adverse events were documented.14 The cohort treated by nonphysicians experienced a higher incidence of laser burns and dyspigmentation, and the use of improper technique was the most frequently implicated cause of developing an adverse event. Approximately 24.6% of American Society for Dermatologic Surgery members reported treating 10 or more complications of cosmetic procedures performed by nonphysicians.14 Beyond laser burns and dyspigmentation, this wide range of complications included inappropriately placed filler product, facial drooping, and scarring. These studies highlight the need for further investigation into the outcomes of procedures performed by physician extenders.

Training of Physician Extenders

Even with medical management, emphasis on proper training of personnel is key and remains a legitimate concern. The training of physician extenders in dermatology differs greatly by location; while some physician extenders operate under meticulous guidance and thus can expand their skill set, other physician extenders shadow dermatologists for an arbitrary amount of time before being thrust into practice.10 It would be a disservice to both patients and nonphysician providers alike to conflate the latter regimen with the 4 years of medical school, 1 year of internship, and 3 years of rigorous specialized dermatologic training that physicians undergo.

This stark discrepancy between the training of physicians and physician extenders raises difficult questions about the patient’s right to make an informed decision regarding how they receive health care. Indeed, the casually regulated autonomous practice of some nonphysician providers has ignited public shock and ire.11

Reducing Health Care Expenditures

As legislatures deliberate over expanding scope of practice, policies should be based on evidence that prioritizes patient safety. In the appropriate setting, physician extenders can be instrumental to mitigating health care disparities; the use of physician extenders can diminish wait times for patients with routine visits for stable dermatologic disease.16 Moreover, reducing health care expenditures often is cited as a major benefit of increased utilization of physician extenders.14 It stands to reason that compensation of nonphysician providers is less expensive for a practice compared with physicians. Physician extenders participating in the management of stable chronic conditions or mild acute conditions may be cost-efficient in these circumstances; however, evidence suggests that physician extenders may incur greater costs than physicians with respect to the utilization of diagnostic tests or prescribing medications. For example, several studies have documented a substantial difference in the number of biopsies needed per malignant neoplasm by physicians compared to physician extenders.17-19 Particularly in patients younger than 65 years and in patients without history of skin cancer, physician extenders had to perform a greater number of biopsies to diagnose malignant neoplasms vs physicians.18 In addition to increased utilization of diagnostic tests, nonphysician providers more frequently prescribe medications of varying classes.20-22 Whether in outpatient offices, emergency departments, or hospital clinics, physician extenders more frequently prescribe antibiotics, which has concerning implications for antibiotic stewardship.20,21 In states with independent prescription authority, physician extenders are more than 20 times more likely to overprescribeopioids compared to physician extenders in states requiring physician supervision.23 These findings warrant additional investigation into how prescription patterns vary by provider type and how these differences impact patient outcomes.

Final Thoughts

Improving patient care is inherently a team endeavor, and the contributions of all members of the health care team are critical to success. Engaging physician extenders may help mitigate disparities in dermatologic care, with respect to surveillance of stable chronic conditions or the diagnosis of mild acute diseases. However, the exact scope of practice of physician extenders remains ambiguous, and their training regimens can vary drastically. Therefore, in the interest of patient safety, new patients or medically complex patients (ie, cutaneous lymphomas, nonstable autoimmune connective tissue disease) should be examined and managed by physicians. In either scenario, the patient should be informed of which providers are available and should be integrated into the decision-making process for their care. Through mutual respect, close collaboration, and candid assessments of patient complexity, different parties within the medical team can unite behind the mission to improve patient outcomes and champion equitable access to health care.

As of 2018, the mean dermatologist to population ratio in the United States was 1.10 per 100,000 people, highlighting a shortage of dermatologists that is only predicted to increase in coming years.1-4 This undersupply is fueled by both an increasing burden of dermatologic disease and population growth.4 Without readily available access to dermatologic care, many patients are left waiting for weeks to see a dermatologist, depending on geographic region.5-7 It is not simply patients who perceive wait times to be prolonged; approximately half of dermatologists surveyed by the American Academy of Dermatology (AAD) reported an undersupply of dermatologists in their communities, a finding that strongly correlated with patient wait times.2 Ensuring the dermatologic workforce is sufficient to fulfill patient needs requires innovation of current practice models. To address this unmet demand, many practices have begun incorporating physician extenders, a term that encompasses physicians not board certified in dermatology, physician assistants, and nurse practitioners.7 The evolving landscape of the dermatologic workforce raises questions about future practice models and patient outcomes.

Scope of Practice for Physician Extenders

In practice, the role of physician extenders is highly variable. Legislation involving the scope of practice for physician extenders constantly is changing and varies by state. As of November 2021, 24 states and the District of Columbia permit nurse practitioners “full practice” authority to triage patients, interpret diagnostic tests, and prescribe treatments without physician oversight, including controlled substances.8,9 Even in states with “reduced practice” and “restricted practice” paradigms, which necessitate physician oversight, there remains ambiguity. Across the country, state regulatory bodies differ in statues governing licensing requirements, accessibility of the supervising physician, and ultimately culpability in the case of patient harm. Lack of consensus guidelines that clearly define roles and responsibilities has kindled controversy regarding extent of autonomy and liability for adverse outcomes.10,11

With respect to procedures, the AAD has explicitly recommended that “only active and properly licensed doctors of medicine and osteopathy shall engage in the practice of medicine” but that “under appropriate circumstances, a physician may delegate certain procedures and services to appropriately trained nonphysician office personnel.”12 This statement does not refer to or explicitly list the procedures that are appropriate for delegation to nonphysician personnel, and there is wide variability in how this recommendation is applied in daily practice. As it was originally intended, the AAD’s “Ethics in Medical Practice” position statement indicated that dermatologists must directly oversee physician extenders, a responsibility that is defined as being “present on-site, immediately available and able to respond promptly” to issues arising during the provision of health care services.12

Adverse Events From Cosmetic Procedures

The American Society for Dermatologic Surgery has documented a steady growth in the demand for cosmetic, medical, and surgical services,13 a trend that has heralded an increase in the number of procedures performed by physician extenders.14,15 One study contrasted the risk for adverse events following minimally invasive cosmetic procedures performed by physicians or nonphysicians. Of 2116 patients surveyed, 50 adverse events were documented.14 The cohort treated by nonphysicians experienced a higher incidence of laser burns and dyspigmentation, and the use of improper technique was the most frequently implicated cause of developing an adverse event. Approximately 24.6% of American Society for Dermatologic Surgery members reported treating 10 or more complications of cosmetic procedures performed by nonphysicians.14 Beyond laser burns and dyspigmentation, this wide range of complications included inappropriately placed filler product, facial drooping, and scarring. These studies highlight the need for further investigation into the outcomes of procedures performed by physician extenders.

Training of Physician Extenders

Even with medical management, emphasis on proper training of personnel is key and remains a legitimate concern. The training of physician extenders in dermatology differs greatly by location; while some physician extenders operate under meticulous guidance and thus can expand their skill set, other physician extenders shadow dermatologists for an arbitrary amount of time before being thrust into practice.10 It would be a disservice to both patients and nonphysician providers alike to conflate the latter regimen with the 4 years of medical school, 1 year of internship, and 3 years of rigorous specialized dermatologic training that physicians undergo.

This stark discrepancy between the training of physicians and physician extenders raises difficult questions about the patient’s right to make an informed decision regarding how they receive health care. Indeed, the casually regulated autonomous practice of some nonphysician providers has ignited public shock and ire.11

Reducing Health Care Expenditures

As legislatures deliberate over expanding scope of practice, policies should be based on evidence that prioritizes patient safety. In the appropriate setting, physician extenders can be instrumental to mitigating health care disparities; the use of physician extenders can diminish wait times for patients with routine visits for stable dermatologic disease.16 Moreover, reducing health care expenditures often is cited as a major benefit of increased utilization of physician extenders.14 It stands to reason that compensation of nonphysician providers is less expensive for a practice compared with physicians. Physician extenders participating in the management of stable chronic conditions or mild acute conditions may be cost-efficient in these circumstances; however, evidence suggests that physician extenders may incur greater costs than physicians with respect to the utilization of diagnostic tests or prescribing medications. For example, several studies have documented a substantial difference in the number of biopsies needed per malignant neoplasm by physicians compared to physician extenders.17-19 Particularly in patients younger than 65 years and in patients without history of skin cancer, physician extenders had to perform a greater number of biopsies to diagnose malignant neoplasms vs physicians.18 In addition to increased utilization of diagnostic tests, nonphysician providers more frequently prescribe medications of varying classes.20-22 Whether in outpatient offices, emergency departments, or hospital clinics, physician extenders more frequently prescribe antibiotics, which has concerning implications for antibiotic stewardship.20,21 In states with independent prescription authority, physician extenders are more than 20 times more likely to overprescribeopioids compared to physician extenders in states requiring physician supervision.23 These findings warrant additional investigation into how prescription patterns vary by provider type and how these differences impact patient outcomes.

Final Thoughts

Improving patient care is inherently a team endeavor, and the contributions of all members of the health care team are critical to success. Engaging physician extenders may help mitigate disparities in dermatologic care, with respect to surveillance of stable chronic conditions or the diagnosis of mild acute diseases. However, the exact scope of practice of physician extenders remains ambiguous, and their training regimens can vary drastically. Therefore, in the interest of patient safety, new patients or medically complex patients (ie, cutaneous lymphomas, nonstable autoimmune connective tissue disease) should be examined and managed by physicians. In either scenario, the patient should be informed of which providers are available and should be integrated into the decision-making process for their care. Through mutual respect, close collaboration, and candid assessments of patient complexity, different parties within the medical team can unite behind the mission to improve patient outcomes and champion equitable access to health care.

References
  1. Vaidya T, Zubritsky L, Alikhan A, et al. Socioeconomic and geographic barriers to dermatology care in urban and rural US populations. J Am Acad Dermatol. 2018;78:406-408.
  2. Resneck J Jr, Kimball AB. The dermatology workforce shortage. J Am Acad Dermatol. 2004;50:50-54.
  3. American Medical Association. Physician Characteristics and Distribution in the US. American Medical Association; 2002.
  4. Kimball AB, Resneck JS Jr. The US dermatology workforce: a specialty remains in shortage. J Am Acad Dermatol. 2008;59:741-755.
  5. Tsang MW, Resneck JS Jr. Even patients with changing moles face long dermatology appointment wait-times: a study of simulated patient calls to dermatologists. J Am Acad Dermatol. 2006;55:54-58.
  6. Suneja T, Smith ED, Chen GJ, et al. Waiting times to see a dermatologist are perceived as too long by dermatologists: implications for the dermatology workforce. Arch Dermatol. 2001;137:1303-1307.
  7. Zurfley F Jr, Mostow EN. Association between the use of a physician extender and dermatology appointment wait times in Ohio. JAMA Dermatol. 2017;153:1323-1324.
  8. Bean M. NP practice authority by state. Becker’s Hospital Review website. Published April 8, 2021. Accessed December 4, 2021. https://www.beckershospitalreview.com/nursing/np-practice-authority-by-state.html
  9. States with full practice authority for nurse practitioners. Maryville University website. Accessed December 15, 2021. https://online.maryville.edu/nursing-degrees/np/resources/states-granting-np-full-practice-authority/
  10. Slade K, Lazenby M, Grant-Kels JM. Ethics of utilizing nurse practitioners and physician’s assistants in the dermatology setting. Clin Dermatol. 2012;30:516-521
  11. Hafner K, Palmer G. Skin cancers rise, along with questionable treatments. New York Times. November 20, 2017. Accessed December 4, 2021. https://www.nytimes.com/2017/11/20/health/dermatology-skin-cancer.html
  12. American Academy of Dermatology. Policy #P-61.500. the use of non-physician office personnel. Published February 22, 2002. Updated July 31, 2004. http://www.aad.org/Forms/Policies/Uploads/AR/COE%20-%20Ethics%20in%20Medical%20Practice%20Booklet.pdf
  13. 2016 ASDS Survey on Dermatologic Procedures. American Society for Dermatologic Surgery website. Published May 30, 2017. Accessed December 15, 2021. https://www.asds.net/skin-experts/news-room/press-releases/asds-survey-nearly-105-million-treatments-performed-in-2016
  14. Rossi AM, Wilson B, Hibler BP, et al. Nonphysician practice of cosmetic dermatology: a patient and physician perspective of outcomes and adverse events. Dermatol Surg. 2019;45:588-597. 
  15. Anderson AM, Matsumoto M, Saul MI, et al. Accuracy of skin cancer diagnosis by physician assistants compared with dermatologists in a large health care system. JAMA Dermatol. 2018;154:569-573.
  16. O’Brien JC, Chong BF. Reducing outpatient dermatology clinic wait times in a safety net health system in Dallas, Texas. J Am Acad Dermatol. 2016;75:631-632.
  17. Aldredge LM, Young MS. Providing guidance for patients with moderate-to-severe psoriasis who are candidates for biologic therapy: role of the nurse practitioner and physician assistant. J Dermatol Nurses Assoc. 2016;8:14-26.
  18. Roblin DW, Howard DH, Becker ER, et al. Use of midlevel practitioners to achieve labor cost savings in the primary care practice of an MCO. Health Serv Res. 2004;39:607-626.
  19. Nault A, Zhang C, Kim K, et al. Biopsy use in skin cancer diagnosis: comparing dermatology physicians and advanced practice professionals. JAMA Dermatol. 2015;151:899-902.
  20. Privalle A, Havighurst T, Kim K, et al. Number of skin biopsies needed per malignancy: comparing the use of skin biopsies among dermatologists and nondermatologist clinicians [published online August 10, 2019]. J Am Acad Dermatol. 2020;82:110-116.
  21. Roumie CL, Halasa NB, Edwards KM, et al. Differences in antibiotic prescribing among physicians, residents, and nonphysician clinicians. Am J Med. 2005;118:641-648.
  22. Sanchez GV, Hersh AL, Shapiro DJ, et al. Outpatient antibiotic prescribing among United States nurse practitioners and physician assistants [published online August 10, 2016]. Open Forum Infect Dis. 2016;3:ofw168.
  23. Lozada MJ, Raji MA, Goodwin JS, et al. Opioid prescribing by primary care providers: a cross-sectional analysis of nurse practitioner, physician assistant, and physician prescribing patterns [published online April 24, 2020]. J Gen Intern Med. 2020;35:2584-2592.
References
  1. Vaidya T, Zubritsky L, Alikhan A, et al. Socioeconomic and geographic barriers to dermatology care in urban and rural US populations. J Am Acad Dermatol. 2018;78:406-408.
  2. Resneck J Jr, Kimball AB. The dermatology workforce shortage. J Am Acad Dermatol. 2004;50:50-54.
  3. American Medical Association. Physician Characteristics and Distribution in the US. American Medical Association; 2002.
  4. Kimball AB, Resneck JS Jr. The US dermatology workforce: a specialty remains in shortage. J Am Acad Dermatol. 2008;59:741-755.
  5. Tsang MW, Resneck JS Jr. Even patients with changing moles face long dermatology appointment wait-times: a study of simulated patient calls to dermatologists. J Am Acad Dermatol. 2006;55:54-58.
  6. Suneja T, Smith ED, Chen GJ, et al. Waiting times to see a dermatologist are perceived as too long by dermatologists: implications for the dermatology workforce. Arch Dermatol. 2001;137:1303-1307.
  7. Zurfley F Jr, Mostow EN. Association between the use of a physician extender and dermatology appointment wait times in Ohio. JAMA Dermatol. 2017;153:1323-1324.
  8. Bean M. NP practice authority by state. Becker’s Hospital Review website. Published April 8, 2021. Accessed December 4, 2021. https://www.beckershospitalreview.com/nursing/np-practice-authority-by-state.html
  9. States with full practice authority for nurse practitioners. Maryville University website. Accessed December 15, 2021. https://online.maryville.edu/nursing-degrees/np/resources/states-granting-np-full-practice-authority/
  10. Slade K, Lazenby M, Grant-Kels JM. Ethics of utilizing nurse practitioners and physician’s assistants in the dermatology setting. Clin Dermatol. 2012;30:516-521
  11. Hafner K, Palmer G. Skin cancers rise, along with questionable treatments. New York Times. November 20, 2017. Accessed December 4, 2021. https://www.nytimes.com/2017/11/20/health/dermatology-skin-cancer.html
  12. American Academy of Dermatology. Policy #P-61.500. the use of non-physician office personnel. Published February 22, 2002. Updated July 31, 2004. http://www.aad.org/Forms/Policies/Uploads/AR/COE%20-%20Ethics%20in%20Medical%20Practice%20Booklet.pdf
  13. 2016 ASDS Survey on Dermatologic Procedures. American Society for Dermatologic Surgery website. Published May 30, 2017. Accessed December 15, 2021. https://www.asds.net/skin-experts/news-room/press-releases/asds-survey-nearly-105-million-treatments-performed-in-2016
  14. Rossi AM, Wilson B, Hibler BP, et al. Nonphysician practice of cosmetic dermatology: a patient and physician perspective of outcomes and adverse events. Dermatol Surg. 2019;45:588-597. 
  15. Anderson AM, Matsumoto M, Saul MI, et al. Accuracy of skin cancer diagnosis by physician assistants compared with dermatologists in a large health care system. JAMA Dermatol. 2018;154:569-573.
  16. O’Brien JC, Chong BF. Reducing outpatient dermatology clinic wait times in a safety net health system in Dallas, Texas. J Am Acad Dermatol. 2016;75:631-632.
  17. Aldredge LM, Young MS. Providing guidance for patients with moderate-to-severe psoriasis who are candidates for biologic therapy: role of the nurse practitioner and physician assistant. J Dermatol Nurses Assoc. 2016;8:14-26.
  18. Roblin DW, Howard DH, Becker ER, et al. Use of midlevel practitioners to achieve labor cost savings in the primary care practice of an MCO. Health Serv Res. 2004;39:607-626.
  19. Nault A, Zhang C, Kim K, et al. Biopsy use in skin cancer diagnosis: comparing dermatology physicians and advanced practice professionals. JAMA Dermatol. 2015;151:899-902.
  20. Privalle A, Havighurst T, Kim K, et al. Number of skin biopsies needed per malignancy: comparing the use of skin biopsies among dermatologists and nondermatologist clinicians [published online August 10, 2019]. J Am Acad Dermatol. 2020;82:110-116.
  21. Roumie CL, Halasa NB, Edwards KM, et al. Differences in antibiotic prescribing among physicians, residents, and nonphysician clinicians. Am J Med. 2005;118:641-648.
  22. Sanchez GV, Hersh AL, Shapiro DJ, et al. Outpatient antibiotic prescribing among United States nurse practitioners and physician assistants [published online August 10, 2016]. Open Forum Infect Dis. 2016;3:ofw168.
  23. Lozada MJ, Raji MA, Goodwin JS, et al. Opioid prescribing by primary care providers: a cross-sectional analysis of nurse practitioner, physician assistant, and physician prescribing patterns [published online April 24, 2020]. J Gen Intern Med. 2020;35:2584-2592.
Issue
Cutis - 108(6)
Issue
Cutis - 108(6)
Page Number
E17-E19
Page Number
E17-E19
Publications
Publications
Topics
Article Type
Display Headline
Navigating the Evolving Landscape of the Dermatologic Workforce
Display Headline
Navigating the Evolving Landscape of the Dermatologic Workforce
Sections
Inside the Article

Resident Pearl

  • Because dermatology residents are immersed in high-volume clinical practice, they offer a unique perspective on current patient needs and daily workflow challenges that can guide the development of health care policies and care models.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Indurated Mass on the Right Central Back

Article Type
Changed
Tue, 03/15/2022 - 10:17
Display Headline
Indurated Mass on the Right Central Back

The Diagnosis: Actinomycetoma

Histopathology revealed evidence of an actinomycete organism within the suppuration, consistent with actinomycosis (quiz image [inset]). Given the clinical presentation and histopathologic findings, our patient was diagnosed with actinomycetoma.

Actinomycetoma is an indolent, progressive, subcutaneous infection characterized by a well-known clinical triad of tumefaction/subcutaneous mass, draining sinuses, and an exudate containing grains on microscopy. The sinus tracts are formed from the chronic infectious process that destroys tissue, creating tunnels. This infectious disease of soft tissue is a clinical subset of mycetoma, which is categorized as eumycetoma (fungal) and actinomycetoma (bacterial). Actinomycetoma resembles the behavior of insidious and chronic fungal infections; however, most mycetoma infections are bacterial.1,2 Actinomycetoma may be confused with actinomycosis, which is caused by Actinomycoses species, commensal organisms commonly located on the teeth and oral mucosa in association with other microorganisms that may pathogenically cause cervicofacial actinomycosis.3,4 Actinomycetoma can be caused by Nocardia, Streptomyces, and Actinomadura. 2,5 The foot is the most common location of involvement followed by the thoracic region. It is more common in tropical or equatorial locations and may be contracted through exposure to soil or wood.5 Mycetoma is considered a neglected tropical disease by the World Health Organization.1 In tropical countries, this disease may go undiagnosed or untreated for so long that surgical amputation may be the only effective treatment.

Actinomycetoma commonly is identifiable by direct microscopy, Gram stain, or bacterial culture, with Gram stain being more sensitive than bacterial culture.3 It is important to indicate the suspected organism to the microbiology laboratory because common bacterial pathogens are detected within 24 to 48 hours, but the causative microorganism in actinomycetoma may require up to 4 weeks for culture,2 leading to possible false negatives due to inadequate culture time.3 Histopathology of actinomycotic infections will demonstrate granulomatous inflammation, focal suppuration, and the presence of grains (ie, a colony of filamentous bacteria in a stellate shaped mass)(quiz image [inset]).

The gold standard of treatment is trimethoprim-sulfamethoxazole for up to several years.4,5 Amoxicillin–clavulanic acid, dapsone, amikacin, streptomycin, and beta-lactams have been used successfully.2,5 The treatment course is dependent on clinical severity and location of the disease. The cure rate with appropriate antibiotics can be as high as 90%,2,5 and thus surgical intervention can be avoided.

In the differential, cutaneous tuberculosis would show tuberculoid granulomas with epithelioid histiocytes with possible caseation on histopathology, typically alongside positive tuberculosis screening. Botryomycosis has a similar clinical presentation of a swollen or indurated lesion with draining sinus tracts, but it less commonly occurs on the trunk. Histopathology also is a close mimic of actinomycetoma with a small grain inside a suppurative infiltrate; however, it has no filamentous bacteria. A foreign body reaction would not histologically present with suppuration or grains, and draining sinuses typically would not be seen on clinical presentation. Sarcoma is a neoplastic process and most commonly would show a proliferation of cells with soft tissue or bone origin on histopathology and not primarily an inflammatory cell process.6

References
  1. Verma P, Jha A. Mycetoma: reviewing a neglected disease. Clin Exp Dermatol. 2019;44:123-129.
  2. Valour F, Sénéchal A, Dupieux C, et al. Actinomycosis: etiology, clinical features, diagnosis, treatment, and management. Infect Drug Resist. 2014;7:183-197.
  3. Bennhoff DF. Actinomycosis: diagnostic and therapeutic considerations and a review of 32 cases. Laryngoscope. 1984;94:1198-1217.
  4. Welsh O, Vera-Cabrera L, Welsh E, et al. Actinomycetoma and advances in its treatment. Clin Dermatol. 2012;30:372-381.
  5. Arenas R, Fernandez Martinez RF, Torres-Guerrero E, et al. Actinomycetoma: an update on diagnosis and treatment. Cutis. 2017;99:E11-E15.
  6. Weedon D. Weedon’s Skin Pathology. 3rd ed. Churchill Livingstone Elsevier; 2010.
Article PDF
Author and Disclosure Information

Drs. Hassani and Ros are from Hackensack Meridian Health, North Bergen, New Jersey. Dr. Chu is from Bridge Dermpath, Tarrytown, New York.

The authors report no conflict of interest.

Correspondence: Paul Chu, MD, 560 White Plains Rd, Tarrytown NY 10591 (paul.chu@bridgedermpath.com).

Issue
Cutis - 108(6)
Publications
Topics
Page Number
E29-E30
Sections
Author and Disclosure Information

Drs. Hassani and Ros are from Hackensack Meridian Health, North Bergen, New Jersey. Dr. Chu is from Bridge Dermpath, Tarrytown, New York.

The authors report no conflict of interest.

Correspondence: Paul Chu, MD, 560 White Plains Rd, Tarrytown NY 10591 (paul.chu@bridgedermpath.com).

Author and Disclosure Information

Drs. Hassani and Ros are from Hackensack Meridian Health, North Bergen, New Jersey. Dr. Chu is from Bridge Dermpath, Tarrytown, New York.

The authors report no conflict of interest.

Correspondence: Paul Chu, MD, 560 White Plains Rd, Tarrytown NY 10591 (paul.chu@bridgedermpath.com).

Article PDF
Article PDF
Related Articles

The Diagnosis: Actinomycetoma

Histopathology revealed evidence of an actinomycete organism within the suppuration, consistent with actinomycosis (quiz image [inset]). Given the clinical presentation and histopathologic findings, our patient was diagnosed with actinomycetoma.

Actinomycetoma is an indolent, progressive, subcutaneous infection characterized by a well-known clinical triad of tumefaction/subcutaneous mass, draining sinuses, and an exudate containing grains on microscopy. The sinus tracts are formed from the chronic infectious process that destroys tissue, creating tunnels. This infectious disease of soft tissue is a clinical subset of mycetoma, which is categorized as eumycetoma (fungal) and actinomycetoma (bacterial). Actinomycetoma resembles the behavior of insidious and chronic fungal infections; however, most mycetoma infections are bacterial.1,2 Actinomycetoma may be confused with actinomycosis, which is caused by Actinomycoses species, commensal organisms commonly located on the teeth and oral mucosa in association with other microorganisms that may pathogenically cause cervicofacial actinomycosis.3,4 Actinomycetoma can be caused by Nocardia, Streptomyces, and Actinomadura. 2,5 The foot is the most common location of involvement followed by the thoracic region. It is more common in tropical or equatorial locations and may be contracted through exposure to soil or wood.5 Mycetoma is considered a neglected tropical disease by the World Health Organization.1 In tropical countries, this disease may go undiagnosed or untreated for so long that surgical amputation may be the only effective treatment.

Actinomycetoma commonly is identifiable by direct microscopy, Gram stain, or bacterial culture, with Gram stain being more sensitive than bacterial culture.3 It is important to indicate the suspected organism to the microbiology laboratory because common bacterial pathogens are detected within 24 to 48 hours, but the causative microorganism in actinomycetoma may require up to 4 weeks for culture,2 leading to possible false negatives due to inadequate culture time.3 Histopathology of actinomycotic infections will demonstrate granulomatous inflammation, focal suppuration, and the presence of grains (ie, a colony of filamentous bacteria in a stellate shaped mass)(quiz image [inset]).

The gold standard of treatment is trimethoprim-sulfamethoxazole for up to several years.4,5 Amoxicillin–clavulanic acid, dapsone, amikacin, streptomycin, and beta-lactams have been used successfully.2,5 The treatment course is dependent on clinical severity and location of the disease. The cure rate with appropriate antibiotics can be as high as 90%,2,5 and thus surgical intervention can be avoided.

In the differential, cutaneous tuberculosis would show tuberculoid granulomas with epithelioid histiocytes with possible caseation on histopathology, typically alongside positive tuberculosis screening. Botryomycosis has a similar clinical presentation of a swollen or indurated lesion with draining sinus tracts, but it less commonly occurs on the trunk. Histopathology also is a close mimic of actinomycetoma with a small grain inside a suppurative infiltrate; however, it has no filamentous bacteria. A foreign body reaction would not histologically present with suppuration or grains, and draining sinuses typically would not be seen on clinical presentation. Sarcoma is a neoplastic process and most commonly would show a proliferation of cells with soft tissue or bone origin on histopathology and not primarily an inflammatory cell process.6

The Diagnosis: Actinomycetoma

Histopathology revealed evidence of an actinomycete organism within the suppuration, consistent with actinomycosis (quiz image [inset]). Given the clinical presentation and histopathologic findings, our patient was diagnosed with actinomycetoma.

Actinomycetoma is an indolent, progressive, subcutaneous infection characterized by a well-known clinical triad of tumefaction/subcutaneous mass, draining sinuses, and an exudate containing grains on microscopy. The sinus tracts are formed from the chronic infectious process that destroys tissue, creating tunnels. This infectious disease of soft tissue is a clinical subset of mycetoma, which is categorized as eumycetoma (fungal) and actinomycetoma (bacterial). Actinomycetoma resembles the behavior of insidious and chronic fungal infections; however, most mycetoma infections are bacterial.1,2 Actinomycetoma may be confused with actinomycosis, which is caused by Actinomycoses species, commensal organisms commonly located on the teeth and oral mucosa in association with other microorganisms that may pathogenically cause cervicofacial actinomycosis.3,4 Actinomycetoma can be caused by Nocardia, Streptomyces, and Actinomadura. 2,5 The foot is the most common location of involvement followed by the thoracic region. It is more common in tropical or equatorial locations and may be contracted through exposure to soil or wood.5 Mycetoma is considered a neglected tropical disease by the World Health Organization.1 In tropical countries, this disease may go undiagnosed or untreated for so long that surgical amputation may be the only effective treatment.

Actinomycetoma commonly is identifiable by direct microscopy, Gram stain, or bacterial culture, with Gram stain being more sensitive than bacterial culture.3 It is important to indicate the suspected organism to the microbiology laboratory because common bacterial pathogens are detected within 24 to 48 hours, but the causative microorganism in actinomycetoma may require up to 4 weeks for culture,2 leading to possible false negatives due to inadequate culture time.3 Histopathology of actinomycotic infections will demonstrate granulomatous inflammation, focal suppuration, and the presence of grains (ie, a colony of filamentous bacteria in a stellate shaped mass)(quiz image [inset]).

The gold standard of treatment is trimethoprim-sulfamethoxazole for up to several years.4,5 Amoxicillin–clavulanic acid, dapsone, amikacin, streptomycin, and beta-lactams have been used successfully.2,5 The treatment course is dependent on clinical severity and location of the disease. The cure rate with appropriate antibiotics can be as high as 90%,2,5 and thus surgical intervention can be avoided.

In the differential, cutaneous tuberculosis would show tuberculoid granulomas with epithelioid histiocytes with possible caseation on histopathology, typically alongside positive tuberculosis screening. Botryomycosis has a similar clinical presentation of a swollen or indurated lesion with draining sinus tracts, but it less commonly occurs on the trunk. Histopathology also is a close mimic of actinomycetoma with a small grain inside a suppurative infiltrate; however, it has no filamentous bacteria. A foreign body reaction would not histologically present with suppuration or grains, and draining sinuses typically would not be seen on clinical presentation. Sarcoma is a neoplastic process and most commonly would show a proliferation of cells with soft tissue or bone origin on histopathology and not primarily an inflammatory cell process.6

References
  1. Verma P, Jha A. Mycetoma: reviewing a neglected disease. Clin Exp Dermatol. 2019;44:123-129.
  2. Valour F, Sénéchal A, Dupieux C, et al. Actinomycosis: etiology, clinical features, diagnosis, treatment, and management. Infect Drug Resist. 2014;7:183-197.
  3. Bennhoff DF. Actinomycosis: diagnostic and therapeutic considerations and a review of 32 cases. Laryngoscope. 1984;94:1198-1217.
  4. Welsh O, Vera-Cabrera L, Welsh E, et al. Actinomycetoma and advances in its treatment. Clin Dermatol. 2012;30:372-381.
  5. Arenas R, Fernandez Martinez RF, Torres-Guerrero E, et al. Actinomycetoma: an update on diagnosis and treatment. Cutis. 2017;99:E11-E15.
  6. Weedon D. Weedon’s Skin Pathology. 3rd ed. Churchill Livingstone Elsevier; 2010.
References
  1. Verma P, Jha A. Mycetoma: reviewing a neglected disease. Clin Exp Dermatol. 2019;44:123-129.
  2. Valour F, Sénéchal A, Dupieux C, et al. Actinomycosis: etiology, clinical features, diagnosis, treatment, and management. Infect Drug Resist. 2014;7:183-197.
  3. Bennhoff DF. Actinomycosis: diagnostic and therapeutic considerations and a review of 32 cases. Laryngoscope. 1984;94:1198-1217.
  4. Welsh O, Vera-Cabrera L, Welsh E, et al. Actinomycetoma and advances in its treatment. Clin Dermatol. 2012;30:372-381.
  5. Arenas R, Fernandez Martinez RF, Torres-Guerrero E, et al. Actinomycetoma: an update on diagnosis and treatment. Cutis. 2017;99:E11-E15.
  6. Weedon D. Weedon’s Skin Pathology. 3rd ed. Churchill Livingstone Elsevier; 2010.
Issue
Cutis - 108(6)
Issue
Cutis - 108(6)
Page Number
E29-E30
Page Number
E29-E30
Publications
Publications
Topics
Article Type
Display Headline
Indurated Mass on the Right Central Back
Display Headline
Indurated Mass on the Right Central Back
Sections
Questionnaire Body

A 26-year-old Guatemalan man who was a former carpenter presented with an indurated, nontender, nonpruritic, subcutaneous mass on the right central back with multiple draining sinus tracts on the surface and several depressed circular atrophic scars on the periphery of the mass. He noticed that the lesion began as a pustule 1.5 years prior and gradually enlarged. He denied any trauma, insect bites, fever, chills, headaches, weight loss, or travel history (he relocated to the United States 3.5 years ago) prior to the skin eruption. A biopsy was performed by an outside dermatologist 1 year prior to the current presentation, with a diagnosis of Pityrosporum folliculitis. Throughout his clinical course, treatment with oral antifungals, oral doxycycline, and topical clindamycin all failed. The mass was removed by plastic surgery 1 year prior.

A tissue biopsy for histology and culture was obtained at presentation to our institution. Laboratory findings showed that the basic metabolic panel was within reference range. Chest radiography indicated no active disease. A tuberculosis screening was negative. A bacterial culture of the lesion identified no growth after 48 hours. Our tissue biopsy revealed fibrosing granulation tissue, but the surgical pathology from a prior mass excision revealed sinus tracts with suppuration, evidence of scarring, foreign body giant cell reaction, and a characteristic finding (inset: H&E, original magnification ×200).

Mass on the back

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 01/04/2022 - 10:45
Un-Gate On Date
Tue, 01/04/2022 - 10:45
Use ProPublica
CFC Schedule Remove Status
Tue, 01/04/2022 - 10:45
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Secretan Syndrome: A Fluctuating Case of Factitious Lymphedema

Article Type
Changed
Mon, 01/10/2022 - 11:21

Secretan syndrome (SS) represents a recurrent or chronic form of factitious lymphedema, usually affecting the dorsal aspect of the hand.1-3 It is accepted as a subtype of Munchausen syndrome whereby the patient self-inflicts and simulates lymphedema.1,2 Historically, many of the cases reported with the term Charcot’s oedème bleu are now believed to represent clinical variants of SS.4-6

 

Case Report

A 38-year-old Turkish woman presented with progressive swelling of the right hand of 2 years’ duration that had caused difficulty in manual work and reduction in manual dexterity. She previously had sought medical treatment for this condition by visiting several hospitals. According to her medical record, the following laboratory or radiologic tests had revealed negative or normal findings, except for obvious soft-tissue edema: bacterial and fungal cultures, plain radiography, Doppler ultrasonography, lymphoscintigraphy, magnetic resonance imaging, fine needle aspiration, and punch biopsy. Reflex sympathetic dystrophy, compartment syndrome, filariasis, tuberculosis, and lymphatic and venous obstruction were all excluded by appropriate testing. Our patient was in good health prior to onset of this disorder, and her medical history was unremarkable. There was no family history of a similar condition.

Dermatologic examination revealed brawny, soft, pitting edema; erythema; and crusts affecting the dorsal aspect of the right hand and proximal parts of the fingers (Figure 1). The yellow discoloration of the skin and nails was attributed to potassium permanganate wet dressings. Under an elastic bandage at the wrist, which the patient unrolled herself, a sharp line of demarcation was evident, separating the lymphedematous and normal parts of the arm. There was no axillary lymphadenopathy.

FIGURE 1. A, Brawny, soft, pitting edema; erythema; and crusting on the dorsal aspect of the right hand and proximal parts of the fingers. B, An evident line of demarcation was noted at the wrist.


The patient’s affect was discordant to the manifestation of the cutaneous findings. She wanted to show every physician in the department how swollen her hand was and seemed to be happy with this condition. Although she displayed no signs of disturbance when the affected extremity was touched or handled, she reported severe pain and tenderness as well as difficulty in housework. She noted that she normally resided in a city and that the swelling had started at the time she had relocated to a rural village to take care of her bedridden mother-in-law. She was under an intensive workload in the village, and the condition of the hand was impeding manual work.

Factitious lymphedema was considered, and hospitalization was recommended. The patient was then lost to follow-up; however, one of her relatives noted that the patient had returned to the city. When she presented again 1 year later, almost all physical signs had disappeared (Figure 2), and a psychiatric referral was recommended. A Minnesota Multiphasic Personality Inventory test yielded an invalid result due to the patient’s exaggeration of her preexisting physical symptoms. Further psychiatric workup was rejected by the patient.

FIGURE 2. Complete regression of lymphedema was noted 1 year after the initial presentation.


Almost a year after the psychiatric referral, the patient’s follow-up photographs revealed that the lymphedema recurred when she went to visit her mother-in-law in the rural village and that it was completely ameliorated when she returned to the city. Thus, a positive “mother-in-law provocation test” was accepted as final proof of the self-inflicted nature of the condition.

 

 

Comment

In 1901, Henri Francois Secretan, a Swiss physician, reported workmen who had persistent hard swellings on the dorsal aspect of the hands after minor work-related trauma for which they had compensation claims.7 In his original report, Secretan did not suggest self-inflicted trauma in the etiology of this disorder.5,8,9 In 1890, Jean Martin Charcot, a French neurologist, described oedème bleu, a term that is now believed to denote a condition similar to SS.4-6 Currently, SS is attributed to self-inflicted injury and is considered a form of factitious lymphedema.9 As in dermatitis artefacta, most patients with SS are young women, and male patients with the condition tend to be older.3,8

The mechanism used to provoke this factitious lymphedema might be of traumatic or obstructive nature. Secretan syndrome either is induced by intermittent or constant application of a tourniquet, ligature, cord, elastic bandage, scarf, kerchief, rubber band, or compress around the affected extremity, or by repetitive blunt trauma, force, or skin irritation.1,4,5,8-10 There was an underlying psychopathology in all reported cases.1,8,11 Factitious lymphedema is unconsciously motivated and consciously produced.4,12 The affected patient often is experiencing a serious emotional conflict and is unlikely to be a malingerer, although exaggeration of symptoms may occur, as in our patient.12 Psychiatric evaluation in SS may uncover neurosis, hysteria, frank psychosis, schizophrenia, masochism, depression, or an abnormal personality disorder.1,12

Patients with SS present with recurrent or chronic lymphedema, usually affecting the dominant hand.1 Involvement usually is unilateral; bilateral cases are rare.3,6 Secretan syndrome is not solely limited to the hands; it also may involve the upper and lower extremities, including the feet.3,11 There may be a clear line of demarcation, a ring, sulcus, distinct circumferential linear bands of erythema, discoloration, or ecchymoses, separating the normal and lymphedematous parts of the extremity.1,4,6,8-10,12 Patients usually attempt to hide the constricted areas from sight.1 Over time, flexion contractures may develop due to peritendinous fibrosis.6 Histopathology displays a hematoma with adhesions to the extensor tendons; a hematoma surrounded by a thickened scar; or changes similar to ganglion tissue with cystic areas of mucin, fibrosis, and myxoid degeneration.4,6

Factitious lymphedema can only be definitively diagnosed when the patient confesses or is caught self-inflicting the injury. Nevertheless, a diagnosis by exclusion is possible.4 Lymphangiography, lymphoscintigraphy, vascular Doppler ultrasonography, and magnetic resonance imaging may be helpful in excluding congenital and acquired causes of lymphedema and venous obstruction.1,3,9,11 Magnetic resonance imaging may show soft tissue and tendon edema as well as diffuse peritendinous fibrosis extending to the fascia of the dorsal interosseous muscles.3,4

Factitious lymphedema should be suspected in all patients with recurrent or chronic unilateral lymphedema without an explicable or apparent predisposing factor.4,11,12 Patients with SS typically visit several hospitals or institutions; see many physicians; and willingly accept, request, and undergo unnecessary extensive, invasive, and costly diagnostic and therapeutic procedures and prolonged hospitalizations.1,2,5,12 The disorder promptly responds to immobilization and elevation of the limb.2,4 Plaster casts may prove useful in prevention of compression and thus amelioration of the lymphedema.1,4,6 Once the diagnosis is confirmed, direct confrontation should be avoided and ideally the patient should be referred for psychiatric evaluation.1,2,4,5,8,12 If the patient admits self-inflicting behavior, psychotherapy and/or behavior modification therapy along with psychotropic medications may be helpful to relieve emotional and behavioral symptoms.12 Unfortunately, if the patient denies a self-inflicting role in the occurrence of lymphedema and persists in self-injurious behavior, psychotherapy or psychotropic medications will be futile.9

 

 

References

1. Miyamoto Y, Hamanaka T, Yokoyama S, et al. Factitious lymphedema of the upper limb. Kawasaki Med J. 1979;5:39-45.

2. de Oliveira RK, Bayer LR, Lauxen D, et al. Factitious lesions of the hand. Rev Bras Ortop. 2013;48:381-386.

3. Hahm MH, Yi JH. A case report of Secretan’s disease in both hands. J Korean Soc Radiol. 2013;68:511-514.

4. Eldridge MP, Grunert BK, Matloub HS. Streamlined classification of psychopathological hand disorders: a literature review. Hand (NY). 2008;3:118-128.

5. Ostlere LS, Harris D, Denton C, et al. Boxing-glove hand: an unusual presentation of dermatitis artefacta. J Am Acad Dermatol. 1993;28:120-122.

6. Winkelmann RK, Barker SM. Factitial traumatic panniculitis. J Am Acad Dermatol. 1985;13:988-994.

7. Secretan H. Oederne dur et hyperplasie traumatique du metacarpe dorsal. RevMed Suisse Romande. 1901;21:409-416.

8. Barth JH, Pegum JS. The case of the speckled band: acquired lymphedema due to constriction bands. J Am Acad Dermatol. 1986;15:296-297.

9. Birman MV, Lee DH. Factitious disorders of the upper extremity. J Am Acad Orthop Surg. 2012;20:78-85.

10. Nwaejike N, Archbold H, Wilson DS. Factitious lymphoedema as a psychiatric condition mimicking reflex sympathetic dystrophy: a case report. J Med Case Rep. 2008;2:216.

11. De Fátima Guerreiro Godoy M, Pereira De Godoy JM. Factitious lymphedema of the arm: case report and review of publications. Eur J Phys Rehabil Med. 2015;51:337-339.

12. Abhari SAA, Alimalayeri N, Abhari SSA, et al. Factitious lymphedema of the hand. Iran J Psychiatry. 2006;1:166-168.

Article PDF
Author and Disclosure Information

 

From the Department of Dermatology, Acıbadem Mehmet Ali Aydınlar University School of Medicine, I·stanbul, Turkey.

The authors report no conflict of interest.

Correspondence: Emel Öztürk Durmaz, MD, Acıbadem Maslak Hospital, Büyükdere Caddesi 40, Maslak 34457, I·stanbul, Turkey (emelerkek@yahoo.com).
 

Issue
Cutis - 108(6)
Publications
Topics
Page Number
E23-E25
Sections
Author and Disclosure Information

 

From the Department of Dermatology, Acıbadem Mehmet Ali Aydınlar University School of Medicine, I·stanbul, Turkey.

The authors report no conflict of interest.

Correspondence: Emel Öztürk Durmaz, MD, Acıbadem Maslak Hospital, Büyükdere Caddesi 40, Maslak 34457, I·stanbul, Turkey (emelerkek@yahoo.com).
 

Author and Disclosure Information

 

From the Department of Dermatology, Acıbadem Mehmet Ali Aydınlar University School of Medicine, I·stanbul, Turkey.

The authors report no conflict of interest.

Correspondence: Emel Öztürk Durmaz, MD, Acıbadem Maslak Hospital, Büyükdere Caddesi 40, Maslak 34457, I·stanbul, Turkey (emelerkek@yahoo.com).
 

Article PDF
Article PDF

Secretan syndrome (SS) represents a recurrent or chronic form of factitious lymphedema, usually affecting the dorsal aspect of the hand.1-3 It is accepted as a subtype of Munchausen syndrome whereby the patient self-inflicts and simulates lymphedema.1,2 Historically, many of the cases reported with the term Charcot’s oedème bleu are now believed to represent clinical variants of SS.4-6

 

Case Report

A 38-year-old Turkish woman presented with progressive swelling of the right hand of 2 years’ duration that had caused difficulty in manual work and reduction in manual dexterity. She previously had sought medical treatment for this condition by visiting several hospitals. According to her medical record, the following laboratory or radiologic tests had revealed negative or normal findings, except for obvious soft-tissue edema: bacterial and fungal cultures, plain radiography, Doppler ultrasonography, lymphoscintigraphy, magnetic resonance imaging, fine needle aspiration, and punch biopsy. Reflex sympathetic dystrophy, compartment syndrome, filariasis, tuberculosis, and lymphatic and venous obstruction were all excluded by appropriate testing. Our patient was in good health prior to onset of this disorder, and her medical history was unremarkable. There was no family history of a similar condition.

Dermatologic examination revealed brawny, soft, pitting edema; erythema; and crusts affecting the dorsal aspect of the right hand and proximal parts of the fingers (Figure 1). The yellow discoloration of the skin and nails was attributed to potassium permanganate wet dressings. Under an elastic bandage at the wrist, which the patient unrolled herself, a sharp line of demarcation was evident, separating the lymphedematous and normal parts of the arm. There was no axillary lymphadenopathy.

FIGURE 1. A, Brawny, soft, pitting edema; erythema; and crusting on the dorsal aspect of the right hand and proximal parts of the fingers. B, An evident line of demarcation was noted at the wrist.


The patient’s affect was discordant to the manifestation of the cutaneous findings. She wanted to show every physician in the department how swollen her hand was and seemed to be happy with this condition. Although she displayed no signs of disturbance when the affected extremity was touched or handled, she reported severe pain and tenderness as well as difficulty in housework. She noted that she normally resided in a city and that the swelling had started at the time she had relocated to a rural village to take care of her bedridden mother-in-law. She was under an intensive workload in the village, and the condition of the hand was impeding manual work.

Factitious lymphedema was considered, and hospitalization was recommended. The patient was then lost to follow-up; however, one of her relatives noted that the patient had returned to the city. When she presented again 1 year later, almost all physical signs had disappeared (Figure 2), and a psychiatric referral was recommended. A Minnesota Multiphasic Personality Inventory test yielded an invalid result due to the patient’s exaggeration of her preexisting physical symptoms. Further psychiatric workup was rejected by the patient.

FIGURE 2. Complete regression of lymphedema was noted 1 year after the initial presentation.


Almost a year after the psychiatric referral, the patient’s follow-up photographs revealed that the lymphedema recurred when she went to visit her mother-in-law in the rural village and that it was completely ameliorated when she returned to the city. Thus, a positive “mother-in-law provocation test” was accepted as final proof of the self-inflicted nature of the condition.

 

 

Comment

In 1901, Henri Francois Secretan, a Swiss physician, reported workmen who had persistent hard swellings on the dorsal aspect of the hands after minor work-related trauma for which they had compensation claims.7 In his original report, Secretan did not suggest self-inflicted trauma in the etiology of this disorder.5,8,9 In 1890, Jean Martin Charcot, a French neurologist, described oedème bleu, a term that is now believed to denote a condition similar to SS.4-6 Currently, SS is attributed to self-inflicted injury and is considered a form of factitious lymphedema.9 As in dermatitis artefacta, most patients with SS are young women, and male patients with the condition tend to be older.3,8

The mechanism used to provoke this factitious lymphedema might be of traumatic or obstructive nature. Secretan syndrome either is induced by intermittent or constant application of a tourniquet, ligature, cord, elastic bandage, scarf, kerchief, rubber band, or compress around the affected extremity, or by repetitive blunt trauma, force, or skin irritation.1,4,5,8-10 There was an underlying psychopathology in all reported cases.1,8,11 Factitious lymphedema is unconsciously motivated and consciously produced.4,12 The affected patient often is experiencing a serious emotional conflict and is unlikely to be a malingerer, although exaggeration of symptoms may occur, as in our patient.12 Psychiatric evaluation in SS may uncover neurosis, hysteria, frank psychosis, schizophrenia, masochism, depression, or an abnormal personality disorder.1,12

Patients with SS present with recurrent or chronic lymphedema, usually affecting the dominant hand.1 Involvement usually is unilateral; bilateral cases are rare.3,6 Secretan syndrome is not solely limited to the hands; it also may involve the upper and lower extremities, including the feet.3,11 There may be a clear line of demarcation, a ring, sulcus, distinct circumferential linear bands of erythema, discoloration, or ecchymoses, separating the normal and lymphedematous parts of the extremity.1,4,6,8-10,12 Patients usually attempt to hide the constricted areas from sight.1 Over time, flexion contractures may develop due to peritendinous fibrosis.6 Histopathology displays a hematoma with adhesions to the extensor tendons; a hematoma surrounded by a thickened scar; or changes similar to ganglion tissue with cystic areas of mucin, fibrosis, and myxoid degeneration.4,6

Factitious lymphedema can only be definitively diagnosed when the patient confesses or is caught self-inflicting the injury. Nevertheless, a diagnosis by exclusion is possible.4 Lymphangiography, lymphoscintigraphy, vascular Doppler ultrasonography, and magnetic resonance imaging may be helpful in excluding congenital and acquired causes of lymphedema and venous obstruction.1,3,9,11 Magnetic resonance imaging may show soft tissue and tendon edema as well as diffuse peritendinous fibrosis extending to the fascia of the dorsal interosseous muscles.3,4

Factitious lymphedema should be suspected in all patients with recurrent or chronic unilateral lymphedema without an explicable or apparent predisposing factor.4,11,12 Patients with SS typically visit several hospitals or institutions; see many physicians; and willingly accept, request, and undergo unnecessary extensive, invasive, and costly diagnostic and therapeutic procedures and prolonged hospitalizations.1,2,5,12 The disorder promptly responds to immobilization and elevation of the limb.2,4 Plaster casts may prove useful in prevention of compression and thus amelioration of the lymphedema.1,4,6 Once the diagnosis is confirmed, direct confrontation should be avoided and ideally the patient should be referred for psychiatric evaluation.1,2,4,5,8,12 If the patient admits self-inflicting behavior, psychotherapy and/or behavior modification therapy along with psychotropic medications may be helpful to relieve emotional and behavioral symptoms.12 Unfortunately, if the patient denies a self-inflicting role in the occurrence of lymphedema and persists in self-injurious behavior, psychotherapy or psychotropic medications will be futile.9

 

 

Secretan syndrome (SS) represents a recurrent or chronic form of factitious lymphedema, usually affecting the dorsal aspect of the hand.1-3 It is accepted as a subtype of Munchausen syndrome whereby the patient self-inflicts and simulates lymphedema.1,2 Historically, many of the cases reported with the term Charcot’s oedème bleu are now believed to represent clinical variants of SS.4-6

 

Case Report

A 38-year-old Turkish woman presented with progressive swelling of the right hand of 2 years’ duration that had caused difficulty in manual work and reduction in manual dexterity. She previously had sought medical treatment for this condition by visiting several hospitals. According to her medical record, the following laboratory or radiologic tests had revealed negative or normal findings, except for obvious soft-tissue edema: bacterial and fungal cultures, plain radiography, Doppler ultrasonography, lymphoscintigraphy, magnetic resonance imaging, fine needle aspiration, and punch biopsy. Reflex sympathetic dystrophy, compartment syndrome, filariasis, tuberculosis, and lymphatic and venous obstruction were all excluded by appropriate testing. Our patient was in good health prior to onset of this disorder, and her medical history was unremarkable. There was no family history of a similar condition.

Dermatologic examination revealed brawny, soft, pitting edema; erythema; and crusts affecting the dorsal aspect of the right hand and proximal parts of the fingers (Figure 1). The yellow discoloration of the skin and nails was attributed to potassium permanganate wet dressings. Under an elastic bandage at the wrist, which the patient unrolled herself, a sharp line of demarcation was evident, separating the lymphedematous and normal parts of the arm. There was no axillary lymphadenopathy.

FIGURE 1. A, Brawny, soft, pitting edema; erythema; and crusting on the dorsal aspect of the right hand and proximal parts of the fingers. B, An evident line of demarcation was noted at the wrist.


The patient’s affect was discordant to the manifestation of the cutaneous findings. She wanted to show every physician in the department how swollen her hand was and seemed to be happy with this condition. Although she displayed no signs of disturbance when the affected extremity was touched or handled, she reported severe pain and tenderness as well as difficulty in housework. She noted that she normally resided in a city and that the swelling had started at the time she had relocated to a rural village to take care of her bedridden mother-in-law. She was under an intensive workload in the village, and the condition of the hand was impeding manual work.

Factitious lymphedema was considered, and hospitalization was recommended. The patient was then lost to follow-up; however, one of her relatives noted that the patient had returned to the city. When she presented again 1 year later, almost all physical signs had disappeared (Figure 2), and a psychiatric referral was recommended. A Minnesota Multiphasic Personality Inventory test yielded an invalid result due to the patient’s exaggeration of her preexisting physical symptoms. Further psychiatric workup was rejected by the patient.

FIGURE 2. Complete regression of lymphedema was noted 1 year after the initial presentation.


Almost a year after the psychiatric referral, the patient’s follow-up photographs revealed that the lymphedema recurred when she went to visit her mother-in-law in the rural village and that it was completely ameliorated when she returned to the city. Thus, a positive “mother-in-law provocation test” was accepted as final proof of the self-inflicted nature of the condition.

 

 

Comment

In 1901, Henri Francois Secretan, a Swiss physician, reported workmen who had persistent hard swellings on the dorsal aspect of the hands after minor work-related trauma for which they had compensation claims.7 In his original report, Secretan did not suggest self-inflicted trauma in the etiology of this disorder.5,8,9 In 1890, Jean Martin Charcot, a French neurologist, described oedème bleu, a term that is now believed to denote a condition similar to SS.4-6 Currently, SS is attributed to self-inflicted injury and is considered a form of factitious lymphedema.9 As in dermatitis artefacta, most patients with SS are young women, and male patients with the condition tend to be older.3,8

The mechanism used to provoke this factitious lymphedema might be of traumatic or obstructive nature. Secretan syndrome either is induced by intermittent or constant application of a tourniquet, ligature, cord, elastic bandage, scarf, kerchief, rubber band, or compress around the affected extremity, or by repetitive blunt trauma, force, or skin irritation.1,4,5,8-10 There was an underlying psychopathology in all reported cases.1,8,11 Factitious lymphedema is unconsciously motivated and consciously produced.4,12 The affected patient often is experiencing a serious emotional conflict and is unlikely to be a malingerer, although exaggeration of symptoms may occur, as in our patient.12 Psychiatric evaluation in SS may uncover neurosis, hysteria, frank psychosis, schizophrenia, masochism, depression, or an abnormal personality disorder.1,12

Patients with SS present with recurrent or chronic lymphedema, usually affecting the dominant hand.1 Involvement usually is unilateral; bilateral cases are rare.3,6 Secretan syndrome is not solely limited to the hands; it also may involve the upper and lower extremities, including the feet.3,11 There may be a clear line of demarcation, a ring, sulcus, distinct circumferential linear bands of erythema, discoloration, or ecchymoses, separating the normal and lymphedematous parts of the extremity.1,4,6,8-10,12 Patients usually attempt to hide the constricted areas from sight.1 Over time, flexion contractures may develop due to peritendinous fibrosis.6 Histopathology displays a hematoma with adhesions to the extensor tendons; a hematoma surrounded by a thickened scar; or changes similar to ganglion tissue with cystic areas of mucin, fibrosis, and myxoid degeneration.4,6

Factitious lymphedema can only be definitively diagnosed when the patient confesses or is caught self-inflicting the injury. Nevertheless, a diagnosis by exclusion is possible.4 Lymphangiography, lymphoscintigraphy, vascular Doppler ultrasonography, and magnetic resonance imaging may be helpful in excluding congenital and acquired causes of lymphedema and venous obstruction.1,3,9,11 Magnetic resonance imaging may show soft tissue and tendon edema as well as diffuse peritendinous fibrosis extending to the fascia of the dorsal interosseous muscles.3,4

Factitious lymphedema should be suspected in all patients with recurrent or chronic unilateral lymphedema without an explicable or apparent predisposing factor.4,11,12 Patients with SS typically visit several hospitals or institutions; see many physicians; and willingly accept, request, and undergo unnecessary extensive, invasive, and costly diagnostic and therapeutic procedures and prolonged hospitalizations.1,2,5,12 The disorder promptly responds to immobilization and elevation of the limb.2,4 Plaster casts may prove useful in prevention of compression and thus amelioration of the lymphedema.1,4,6 Once the diagnosis is confirmed, direct confrontation should be avoided and ideally the patient should be referred for psychiatric evaluation.1,2,4,5,8,12 If the patient admits self-inflicting behavior, psychotherapy and/or behavior modification therapy along with psychotropic medications may be helpful to relieve emotional and behavioral symptoms.12 Unfortunately, if the patient denies a self-inflicting role in the occurrence of lymphedema and persists in self-injurious behavior, psychotherapy or psychotropic medications will be futile.9

 

 

References

1. Miyamoto Y, Hamanaka T, Yokoyama S, et al. Factitious lymphedema of the upper limb. Kawasaki Med J. 1979;5:39-45.

2. de Oliveira RK, Bayer LR, Lauxen D, et al. Factitious lesions of the hand. Rev Bras Ortop. 2013;48:381-386.

3. Hahm MH, Yi JH. A case report of Secretan’s disease in both hands. J Korean Soc Radiol. 2013;68:511-514.

4. Eldridge MP, Grunert BK, Matloub HS. Streamlined classification of psychopathological hand disorders: a literature review. Hand (NY). 2008;3:118-128.

5. Ostlere LS, Harris D, Denton C, et al. Boxing-glove hand: an unusual presentation of dermatitis artefacta. J Am Acad Dermatol. 1993;28:120-122.

6. Winkelmann RK, Barker SM. Factitial traumatic panniculitis. J Am Acad Dermatol. 1985;13:988-994.

7. Secretan H. Oederne dur et hyperplasie traumatique du metacarpe dorsal. RevMed Suisse Romande. 1901;21:409-416.

8. Barth JH, Pegum JS. The case of the speckled band: acquired lymphedema due to constriction bands. J Am Acad Dermatol. 1986;15:296-297.

9. Birman MV, Lee DH. Factitious disorders of the upper extremity. J Am Acad Orthop Surg. 2012;20:78-85.

10. Nwaejike N, Archbold H, Wilson DS. Factitious lymphoedema as a psychiatric condition mimicking reflex sympathetic dystrophy: a case report. J Med Case Rep. 2008;2:216.

11. De Fátima Guerreiro Godoy M, Pereira De Godoy JM. Factitious lymphedema of the arm: case report and review of publications. Eur J Phys Rehabil Med. 2015;51:337-339.

12. Abhari SAA, Alimalayeri N, Abhari SSA, et al. Factitious lymphedema of the hand. Iran J Psychiatry. 2006;1:166-168.

References

1. Miyamoto Y, Hamanaka T, Yokoyama S, et al. Factitious lymphedema of the upper limb. Kawasaki Med J. 1979;5:39-45.

2. de Oliveira RK, Bayer LR, Lauxen D, et al. Factitious lesions of the hand. Rev Bras Ortop. 2013;48:381-386.

3. Hahm MH, Yi JH. A case report of Secretan’s disease in both hands. J Korean Soc Radiol. 2013;68:511-514.

4. Eldridge MP, Grunert BK, Matloub HS. Streamlined classification of psychopathological hand disorders: a literature review. Hand (NY). 2008;3:118-128.

5. Ostlere LS, Harris D, Denton C, et al. Boxing-glove hand: an unusual presentation of dermatitis artefacta. J Am Acad Dermatol. 1993;28:120-122.

6. Winkelmann RK, Barker SM. Factitial traumatic panniculitis. J Am Acad Dermatol. 1985;13:988-994.

7. Secretan H. Oederne dur et hyperplasie traumatique du metacarpe dorsal. RevMed Suisse Romande. 1901;21:409-416.

8. Barth JH, Pegum JS. The case of the speckled band: acquired lymphedema due to constriction bands. J Am Acad Dermatol. 1986;15:296-297.

9. Birman MV, Lee DH. Factitious disorders of the upper extremity. J Am Acad Orthop Surg. 2012;20:78-85.

10. Nwaejike N, Archbold H, Wilson DS. Factitious lymphoedema as a psychiatric condition mimicking reflex sympathetic dystrophy: a case report. J Med Case Rep. 2008;2:216.

11. De Fátima Guerreiro Godoy M, Pereira De Godoy JM. Factitious lymphedema of the arm: case report and review of publications. Eur J Phys Rehabil Med. 2015;51:337-339.

12. Abhari SAA, Alimalayeri N, Abhari SSA, et al. Factitious lymphedema of the hand. Iran J Psychiatry. 2006;1:166-168.

Issue
Cutis - 108(6)
Issue
Cutis - 108(6)
Page Number
E23-E25
Page Number
E23-E25
Publications
Publications
Topics
Article Type
Sections
Inside the Article

 

Practice Points

  • Secretan syndrome is a recurrent or chronic form of factitious lymphedema that usually affects the dorsal aspect of the hand; it is accepted as a subtype of Munchausen syndrome.
  • Secretan syndrome usually is induced by compression of the extremity by tourniquets, ligatures, cords, or similar equipment.
  • This unconsciously motivated and consciously produced lymphedema is an expression of underlying psychiatric disease.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Zosteriform Eruption on the Chest and Abdomen

Article Type
Changed
Mon, 05/16/2022 - 12:32

THE DIAGNOSIS:

Cutaneous Metastatic Mesothelioma

Biopsies of the larger erythematous papules revealed an infiltrate of atypical tumor cells with mitoses (Figure 1) that were immunoreactive for calretinin (Figure 2) and lacked nuclear BRCA1 associated protein-1, BAP1, expression (not shown). The patient’s prior mesothelioma was re-reviewed, and the cutaneous tumor cells were similar to the primary mesothelioma. A diagnosis of cutaneous metastatic mesothelioma (CMM) was made.

FIGURE 1. A, A shave biopsy of the left chest revealed infiltration of the dermis by a proliferation of spindle and epithelioid cells (H&E, original magnification ×40). Reference bar indicates 500 μm. B, The tumor cells showed marked nuclear atypia, and several mitoses were seen with calretinin staining (original magnification ×40). Reference bar indicates 100 μm.

FIGURE 2. Immunohistochemistry showed tumor cells that were positive for calretinin (original magnification ×40). Reference bar indicates 500 μm

Mesothelioma is a rare neoplasm arising from the pleura, pericardium, peritoneum, and tunica vaginalis,1 with an estimated annual incidence of 2500 cases.2 The predominant risk factor for the development of pleural mesothelioma is asbestos exposure, which has been identified in up to 90% of cases. Mesothelioma can give rise to local and less frequently distant hematogenous metastases. Cutaneous involvement of mesothelioma is rare.3 More than 80% of CMM cases are attributed to seeding the skin at procedure sites or by direct infiltration of scars. Distant CMM is rare and typically presents as subcutaneous nodules.4 Few cases of inflammatory CMM have been published,1,4,5 with even fewer mimicking herpes zoster infection (HZI), as seen in our patient.

The most specific stain for mesothelioma is calretinin, which strongly and diffusely stains both the nucleus and cytoplasm. Other markers include Wilms tumor 1, cytokeratin 5/6, thrombomodulin, and HBME-1. Immunohistochemistry to detect the loss of BAP1 staining in the nucleus is important for differentiating between mesothelioma and mesothelial hyperplasia.3

Cutaneous metastases occur in 0.7% to 9% of patients with internal malignant disease. Most commonly, cutaneous metastases present as cutaneous nodules, though other reported inflammatory presentations include erysipeloides, generalized erythematous patches, telangiectasia, and zosteriform distributions.6 Zosteriform distributions are particularly rare and most commonly are due to breast carcinomas or lymphomas. The mechanism of zosteriform metastasis is unknown, but theories include tumoral spread along vessels, invasion of the thoracic perineural sheaths, localized spread of tumor cells from a surgical site, or a Koebner-like reaction at the site of an existing HZI. Regardless of primary tumor type or presentation, cutaneous metastasis is a poor prognostic sign, with survival rates varying based on primary tumor type.7

Other differential diagnoses include herpes zoster granulomatous dermatitis, radiation recall dermatitis, cutaneous Rosai-Dorfman disease, and zosteriform lichen planus, all of which have been reported after HZI.8-10 Herpes zoster granulomatous dermatitis typically presents weeks to years after acute HZI with erythematous to violaceous papules and plaques at the site of the prior HZI. A biopsy reveals interstitial granulomatous dermatitis and multinucleated giant cells.8 Radiation recall dermatitis is a cutaneous inflammatory reaction limited to regions of prior radiation exposure after the administration of a triggering medication. Radiation recall dermatitis can present days to many years after the completion of treatment.9 Although the eruption in our patient was at the site of prior radiation, the pathologic and clinical presentation was not consistent with radiation recall dermatitis. Cutaneous Rosai-Dorfman disease is a non-Langerhans cell histiocytosis that may present as either solitary or numerous papules, plaques, or nodules and has been reported to occur after HZI. Biopsy reveals a diffuse dermal histiocytic infiltration with plasma cells and lymphocytes. In contrast to metastatic disease, mitoses and nuclear atypia are rare in cutaneous RosaiDorfman disease.11 Lichen planus is an inflammatory disease of unknown etiology presenting as flat-topped, violaceous, pruritic papules12 that may present in a zosteriform pattern.13

Although it is uncommon, metastatic spread should be considered in patients with known malignancy presenting with zosteriform eruptions.2 Our patient remained on treatment with immunotherapy, as he was unable to undergo additional radiation and had failed multiple other lines of therapy. He died 3 months after presentation.

References
  1. Klebanov N, Reddy BY, Husain S, et al. Cutaneous presentation of mesothelioma with a sarcomatoid transformation. Am J Dermatopathol. 2018;40:378-382.
  2. Patel SC, Dowell JE. Modern management of malignant pleural mesothelioma. Lung Cancer (Auckl). 2016;7:63-72.
  3. Ward RE, Ali SA, Kuhar M. Epithelioid malignant mesothelioma metastatic to the skin: a case report and review of the literature. J Cutan Pathol. 2017;44:1057-1063.
  4. Prieto VG, Kenet BJ, Varghese M. Malignant mesothelioma metastatic to the skin, presenting as inflammatory carcinoma. Am J Dermatopathol. 1997;19:261-265.
  5. Gaudy-Marqueste C, Dales JP, Collet-Villette AM, et al. Cutaneous metastasis of pleural mesothelioma: two cases [in French]. Ann Dermatol Venereol. 2003;130:455-459.
  6. Chiang A, Salomon N, Gaikwad R, et al. A case of cutaneous metastasis mimicking herpes zoster rash. IDCases. 2018;12:167-168.
  7. Thomaidou E, Armon G, Klapholz L, et al. Zosteriform cutaneous metastases. Clin Exp Dermatol. 2018;43:734-736.
  8. Ferenczi K, Rosenberg AS, McCalmont TH, et al. Herpes zoster granulomatous dermatitis: histopathologic findings in a case series. J Cutan Pathol. 2015;42:739-745.
  9. Carrasco L, Pastor MA, Izquierdo MJ, et al. Drug eruption secondary to acyclovir with recall phenomenon in a dermatome previously affected by herpes zoster. Clin Exp Dermatol. 2002;27:132-134.
  10. Malviya N, Marzuka A, Maamed-Tayeb M, et al. Cutaneous involvement of pre-existing Rosai-Dorfman disease via post-herpetic isotopic response. J Cutan Pathol. 2016;43:1211-1214.
  11. Fang S, Chen AJ. Facial cutaneous Rosai-Dorfman disease: a case report and literature review. Exp Ther Med. 2015;9:1389-1392.
  12. Le Cleach L, Chosidow O. Clinical practice. lichen planus. N Engl J Med. 2012;366:723-732.
  13. Fink-Puches R, Hofmann-Wellenhof R, Smolle J. Zosteriform lichen planus. Dermatology. 1996;192:375-377.
Article PDF
Author and Disclosure Information

Ms. Batarseh is from the Albert Einstein College of Medicine, Bronx, New York. Dr. Quigley is from Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey.

The authors report no conflict of interest.

Correspondence: Paola Batarseh, BS, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461 (batarseh@mail.einstein.yu.edu).

Issue
Cutis - 108(6)
Publications
Topics
Page Number
E14-E16
Sections
Author and Disclosure Information

Ms. Batarseh is from the Albert Einstein College of Medicine, Bronx, New York. Dr. Quigley is from Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey.

The authors report no conflict of interest.

Correspondence: Paola Batarseh, BS, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461 (batarseh@mail.einstein.yu.edu).

Author and Disclosure Information

Ms. Batarseh is from the Albert Einstein College of Medicine, Bronx, New York. Dr. Quigley is from Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey.

The authors report no conflict of interest.

Correspondence: Paola Batarseh, BS, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461 (batarseh@mail.einstein.yu.edu).

Article PDF
Article PDF

THE DIAGNOSIS:

Cutaneous Metastatic Mesothelioma

Biopsies of the larger erythematous papules revealed an infiltrate of atypical tumor cells with mitoses (Figure 1) that were immunoreactive for calretinin (Figure 2) and lacked nuclear BRCA1 associated protein-1, BAP1, expression (not shown). The patient’s prior mesothelioma was re-reviewed, and the cutaneous tumor cells were similar to the primary mesothelioma. A diagnosis of cutaneous metastatic mesothelioma (CMM) was made.

FIGURE 1. A, A shave biopsy of the left chest revealed infiltration of the dermis by a proliferation of spindle and epithelioid cells (H&E, original magnification ×40). Reference bar indicates 500 μm. B, The tumor cells showed marked nuclear atypia, and several mitoses were seen with calretinin staining (original magnification ×40). Reference bar indicates 100 μm.

FIGURE 2. Immunohistochemistry showed tumor cells that were positive for calretinin (original magnification ×40). Reference bar indicates 500 μm

Mesothelioma is a rare neoplasm arising from the pleura, pericardium, peritoneum, and tunica vaginalis,1 with an estimated annual incidence of 2500 cases.2 The predominant risk factor for the development of pleural mesothelioma is asbestos exposure, which has been identified in up to 90% of cases. Mesothelioma can give rise to local and less frequently distant hematogenous metastases. Cutaneous involvement of mesothelioma is rare.3 More than 80% of CMM cases are attributed to seeding the skin at procedure sites or by direct infiltration of scars. Distant CMM is rare and typically presents as subcutaneous nodules.4 Few cases of inflammatory CMM have been published,1,4,5 with even fewer mimicking herpes zoster infection (HZI), as seen in our patient.

The most specific stain for mesothelioma is calretinin, which strongly and diffusely stains both the nucleus and cytoplasm. Other markers include Wilms tumor 1, cytokeratin 5/6, thrombomodulin, and HBME-1. Immunohistochemistry to detect the loss of BAP1 staining in the nucleus is important for differentiating between mesothelioma and mesothelial hyperplasia.3

Cutaneous metastases occur in 0.7% to 9% of patients with internal malignant disease. Most commonly, cutaneous metastases present as cutaneous nodules, though other reported inflammatory presentations include erysipeloides, generalized erythematous patches, telangiectasia, and zosteriform distributions.6 Zosteriform distributions are particularly rare and most commonly are due to breast carcinomas or lymphomas. The mechanism of zosteriform metastasis is unknown, but theories include tumoral spread along vessels, invasion of the thoracic perineural sheaths, localized spread of tumor cells from a surgical site, or a Koebner-like reaction at the site of an existing HZI. Regardless of primary tumor type or presentation, cutaneous metastasis is a poor prognostic sign, with survival rates varying based on primary tumor type.7

Other differential diagnoses include herpes zoster granulomatous dermatitis, radiation recall dermatitis, cutaneous Rosai-Dorfman disease, and zosteriform lichen planus, all of which have been reported after HZI.8-10 Herpes zoster granulomatous dermatitis typically presents weeks to years after acute HZI with erythematous to violaceous papules and plaques at the site of the prior HZI. A biopsy reveals interstitial granulomatous dermatitis and multinucleated giant cells.8 Radiation recall dermatitis is a cutaneous inflammatory reaction limited to regions of prior radiation exposure after the administration of a triggering medication. Radiation recall dermatitis can present days to many years after the completion of treatment.9 Although the eruption in our patient was at the site of prior radiation, the pathologic and clinical presentation was not consistent with radiation recall dermatitis. Cutaneous Rosai-Dorfman disease is a non-Langerhans cell histiocytosis that may present as either solitary or numerous papules, plaques, or nodules and has been reported to occur after HZI. Biopsy reveals a diffuse dermal histiocytic infiltration with plasma cells and lymphocytes. In contrast to metastatic disease, mitoses and nuclear atypia are rare in cutaneous RosaiDorfman disease.11 Lichen planus is an inflammatory disease of unknown etiology presenting as flat-topped, violaceous, pruritic papules12 that may present in a zosteriform pattern.13

Although it is uncommon, metastatic spread should be considered in patients with known malignancy presenting with zosteriform eruptions.2 Our patient remained on treatment with immunotherapy, as he was unable to undergo additional radiation and had failed multiple other lines of therapy. He died 3 months after presentation.

THE DIAGNOSIS:

Cutaneous Metastatic Mesothelioma

Biopsies of the larger erythematous papules revealed an infiltrate of atypical tumor cells with mitoses (Figure 1) that were immunoreactive for calretinin (Figure 2) and lacked nuclear BRCA1 associated protein-1, BAP1, expression (not shown). The patient’s prior mesothelioma was re-reviewed, and the cutaneous tumor cells were similar to the primary mesothelioma. A diagnosis of cutaneous metastatic mesothelioma (CMM) was made.

FIGURE 1. A, A shave biopsy of the left chest revealed infiltration of the dermis by a proliferation of spindle and epithelioid cells (H&E, original magnification ×40). Reference bar indicates 500 μm. B, The tumor cells showed marked nuclear atypia, and several mitoses were seen with calretinin staining (original magnification ×40). Reference bar indicates 100 μm.

FIGURE 2. Immunohistochemistry showed tumor cells that were positive for calretinin (original magnification ×40). Reference bar indicates 500 μm

Mesothelioma is a rare neoplasm arising from the pleura, pericardium, peritoneum, and tunica vaginalis,1 with an estimated annual incidence of 2500 cases.2 The predominant risk factor for the development of pleural mesothelioma is asbestos exposure, which has been identified in up to 90% of cases. Mesothelioma can give rise to local and less frequently distant hematogenous metastases. Cutaneous involvement of mesothelioma is rare.3 More than 80% of CMM cases are attributed to seeding the skin at procedure sites or by direct infiltration of scars. Distant CMM is rare and typically presents as subcutaneous nodules.4 Few cases of inflammatory CMM have been published,1,4,5 with even fewer mimicking herpes zoster infection (HZI), as seen in our patient.

The most specific stain for mesothelioma is calretinin, which strongly and diffusely stains both the nucleus and cytoplasm. Other markers include Wilms tumor 1, cytokeratin 5/6, thrombomodulin, and HBME-1. Immunohistochemistry to detect the loss of BAP1 staining in the nucleus is important for differentiating between mesothelioma and mesothelial hyperplasia.3

Cutaneous metastases occur in 0.7% to 9% of patients with internal malignant disease. Most commonly, cutaneous metastases present as cutaneous nodules, though other reported inflammatory presentations include erysipeloides, generalized erythematous patches, telangiectasia, and zosteriform distributions.6 Zosteriform distributions are particularly rare and most commonly are due to breast carcinomas or lymphomas. The mechanism of zosteriform metastasis is unknown, but theories include tumoral spread along vessels, invasion of the thoracic perineural sheaths, localized spread of tumor cells from a surgical site, or a Koebner-like reaction at the site of an existing HZI. Regardless of primary tumor type or presentation, cutaneous metastasis is a poor prognostic sign, with survival rates varying based on primary tumor type.7

Other differential diagnoses include herpes zoster granulomatous dermatitis, radiation recall dermatitis, cutaneous Rosai-Dorfman disease, and zosteriform lichen planus, all of which have been reported after HZI.8-10 Herpes zoster granulomatous dermatitis typically presents weeks to years after acute HZI with erythematous to violaceous papules and plaques at the site of the prior HZI. A biopsy reveals interstitial granulomatous dermatitis and multinucleated giant cells.8 Radiation recall dermatitis is a cutaneous inflammatory reaction limited to regions of prior radiation exposure after the administration of a triggering medication. Radiation recall dermatitis can present days to many years after the completion of treatment.9 Although the eruption in our patient was at the site of prior radiation, the pathologic and clinical presentation was not consistent with radiation recall dermatitis. Cutaneous Rosai-Dorfman disease is a non-Langerhans cell histiocytosis that may present as either solitary or numerous papules, plaques, or nodules and has been reported to occur after HZI. Biopsy reveals a diffuse dermal histiocytic infiltration with plasma cells and lymphocytes. In contrast to metastatic disease, mitoses and nuclear atypia are rare in cutaneous RosaiDorfman disease.11 Lichen planus is an inflammatory disease of unknown etiology presenting as flat-topped, violaceous, pruritic papules12 that may present in a zosteriform pattern.13

Although it is uncommon, metastatic spread should be considered in patients with known malignancy presenting with zosteriform eruptions.2 Our patient remained on treatment with immunotherapy, as he was unable to undergo additional radiation and had failed multiple other lines of therapy. He died 3 months after presentation.

References
  1. Klebanov N, Reddy BY, Husain S, et al. Cutaneous presentation of mesothelioma with a sarcomatoid transformation. Am J Dermatopathol. 2018;40:378-382.
  2. Patel SC, Dowell JE. Modern management of malignant pleural mesothelioma. Lung Cancer (Auckl). 2016;7:63-72.
  3. Ward RE, Ali SA, Kuhar M. Epithelioid malignant mesothelioma metastatic to the skin: a case report and review of the literature. J Cutan Pathol. 2017;44:1057-1063.
  4. Prieto VG, Kenet BJ, Varghese M. Malignant mesothelioma metastatic to the skin, presenting as inflammatory carcinoma. Am J Dermatopathol. 1997;19:261-265.
  5. Gaudy-Marqueste C, Dales JP, Collet-Villette AM, et al. Cutaneous metastasis of pleural mesothelioma: two cases [in French]. Ann Dermatol Venereol. 2003;130:455-459.
  6. Chiang A, Salomon N, Gaikwad R, et al. A case of cutaneous metastasis mimicking herpes zoster rash. IDCases. 2018;12:167-168.
  7. Thomaidou E, Armon G, Klapholz L, et al. Zosteriform cutaneous metastases. Clin Exp Dermatol. 2018;43:734-736.
  8. Ferenczi K, Rosenberg AS, McCalmont TH, et al. Herpes zoster granulomatous dermatitis: histopathologic findings in a case series. J Cutan Pathol. 2015;42:739-745.
  9. Carrasco L, Pastor MA, Izquierdo MJ, et al. Drug eruption secondary to acyclovir with recall phenomenon in a dermatome previously affected by herpes zoster. Clin Exp Dermatol. 2002;27:132-134.
  10. Malviya N, Marzuka A, Maamed-Tayeb M, et al. Cutaneous involvement of pre-existing Rosai-Dorfman disease via post-herpetic isotopic response. J Cutan Pathol. 2016;43:1211-1214.
  11. Fang S, Chen AJ. Facial cutaneous Rosai-Dorfman disease: a case report and literature review. Exp Ther Med. 2015;9:1389-1392.
  12. Le Cleach L, Chosidow O. Clinical practice. lichen planus. N Engl J Med. 2012;366:723-732.
  13. Fink-Puches R, Hofmann-Wellenhof R, Smolle J. Zosteriform lichen planus. Dermatology. 1996;192:375-377.
References
  1. Klebanov N, Reddy BY, Husain S, et al. Cutaneous presentation of mesothelioma with a sarcomatoid transformation. Am J Dermatopathol. 2018;40:378-382.
  2. Patel SC, Dowell JE. Modern management of malignant pleural mesothelioma. Lung Cancer (Auckl). 2016;7:63-72.
  3. Ward RE, Ali SA, Kuhar M. Epithelioid malignant mesothelioma metastatic to the skin: a case report and review of the literature. J Cutan Pathol. 2017;44:1057-1063.
  4. Prieto VG, Kenet BJ, Varghese M. Malignant mesothelioma metastatic to the skin, presenting as inflammatory carcinoma. Am J Dermatopathol. 1997;19:261-265.
  5. Gaudy-Marqueste C, Dales JP, Collet-Villette AM, et al. Cutaneous metastasis of pleural mesothelioma: two cases [in French]. Ann Dermatol Venereol. 2003;130:455-459.
  6. Chiang A, Salomon N, Gaikwad R, et al. A case of cutaneous metastasis mimicking herpes zoster rash. IDCases. 2018;12:167-168.
  7. Thomaidou E, Armon G, Klapholz L, et al. Zosteriform cutaneous metastases. Clin Exp Dermatol. 2018;43:734-736.
  8. Ferenczi K, Rosenberg AS, McCalmont TH, et al. Herpes zoster granulomatous dermatitis: histopathologic findings in a case series. J Cutan Pathol. 2015;42:739-745.
  9. Carrasco L, Pastor MA, Izquierdo MJ, et al. Drug eruption secondary to acyclovir with recall phenomenon in a dermatome previously affected by herpes zoster. Clin Exp Dermatol. 2002;27:132-134.
  10. Malviya N, Marzuka A, Maamed-Tayeb M, et al. Cutaneous involvement of pre-existing Rosai-Dorfman disease via post-herpetic isotopic response. J Cutan Pathol. 2016;43:1211-1214.
  11. Fang S, Chen AJ. Facial cutaneous Rosai-Dorfman disease: a case report and literature review. Exp Ther Med. 2015;9:1389-1392.
  12. Le Cleach L, Chosidow O. Clinical practice. lichen planus. N Engl J Med. 2012;366:723-732.
  13. Fink-Puches R, Hofmann-Wellenhof R, Smolle J. Zosteriform lichen planus. Dermatology. 1996;192:375-377.
Issue
Cutis - 108(6)
Issue
Cutis - 108(6)
Page Number
E14-E16
Page Number
E14-E16
Publications
Publications
Topics
Article Type
Sections
Questionnaire Body

A 50-year-old man presented with erythematous macules and papules with a dermatomal distribution on the left thoracic region with associated pain of 3 weeks’ duration. The lesions persisted after treatment for herpes zoster. His medical history was notable for mesothelioma that was diagnosed 6 years prior and was treated with ipilimumab and nivolumab following multiple lines of chemotherapy and investigational agents, left thoracotomy, extrapleural pneumonectomy, diaphragmatic reconstruction, and left chest radiation. His medical history also included Hodgkin lymphoma diagnosed 36 years prior that was treated with an appendectomy, splenectomy, systemic chemotherapy, and radiation. Three weeks prior to the current presentation, he was treated by oncology with valacyclovir 1 g 3 times daily for 7 days for presumed herpes zoster without improvement. Physical examination revealed the absence of vesicles, as well as firm, 1- to 6-mm, erythematous papules and plaques, including a few outside of the most affected dermatomes.

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Mon, 12/20/2021 - 18:00
Un-Gate On Date
Mon, 12/20/2021 - 18:00
Use ProPublica
CFC Schedule Remove Status
Mon, 12/20/2021 - 18:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Blastomycosislike Pyoderma: Verrucous Hyperpigmented Plaques on the Pretibial Shins

Article Type
Changed
Mon, 12/20/2021 - 15:32

 

To the Editor:

Blastomycosislike pyoderma (BLP), also commonly referred to as pyoderma vegetans, is a rare cutaneous bacterial infection that often mimics other fungal, inflammatory, or neoplastic disorders.1 It is characterized by a collection of neutrophilic abscesses with pseudoepitheliomatous hyperplasia that coalesce into crusted plaques.

A 15-year-old adolescent girl with a history of type 1 diabetes mellitus was admitted for diabetic ketoacidosis. The patient presented with bilateral pretibial lesions of 6 years’ duration that developed after swimming in a pool following reported trauma to the site. These pruritic plaques had grown slowly and were occasionally tender. Of note, with episodes of hyperglycemia, the lesions developed purulent drainage.

Upon admission to the hospital and subsequent dermatology consultation, physical examination revealed the right pretibial shin had a 15×5-cm, gray-brown, hyperpigmented, verrucous, tender plaque with purulent drainage and overlying crust (Figure 1). The left pretibial shin had a similar smaller lesion (Figure 2). Laboratory test results were notable for a white blood cell count of 41.84 cells/µL (reference range, 3.8–10.5 cells/µL), blood glucose level of 586 mg/dL (reference range, 70–99 mg/dL), and hemoglobin A1c of 11.7% (reference range, 4.0%–5.6%). A biopsy specimen from the right pretibial shin was stained with hematoxylin and eosin for dermatopathologic evaluation as well as sent for tissue culture. Tissue and wound cultures grew Staphylococcus aureus and group B Streptococcus with no fungal or acid-fast bacilli growth.

FIGURE 1. Right pretibial shin with a verrucous hyperpigmented plaque with purulent drainage measuring 15×5 cm.

FIGURE 2. Left pretibial plateau with a similar verrucous hyperpigmented plaque.


Blood cultures were negative for bacteria. Results of radiographic imaging were negative for osteomyelitis. Biopsy specimens from the right pretibial plaque showed a markedly inflamed, ruptured follicular unit with a dense dermal lympho-neutrophilic infiltrate and overlying pseudoepitheliomatous hyperplasia (Figure 3). Periodic acid–Schiff, Gomori methenamine-silver, acid-fast bacilli, and Giemsa stains were negative for organisms. No granules consistent with a Splendore-Hoeppli phenomenon were observed. These observations were consistent with a diagnosis of BLP.

FIGURE 3. Biopsy specimens from the right pretibial plateau showed a dense dermal lympho-neutrophilic infiltrate and overlying pseudoepitheliomatous hyperplasia (H&E, original magnification ×25). No granules consistent with a Splendore-Hoeppli phenomenon were observed.

Blastomycosislike pyoderma is a rare cutaneous bacterial infection that often mimics other fungal, inflammatory, or neoplastic disorders.1 Pediatric cases also are uncommon. Blastomycosislike pyoderma most commonly is caused by infection with S aureus or group A streptococci, but several other organisms have been implicated.2 Clinically, BLP is similar to cutaneous botryomycosis, as both are caused by similar organisms.3 However, while BLP is limited to the skin, botryomycosis may involve visceral organs.

Blastomycosislike pyoderma typically presents as verrucous, hyperkeratotic, purulent plaques with raised borders. It most commonly occurs on the face, scalp, axillae, trunk, and distal extremities. Predisposing factors include immunosuppressed states such as poor nutrition, HIV, malignancy, alcoholism, and diabetes mellitus.3,4 Hyperglycemia is thought to suppress helper T cell (TH1)–dependent immunity, which may explain why our patient’s lesions worsened with hyperglycemic episodes.5Histopathology revealed pseudoepitheliomatous hyperplasia with neutrophilic abscesses.1 The distinguishing feature between botryomycosis and BLP is the development of grains known as the Splendore-Hoeppli phenomenon in botryomycosis.6 The grains are eosinophilic and contain the causative infectious agent. The presence of these grains is consistent with botryomycosis but is not pathognomonic, as it also can be found in several bacterial, fungal, and parasitic infections.3,6

The differential diagnosis of BLP includes atypical mycobacterial infection, pyoderma gangrenosum, fungal infection, and tuberculosis verrucosa cutis.7

Although BLP is caused by bacteria, response to systemic antibiotics is variable. Other treatment modalities include dapsone, systemic and intralesional corticosteroids, retinoids, debridement, CO2 laser, and excision.6,8 Lesions typically start out localized, but it is not uncommon for them to spread to distal or vulnerable tissue, such as sites of trauma or inflammation. Our patient was started on oral trimethoprim-sulfamethoxazole and showed improvement, but she worsened with subsequent hyperglycemic episodes when antibiotics were discontinued.

 

 

References

1. Adis¸en E, Tezel F, Gürer MA. Pyoderma vegetans: a case for discussion. Acta Derm Venereol. 2009;89:186-188.

2. Scuderi S, O’Brien B, Robertson I, et al. Heterogeneity of blastomycosis-like pyoderma: a selection of cases from the last 35 years. Australas J Dermatol. 2017;58:139-141.

3. Marschalko, M. Pyoderma vegetans: report on a case and review of data on pyoderma vegetans and cutaneous botryomycosis. Acta Dermatovenerol Alp Pannonica Adriat. 1995;4:55-59.

4. Cerullo L, Zussman J, Young L. An unusual presentation of blastomycosislike pyoderma (pyoderma vegetans) and a review of the literature. Cutis. 2009;84:201-204.

5. Tanaka Y. Immunosuppressive mechanisms in diabetes mellitus [in Japanese]. Nihon Rinsho. 2008;66:2233-2237.

6. Hussein MR. Mucocutaneous Splendore-Hoeppli phenomenon. J Cutan Pathol. 2008;35:979-988.

7. Lee YS, Jung SW, Sim HS, et al. Blastomycosis-like pyoderma with good response to acitretin. Ann Dermatol. 2011;23:365-368.

8. Kobraei KB, Wesson SK. Blastomycosis-like pyoderma: response to systemic retinoid therapy. Int J Dermatol. 2010;49:1336-1338.

Article PDF
Author and Disclosure Information

 

Dr. Cotter is from the Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison. Dr. Cheng is from the Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles. Dr. Marathe is from Children’s National Health System, Washington, DC.

The authors report no conflict of interest.

Correspondence: Lisa Cotter, MD, 1 S Park St, 7th Floor, Madison, WI 53715 (Lisa.keller17@gmail.com).
 

Issue
Cutis - 108(6)
Publications
Topics
Page Number
E12-E13
Sections
Author and Disclosure Information

 

Dr. Cotter is from the Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison. Dr. Cheng is from the Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles. Dr. Marathe is from Children’s National Health System, Washington, DC.

The authors report no conflict of interest.

Correspondence: Lisa Cotter, MD, 1 S Park St, 7th Floor, Madison, WI 53715 (Lisa.keller17@gmail.com).
 

Author and Disclosure Information

 

Dr. Cotter is from the Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison. Dr. Cheng is from the Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles. Dr. Marathe is from Children’s National Health System, Washington, DC.

The authors report no conflict of interest.

Correspondence: Lisa Cotter, MD, 1 S Park St, 7th Floor, Madison, WI 53715 (Lisa.keller17@gmail.com).
 

Article PDF
Article PDF

 

To the Editor:

Blastomycosislike pyoderma (BLP), also commonly referred to as pyoderma vegetans, is a rare cutaneous bacterial infection that often mimics other fungal, inflammatory, or neoplastic disorders.1 It is characterized by a collection of neutrophilic abscesses with pseudoepitheliomatous hyperplasia that coalesce into crusted plaques.

A 15-year-old adolescent girl with a history of type 1 diabetes mellitus was admitted for diabetic ketoacidosis. The patient presented with bilateral pretibial lesions of 6 years’ duration that developed after swimming in a pool following reported trauma to the site. These pruritic plaques had grown slowly and were occasionally tender. Of note, with episodes of hyperglycemia, the lesions developed purulent drainage.

Upon admission to the hospital and subsequent dermatology consultation, physical examination revealed the right pretibial shin had a 15×5-cm, gray-brown, hyperpigmented, verrucous, tender plaque with purulent drainage and overlying crust (Figure 1). The left pretibial shin had a similar smaller lesion (Figure 2). Laboratory test results were notable for a white blood cell count of 41.84 cells/µL (reference range, 3.8–10.5 cells/µL), blood glucose level of 586 mg/dL (reference range, 70–99 mg/dL), and hemoglobin A1c of 11.7% (reference range, 4.0%–5.6%). A biopsy specimen from the right pretibial shin was stained with hematoxylin and eosin for dermatopathologic evaluation as well as sent for tissue culture. Tissue and wound cultures grew Staphylococcus aureus and group B Streptococcus with no fungal or acid-fast bacilli growth.

FIGURE 1. Right pretibial shin with a verrucous hyperpigmented plaque with purulent drainage measuring 15×5 cm.

FIGURE 2. Left pretibial plateau with a similar verrucous hyperpigmented plaque.


Blood cultures were negative for bacteria. Results of radiographic imaging were negative for osteomyelitis. Biopsy specimens from the right pretibial plaque showed a markedly inflamed, ruptured follicular unit with a dense dermal lympho-neutrophilic infiltrate and overlying pseudoepitheliomatous hyperplasia (Figure 3). Periodic acid–Schiff, Gomori methenamine-silver, acid-fast bacilli, and Giemsa stains were negative for organisms. No granules consistent with a Splendore-Hoeppli phenomenon were observed. These observations were consistent with a diagnosis of BLP.

FIGURE 3. Biopsy specimens from the right pretibial plateau showed a dense dermal lympho-neutrophilic infiltrate and overlying pseudoepitheliomatous hyperplasia (H&E, original magnification ×25). No granules consistent with a Splendore-Hoeppli phenomenon were observed.

Blastomycosislike pyoderma is a rare cutaneous bacterial infection that often mimics other fungal, inflammatory, or neoplastic disorders.1 Pediatric cases also are uncommon. Blastomycosislike pyoderma most commonly is caused by infection with S aureus or group A streptococci, but several other organisms have been implicated.2 Clinically, BLP is similar to cutaneous botryomycosis, as both are caused by similar organisms.3 However, while BLP is limited to the skin, botryomycosis may involve visceral organs.

Blastomycosislike pyoderma typically presents as verrucous, hyperkeratotic, purulent plaques with raised borders. It most commonly occurs on the face, scalp, axillae, trunk, and distal extremities. Predisposing factors include immunosuppressed states such as poor nutrition, HIV, malignancy, alcoholism, and diabetes mellitus.3,4 Hyperglycemia is thought to suppress helper T cell (TH1)–dependent immunity, which may explain why our patient’s lesions worsened with hyperglycemic episodes.5Histopathology revealed pseudoepitheliomatous hyperplasia with neutrophilic abscesses.1 The distinguishing feature between botryomycosis and BLP is the development of grains known as the Splendore-Hoeppli phenomenon in botryomycosis.6 The grains are eosinophilic and contain the causative infectious agent. The presence of these grains is consistent with botryomycosis but is not pathognomonic, as it also can be found in several bacterial, fungal, and parasitic infections.3,6

The differential diagnosis of BLP includes atypical mycobacterial infection, pyoderma gangrenosum, fungal infection, and tuberculosis verrucosa cutis.7

Although BLP is caused by bacteria, response to systemic antibiotics is variable. Other treatment modalities include dapsone, systemic and intralesional corticosteroids, retinoids, debridement, CO2 laser, and excision.6,8 Lesions typically start out localized, but it is not uncommon for them to spread to distal or vulnerable tissue, such as sites of trauma or inflammation. Our patient was started on oral trimethoprim-sulfamethoxazole and showed improvement, but she worsened with subsequent hyperglycemic episodes when antibiotics were discontinued.

 

 

 

To the Editor:

Blastomycosislike pyoderma (BLP), also commonly referred to as pyoderma vegetans, is a rare cutaneous bacterial infection that often mimics other fungal, inflammatory, or neoplastic disorders.1 It is characterized by a collection of neutrophilic abscesses with pseudoepitheliomatous hyperplasia that coalesce into crusted plaques.

A 15-year-old adolescent girl with a history of type 1 diabetes mellitus was admitted for diabetic ketoacidosis. The patient presented with bilateral pretibial lesions of 6 years’ duration that developed after swimming in a pool following reported trauma to the site. These pruritic plaques had grown slowly and were occasionally tender. Of note, with episodes of hyperglycemia, the lesions developed purulent drainage.

Upon admission to the hospital and subsequent dermatology consultation, physical examination revealed the right pretibial shin had a 15×5-cm, gray-brown, hyperpigmented, verrucous, tender plaque with purulent drainage and overlying crust (Figure 1). The left pretibial shin had a similar smaller lesion (Figure 2). Laboratory test results were notable for a white blood cell count of 41.84 cells/µL (reference range, 3.8–10.5 cells/µL), blood glucose level of 586 mg/dL (reference range, 70–99 mg/dL), and hemoglobin A1c of 11.7% (reference range, 4.0%–5.6%). A biopsy specimen from the right pretibial shin was stained with hematoxylin and eosin for dermatopathologic evaluation as well as sent for tissue culture. Tissue and wound cultures grew Staphylococcus aureus and group B Streptococcus with no fungal or acid-fast bacilli growth.

FIGURE 1. Right pretibial shin with a verrucous hyperpigmented plaque with purulent drainage measuring 15×5 cm.

FIGURE 2. Left pretibial plateau with a similar verrucous hyperpigmented plaque.


Blood cultures were negative for bacteria. Results of radiographic imaging were negative for osteomyelitis. Biopsy specimens from the right pretibial plaque showed a markedly inflamed, ruptured follicular unit with a dense dermal lympho-neutrophilic infiltrate and overlying pseudoepitheliomatous hyperplasia (Figure 3). Periodic acid–Schiff, Gomori methenamine-silver, acid-fast bacilli, and Giemsa stains were negative for organisms. No granules consistent with a Splendore-Hoeppli phenomenon were observed. These observations were consistent with a diagnosis of BLP.

FIGURE 3. Biopsy specimens from the right pretibial plateau showed a dense dermal lympho-neutrophilic infiltrate and overlying pseudoepitheliomatous hyperplasia (H&E, original magnification ×25). No granules consistent with a Splendore-Hoeppli phenomenon were observed.

Blastomycosislike pyoderma is a rare cutaneous bacterial infection that often mimics other fungal, inflammatory, or neoplastic disorders.1 Pediatric cases also are uncommon. Blastomycosislike pyoderma most commonly is caused by infection with S aureus or group A streptococci, but several other organisms have been implicated.2 Clinically, BLP is similar to cutaneous botryomycosis, as both are caused by similar organisms.3 However, while BLP is limited to the skin, botryomycosis may involve visceral organs.

Blastomycosislike pyoderma typically presents as verrucous, hyperkeratotic, purulent plaques with raised borders. It most commonly occurs on the face, scalp, axillae, trunk, and distal extremities. Predisposing factors include immunosuppressed states such as poor nutrition, HIV, malignancy, alcoholism, and diabetes mellitus.3,4 Hyperglycemia is thought to suppress helper T cell (TH1)–dependent immunity, which may explain why our patient’s lesions worsened with hyperglycemic episodes.5Histopathology revealed pseudoepitheliomatous hyperplasia with neutrophilic abscesses.1 The distinguishing feature between botryomycosis and BLP is the development of grains known as the Splendore-Hoeppli phenomenon in botryomycosis.6 The grains are eosinophilic and contain the causative infectious agent. The presence of these grains is consistent with botryomycosis but is not pathognomonic, as it also can be found in several bacterial, fungal, and parasitic infections.3,6

The differential diagnosis of BLP includes atypical mycobacterial infection, pyoderma gangrenosum, fungal infection, and tuberculosis verrucosa cutis.7

Although BLP is caused by bacteria, response to systemic antibiotics is variable. Other treatment modalities include dapsone, systemic and intralesional corticosteroids, retinoids, debridement, CO2 laser, and excision.6,8 Lesions typically start out localized, but it is not uncommon for them to spread to distal or vulnerable tissue, such as sites of trauma or inflammation. Our patient was started on oral trimethoprim-sulfamethoxazole and showed improvement, but she worsened with subsequent hyperglycemic episodes when antibiotics were discontinued.

 

 

References

1. Adis¸en E, Tezel F, Gürer MA. Pyoderma vegetans: a case for discussion. Acta Derm Venereol. 2009;89:186-188.

2. Scuderi S, O’Brien B, Robertson I, et al. Heterogeneity of blastomycosis-like pyoderma: a selection of cases from the last 35 years. Australas J Dermatol. 2017;58:139-141.

3. Marschalko, M. Pyoderma vegetans: report on a case and review of data on pyoderma vegetans and cutaneous botryomycosis. Acta Dermatovenerol Alp Pannonica Adriat. 1995;4:55-59.

4. Cerullo L, Zussman J, Young L. An unusual presentation of blastomycosislike pyoderma (pyoderma vegetans) and a review of the literature. Cutis. 2009;84:201-204.

5. Tanaka Y. Immunosuppressive mechanisms in diabetes mellitus [in Japanese]. Nihon Rinsho. 2008;66:2233-2237.

6. Hussein MR. Mucocutaneous Splendore-Hoeppli phenomenon. J Cutan Pathol. 2008;35:979-988.

7. Lee YS, Jung SW, Sim HS, et al. Blastomycosis-like pyoderma with good response to acitretin. Ann Dermatol. 2011;23:365-368.

8. Kobraei KB, Wesson SK. Blastomycosis-like pyoderma: response to systemic retinoid therapy. Int J Dermatol. 2010;49:1336-1338.

References

1. Adis¸en E, Tezel F, Gürer MA. Pyoderma vegetans: a case for discussion. Acta Derm Venereol. 2009;89:186-188.

2. Scuderi S, O’Brien B, Robertson I, et al. Heterogeneity of blastomycosis-like pyoderma: a selection of cases from the last 35 years. Australas J Dermatol. 2017;58:139-141.

3. Marschalko, M. Pyoderma vegetans: report on a case and review of data on pyoderma vegetans and cutaneous botryomycosis. Acta Dermatovenerol Alp Pannonica Adriat. 1995;4:55-59.

4. Cerullo L, Zussman J, Young L. An unusual presentation of blastomycosislike pyoderma (pyoderma vegetans) and a review of the literature. Cutis. 2009;84:201-204.

5. Tanaka Y. Immunosuppressive mechanisms in diabetes mellitus [in Japanese]. Nihon Rinsho. 2008;66:2233-2237.

6. Hussein MR. Mucocutaneous Splendore-Hoeppli phenomenon. J Cutan Pathol. 2008;35:979-988.

7. Lee YS, Jung SW, Sim HS, et al. Blastomycosis-like pyoderma with good response to acitretin. Ann Dermatol. 2011;23:365-368.

8. Kobraei KB, Wesson SK. Blastomycosis-like pyoderma: response to systemic retinoid therapy. Int J Dermatol. 2010;49:1336-1338.

Issue
Cutis - 108(6)
Issue
Cutis - 108(6)
Page Number
E12-E13
Page Number
E12-E13
Publications
Publications
Topics
Article Type
Sections
Inside the Article

 

Practice Points

  • Blastomycosislike pyoderma is a rare condition secondary to bacterial infection, but as the name suggests, it also can resemble cutaneous blastomycosis.
  • Blastomycosislike pyoderma most commonly occurs in immunocompromised patients.
  • The most common histologic findings include suppurative and neutrophilic inflammation with pseudoepitheliomatous hyperplasia.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap in a Pregnant Patient

Article Type
Changed
Tue, 12/21/2021 - 09:36

 

To the Editor:

A 34-year-old pregnant woman at 5 weeks’ gestation was transferred to dermatology from an outside hospital with a full-body rash. Three days after noting a fever and generalized body aches, she developed a painful rash on the legs that had gradually spread to the arms, trunk, and face. Symptoms of eyelid pruritus and edema initially were improved with intravenous (IV) steroids at an emergency department visit, but they started to flare soon thereafter with worsening mucosal involvement and dysphagia. After a second visit to the emergency department and repeat treatment with IV steroids, she was transferred to our institution for a higher level of care.

The patient denied taking any new medications in the 2 months prior to the onset of the rash. Her medication history only consisted of over-the-counter prenatal vitamins, a single use of over-the-counter migraine medication (containing acetaminophen, aspirin, and caffeine as active ingredients), and a possible use of ibuprofen or acetaminophen separately. She reported ocular discomfort and blurriness, dysphagia, dysuria, and vaginal discomfort. Physical examination revealed dusky red to violaceous macules and patches that involved approximately 65% of the body surface area (BSA), with bullae involving approximately 10% BSA. The face was diffusely red and edematous with crusted erosions and scattered bullae on the cheeks. Mucosal involvement was notable for injected conjunctivae and erosions present on the upper hard palate of the mouth and lips (Figure, A). Erythematous macules with dusky centers coalescing into patches with overlying vesicles and bullae were scattered on the arms (Figure, B), hands, trunk (Figure, C), and legs. The Nikolsky sign was positive. The vulva was swollen and covered with erythematous macules with dusky centers.

Stevens-Johnson syndrome/toxic epidermal necrolysis in a pregnant woman. A, Erosions of the mouth and lips. B, Erythematous papules and bullae scattered on the arm. C, Confluent papules with dusky centers coalescing into plaques on the back.

A biopsy from the upper back revealed a vacuolar interface with subepidermal bullae and confluent keratinocyte necrosis with many CD8+ cells and scattered granzyme B. Given these results in conjunction with the clinical findings, a diagnosis of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) overlap was made. In addition to providing supportive care, the patient was started on a 4-day course of IV immunoglobulin (IVIG)(3g/kg total) and prednisone 60 mg daily, tapered over several weeks with a good clinical response. At outpatient follow-up she was found to have postinflammatory hypopigmentation on the face, trunk, and extremities, as well as tear duct scarring, but she had no vulvovaginal scarring or stenosis. She was progressing well in her pregnancy with no serious complications for 4 months after admission, at which point she was lost to follow-up.

Stevens-Johnson syndrome and TEN represent a spectrum of severe mucocutaneous reactions with high morbidity and mortality. Medications are the leading trigger, followed by infection. The most common inciting medications include antibacterial sulfonamides, antiepileptics such as carbamazepine and lamotrigine, nonsteroidal anti-inflammatory drugs, nevirapine, and allopurinol. The onset of symptoms from 1 to 4 weeks combined with characteristic morphologic features helps distinguish SJS/TEN from other drug eruptions. The initial presentation classically consists of a flulike prodrome followed by mucocutaneous eruption. Skin lesions often present as a diffuse erythema or ill-defined, coalescing, erythematous macules with purpuric centers that may evolve into vesicles and bullae with sloughing of the skin. Histopathology reveals full-thickness epidermal necrosis with detachment.1

Erythema multiforme and Mycoplasma-induced rash and mucositis (MIRM) are high on the differential diagnosis. Distinguishing features of erythema multiforme include the morphology of targetoid lesions and a common distribution on the extremities, in addition to the limited bullae and epidermal detachment in comparison with SJS/TEN. In MIRM, mucositis often is more severe and extensive, with multiple mucosal surfaces affected. It typically has less cutaneous involvement than SJS/TEN, though clinical variants can include diffuse rash and affect fewer than 2 mucosal sites.2 Depending on the timing of rash onset, Mycoplasma IgM/IgG titers may be drawn to further support the diagnosis. A diagnosis of MIRM was not favored in our patient due to lack of respiratory symptoms, normal chest radiography, and negative Mycoplasma IgM and IgG titers.

Stevens-Johnson syndrome/toxic epidermal necrolysis overlap has been reported in pregnant patients, typically in association with HIV infection or new medication exposure.3 A combination of genetic susceptibility and an altered immune system during pregnancy may contribute to the pathogenesis, involving a cytotoxic T-cell mediated reaction with release of inflammatory cytokines.1 Interestingly, these factors that may predispose a patient to developing SJS/TEN may not pass on to the neonate, evidenced by a few cases that showed no reaction in the newborn when given the same offending drug.4

Stevens-Johnson syndrome/toxic epidermal necrolysis more frequently presents in the second or third trimester, with no increase in maternal mortality and an equally high survival rate of the fetus.1,5 Unique sequelae in pregnant patients may include vaginal stenosis, vulvar swelling, and postpartum sepsis. Fetal complications can include low birth weight, preterm delivery, and respiratory distress. The fetus rarely exhibits cutaneous manifestations of the disease.6

A multidisciplinary approach to the diagnosis and management of SJS/TEN overlap in special patient populations such as pregnant women is vital. Supportive measures consisting of wound care, fluid and electrolyte management, infection monitoring, and nutritional support have sufficed in treating SJS/TEN in pregnant patients.3 Although adjunctive therapy with systemic corticosteroids, IVIG, cyclosporine, and tumor necrosis factor inhibitors commonly are used in clinical practice, the safety of these treatments in pregnant patients affected by SJS/TEN has not been established. However, use of these medications for other indications, primarily rheumatologic diseases, has been reported to be safe in the pregnant population.7 If necessary, glucocorticoids should be used in the lowest effective dose to avoid complications such as premature rupture of membranes; intrauterine growth restriction; and increased risk for pregnancy-induced hypertension, gestational diabetes, osteoporosis, and infection. Little is known about IVIG use in pregnancy. While it has not been associated with increased risk of fetal malformations, it may cross the placenta in a notable amount when administered after 30 weeks’ gestation.7

Unlike most cases of SJS/TEN in pregnancy that largely were associated with HIV infection or drug exposure, primarily antiretrovirals such as nevirapine or antiepileptics, our case is a rare incidence of SJS/TEN in a pregnant patient with no clear medication or infectious trigger. Although the causative drug was unclear, we suspected it was secondary to nonsteroidal anti-inflammatory drug use. The patient had a SCORTEN (SCORe of Toxic Epidermal Necrosis) of 0, which portends a relatively good prognosis with an estimated mortality rate of approximately 3% (Table).8 However, the large BSA involvement of the morbilliform rash warranted aggressive management to prevent the involved skin from fully detaching.

References

1. Struck MF, Illert T, Liss Y, et al. Toxic epidermal necrolysis in pregnancy: case report and review of the literature. J Burn Care Res. 2010;31:816-821. doi:10.1097/BCR.0b013e3181eed441

2. Canavan TN, Mathes EF, Frieden I, et al. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015;72:239-245.e4. doi:10.1016/j.jaad.2014.06.026

3. Knight L, Todd G, Muloiwa R, et al. Stevens Johnson syndrome and toxic epidermal necrolysis: maternal and foetal outcomes in twenty-two consecutive pregnant HIV infected women. PLoS One. 2015;10:1-11. doi:10.1371/journal.pone.0135501

4. Velter C, Hotz C, Ingen-Housz-Oro S. Stevens-Johnson syndrome during pregnancy: case report of a newborn treated with the culprit drug. JAMA Dermatol. 2018;154:224-225. doi:10.1001/jamadermatol.2017.4607

5. El Daief SG, Das S, Ekekwe G, et al. A successful pregnancy outcome after Stevens-Johnson syndrome. J Obstet Gynaecol (Lahore). 2014;34:445-446. doi:10.3109/01443615.2014.914897

6. Rodriguez G, Trent JT, Mirzabeigi M. Toxic epidermal necrolysis in a mother and fetus. J Am Acad Dermatol. 2006;55(5 suppl):96-98. doi:10.1016/j.jaad.2005.09.023

7. Bermas BL. Safety of rheumatic disease medication use during pregnancy and lactation. UptoDate website. Updated March 24, 2021. Accessed December 16, 2021. https://www.uptodate.com/contents/safety-of-rheumatic-disease-medication-use-during-pregnancy-and-lactation#H11

8. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149-153. doi:10.1046/j.1523-1747.2000.00061.x

Article PDF
Author and Disclosure Information

 

From the Department of Dermatology, University of California, Irvine.

The authors report no conflict of interest.

Correspondence: Nathan W. Rojek, MD, Department of Dermatology, University of California, Irvine, 118 Med Surge 1, Irvine, CA 92697-2400.

Issue
Cutis - 108(6)
Publications
Topics
Page Number
E20-E22
Sections
Author and Disclosure Information

 

From the Department of Dermatology, University of California, Irvine.

The authors report no conflict of interest.

Correspondence: Nathan W. Rojek, MD, Department of Dermatology, University of California, Irvine, 118 Med Surge 1, Irvine, CA 92697-2400.

Author and Disclosure Information

 

From the Department of Dermatology, University of California, Irvine.

The authors report no conflict of interest.

Correspondence: Nathan W. Rojek, MD, Department of Dermatology, University of California, Irvine, 118 Med Surge 1, Irvine, CA 92697-2400.

Article PDF
Article PDF

 

To the Editor:

A 34-year-old pregnant woman at 5 weeks’ gestation was transferred to dermatology from an outside hospital with a full-body rash. Three days after noting a fever and generalized body aches, she developed a painful rash on the legs that had gradually spread to the arms, trunk, and face. Symptoms of eyelid pruritus and edema initially were improved with intravenous (IV) steroids at an emergency department visit, but they started to flare soon thereafter with worsening mucosal involvement and dysphagia. After a second visit to the emergency department and repeat treatment with IV steroids, she was transferred to our institution for a higher level of care.

The patient denied taking any new medications in the 2 months prior to the onset of the rash. Her medication history only consisted of over-the-counter prenatal vitamins, a single use of over-the-counter migraine medication (containing acetaminophen, aspirin, and caffeine as active ingredients), and a possible use of ibuprofen or acetaminophen separately. She reported ocular discomfort and blurriness, dysphagia, dysuria, and vaginal discomfort. Physical examination revealed dusky red to violaceous macules and patches that involved approximately 65% of the body surface area (BSA), with bullae involving approximately 10% BSA. The face was diffusely red and edematous with crusted erosions and scattered bullae on the cheeks. Mucosal involvement was notable for injected conjunctivae and erosions present on the upper hard palate of the mouth and lips (Figure, A). Erythematous macules with dusky centers coalescing into patches with overlying vesicles and bullae were scattered on the arms (Figure, B), hands, trunk (Figure, C), and legs. The Nikolsky sign was positive. The vulva was swollen and covered with erythematous macules with dusky centers.

Stevens-Johnson syndrome/toxic epidermal necrolysis in a pregnant woman. A, Erosions of the mouth and lips. B, Erythematous papules and bullae scattered on the arm. C, Confluent papules with dusky centers coalescing into plaques on the back.

A biopsy from the upper back revealed a vacuolar interface with subepidermal bullae and confluent keratinocyte necrosis with many CD8+ cells and scattered granzyme B. Given these results in conjunction with the clinical findings, a diagnosis of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) overlap was made. In addition to providing supportive care, the patient was started on a 4-day course of IV immunoglobulin (IVIG)(3g/kg total) and prednisone 60 mg daily, tapered over several weeks with a good clinical response. At outpatient follow-up she was found to have postinflammatory hypopigmentation on the face, trunk, and extremities, as well as tear duct scarring, but she had no vulvovaginal scarring or stenosis. She was progressing well in her pregnancy with no serious complications for 4 months after admission, at which point she was lost to follow-up.

Stevens-Johnson syndrome and TEN represent a spectrum of severe mucocutaneous reactions with high morbidity and mortality. Medications are the leading trigger, followed by infection. The most common inciting medications include antibacterial sulfonamides, antiepileptics such as carbamazepine and lamotrigine, nonsteroidal anti-inflammatory drugs, nevirapine, and allopurinol. The onset of symptoms from 1 to 4 weeks combined with characteristic morphologic features helps distinguish SJS/TEN from other drug eruptions. The initial presentation classically consists of a flulike prodrome followed by mucocutaneous eruption. Skin lesions often present as a diffuse erythema or ill-defined, coalescing, erythematous macules with purpuric centers that may evolve into vesicles and bullae with sloughing of the skin. Histopathology reveals full-thickness epidermal necrosis with detachment.1

Erythema multiforme and Mycoplasma-induced rash and mucositis (MIRM) are high on the differential diagnosis. Distinguishing features of erythema multiforme include the morphology of targetoid lesions and a common distribution on the extremities, in addition to the limited bullae and epidermal detachment in comparison with SJS/TEN. In MIRM, mucositis often is more severe and extensive, with multiple mucosal surfaces affected. It typically has less cutaneous involvement than SJS/TEN, though clinical variants can include diffuse rash and affect fewer than 2 mucosal sites.2 Depending on the timing of rash onset, Mycoplasma IgM/IgG titers may be drawn to further support the diagnosis. A diagnosis of MIRM was not favored in our patient due to lack of respiratory symptoms, normal chest radiography, and negative Mycoplasma IgM and IgG titers.

Stevens-Johnson syndrome/toxic epidermal necrolysis overlap has been reported in pregnant patients, typically in association with HIV infection or new medication exposure.3 A combination of genetic susceptibility and an altered immune system during pregnancy may contribute to the pathogenesis, involving a cytotoxic T-cell mediated reaction with release of inflammatory cytokines.1 Interestingly, these factors that may predispose a patient to developing SJS/TEN may not pass on to the neonate, evidenced by a few cases that showed no reaction in the newborn when given the same offending drug.4

Stevens-Johnson syndrome/toxic epidermal necrolysis more frequently presents in the second or third trimester, with no increase in maternal mortality and an equally high survival rate of the fetus.1,5 Unique sequelae in pregnant patients may include vaginal stenosis, vulvar swelling, and postpartum sepsis. Fetal complications can include low birth weight, preterm delivery, and respiratory distress. The fetus rarely exhibits cutaneous manifestations of the disease.6

A multidisciplinary approach to the diagnosis and management of SJS/TEN overlap in special patient populations such as pregnant women is vital. Supportive measures consisting of wound care, fluid and electrolyte management, infection monitoring, and nutritional support have sufficed in treating SJS/TEN in pregnant patients.3 Although adjunctive therapy with systemic corticosteroids, IVIG, cyclosporine, and tumor necrosis factor inhibitors commonly are used in clinical practice, the safety of these treatments in pregnant patients affected by SJS/TEN has not been established. However, use of these medications for other indications, primarily rheumatologic diseases, has been reported to be safe in the pregnant population.7 If necessary, glucocorticoids should be used in the lowest effective dose to avoid complications such as premature rupture of membranes; intrauterine growth restriction; and increased risk for pregnancy-induced hypertension, gestational diabetes, osteoporosis, and infection. Little is known about IVIG use in pregnancy. While it has not been associated with increased risk of fetal malformations, it may cross the placenta in a notable amount when administered after 30 weeks’ gestation.7

Unlike most cases of SJS/TEN in pregnancy that largely were associated with HIV infection or drug exposure, primarily antiretrovirals such as nevirapine or antiepileptics, our case is a rare incidence of SJS/TEN in a pregnant patient with no clear medication or infectious trigger. Although the causative drug was unclear, we suspected it was secondary to nonsteroidal anti-inflammatory drug use. The patient had a SCORTEN (SCORe of Toxic Epidermal Necrosis) of 0, which portends a relatively good prognosis with an estimated mortality rate of approximately 3% (Table).8 However, the large BSA involvement of the morbilliform rash warranted aggressive management to prevent the involved skin from fully detaching.

 

To the Editor:

A 34-year-old pregnant woman at 5 weeks’ gestation was transferred to dermatology from an outside hospital with a full-body rash. Three days after noting a fever and generalized body aches, she developed a painful rash on the legs that had gradually spread to the arms, trunk, and face. Symptoms of eyelid pruritus and edema initially were improved with intravenous (IV) steroids at an emergency department visit, but they started to flare soon thereafter with worsening mucosal involvement and dysphagia. After a second visit to the emergency department and repeat treatment with IV steroids, she was transferred to our institution for a higher level of care.

The patient denied taking any new medications in the 2 months prior to the onset of the rash. Her medication history only consisted of over-the-counter prenatal vitamins, a single use of over-the-counter migraine medication (containing acetaminophen, aspirin, and caffeine as active ingredients), and a possible use of ibuprofen or acetaminophen separately. She reported ocular discomfort and blurriness, dysphagia, dysuria, and vaginal discomfort. Physical examination revealed dusky red to violaceous macules and patches that involved approximately 65% of the body surface area (BSA), with bullae involving approximately 10% BSA. The face was diffusely red and edematous with crusted erosions and scattered bullae on the cheeks. Mucosal involvement was notable for injected conjunctivae and erosions present on the upper hard palate of the mouth and lips (Figure, A). Erythematous macules with dusky centers coalescing into patches with overlying vesicles and bullae were scattered on the arms (Figure, B), hands, trunk (Figure, C), and legs. The Nikolsky sign was positive. The vulva was swollen and covered with erythematous macules with dusky centers.

Stevens-Johnson syndrome/toxic epidermal necrolysis in a pregnant woman. A, Erosions of the mouth and lips. B, Erythematous papules and bullae scattered on the arm. C, Confluent papules with dusky centers coalescing into plaques on the back.

A biopsy from the upper back revealed a vacuolar interface with subepidermal bullae and confluent keratinocyte necrosis with many CD8+ cells and scattered granzyme B. Given these results in conjunction with the clinical findings, a diagnosis of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) overlap was made. In addition to providing supportive care, the patient was started on a 4-day course of IV immunoglobulin (IVIG)(3g/kg total) and prednisone 60 mg daily, tapered over several weeks with a good clinical response. At outpatient follow-up she was found to have postinflammatory hypopigmentation on the face, trunk, and extremities, as well as tear duct scarring, but she had no vulvovaginal scarring or stenosis. She was progressing well in her pregnancy with no serious complications for 4 months after admission, at which point she was lost to follow-up.

Stevens-Johnson syndrome and TEN represent a spectrum of severe mucocutaneous reactions with high morbidity and mortality. Medications are the leading trigger, followed by infection. The most common inciting medications include antibacterial sulfonamides, antiepileptics such as carbamazepine and lamotrigine, nonsteroidal anti-inflammatory drugs, nevirapine, and allopurinol. The onset of symptoms from 1 to 4 weeks combined with characteristic morphologic features helps distinguish SJS/TEN from other drug eruptions. The initial presentation classically consists of a flulike prodrome followed by mucocutaneous eruption. Skin lesions often present as a diffuse erythema or ill-defined, coalescing, erythematous macules with purpuric centers that may evolve into vesicles and bullae with sloughing of the skin. Histopathology reveals full-thickness epidermal necrosis with detachment.1

Erythema multiforme and Mycoplasma-induced rash and mucositis (MIRM) are high on the differential diagnosis. Distinguishing features of erythema multiforme include the morphology of targetoid lesions and a common distribution on the extremities, in addition to the limited bullae and epidermal detachment in comparison with SJS/TEN. In MIRM, mucositis often is more severe and extensive, with multiple mucosal surfaces affected. It typically has less cutaneous involvement than SJS/TEN, though clinical variants can include diffuse rash and affect fewer than 2 mucosal sites.2 Depending on the timing of rash onset, Mycoplasma IgM/IgG titers may be drawn to further support the diagnosis. A diagnosis of MIRM was not favored in our patient due to lack of respiratory symptoms, normal chest radiography, and negative Mycoplasma IgM and IgG titers.

Stevens-Johnson syndrome/toxic epidermal necrolysis overlap has been reported in pregnant patients, typically in association with HIV infection or new medication exposure.3 A combination of genetic susceptibility and an altered immune system during pregnancy may contribute to the pathogenesis, involving a cytotoxic T-cell mediated reaction with release of inflammatory cytokines.1 Interestingly, these factors that may predispose a patient to developing SJS/TEN may not pass on to the neonate, evidenced by a few cases that showed no reaction in the newborn when given the same offending drug.4

Stevens-Johnson syndrome/toxic epidermal necrolysis more frequently presents in the second or third trimester, with no increase in maternal mortality and an equally high survival rate of the fetus.1,5 Unique sequelae in pregnant patients may include vaginal stenosis, vulvar swelling, and postpartum sepsis. Fetal complications can include low birth weight, preterm delivery, and respiratory distress. The fetus rarely exhibits cutaneous manifestations of the disease.6

A multidisciplinary approach to the diagnosis and management of SJS/TEN overlap in special patient populations such as pregnant women is vital. Supportive measures consisting of wound care, fluid and electrolyte management, infection monitoring, and nutritional support have sufficed in treating SJS/TEN in pregnant patients.3 Although adjunctive therapy with systemic corticosteroids, IVIG, cyclosporine, and tumor necrosis factor inhibitors commonly are used in clinical practice, the safety of these treatments in pregnant patients affected by SJS/TEN has not been established. However, use of these medications for other indications, primarily rheumatologic diseases, has been reported to be safe in the pregnant population.7 If necessary, glucocorticoids should be used in the lowest effective dose to avoid complications such as premature rupture of membranes; intrauterine growth restriction; and increased risk for pregnancy-induced hypertension, gestational diabetes, osteoporosis, and infection. Little is known about IVIG use in pregnancy. While it has not been associated with increased risk of fetal malformations, it may cross the placenta in a notable amount when administered after 30 weeks’ gestation.7

Unlike most cases of SJS/TEN in pregnancy that largely were associated with HIV infection or drug exposure, primarily antiretrovirals such as nevirapine or antiepileptics, our case is a rare incidence of SJS/TEN in a pregnant patient with no clear medication or infectious trigger. Although the causative drug was unclear, we suspected it was secondary to nonsteroidal anti-inflammatory drug use. The patient had a SCORTEN (SCORe of Toxic Epidermal Necrosis) of 0, which portends a relatively good prognosis with an estimated mortality rate of approximately 3% (Table).8 However, the large BSA involvement of the morbilliform rash warranted aggressive management to prevent the involved skin from fully detaching.

References

1. Struck MF, Illert T, Liss Y, et al. Toxic epidermal necrolysis in pregnancy: case report and review of the literature. J Burn Care Res. 2010;31:816-821. doi:10.1097/BCR.0b013e3181eed441

2. Canavan TN, Mathes EF, Frieden I, et al. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015;72:239-245.e4. doi:10.1016/j.jaad.2014.06.026

3. Knight L, Todd G, Muloiwa R, et al. Stevens Johnson syndrome and toxic epidermal necrolysis: maternal and foetal outcomes in twenty-two consecutive pregnant HIV infected women. PLoS One. 2015;10:1-11. doi:10.1371/journal.pone.0135501

4. Velter C, Hotz C, Ingen-Housz-Oro S. Stevens-Johnson syndrome during pregnancy: case report of a newborn treated with the culprit drug. JAMA Dermatol. 2018;154:224-225. doi:10.1001/jamadermatol.2017.4607

5. El Daief SG, Das S, Ekekwe G, et al. A successful pregnancy outcome after Stevens-Johnson syndrome. J Obstet Gynaecol (Lahore). 2014;34:445-446. doi:10.3109/01443615.2014.914897

6. Rodriguez G, Trent JT, Mirzabeigi M. Toxic epidermal necrolysis in a mother and fetus. J Am Acad Dermatol. 2006;55(5 suppl):96-98. doi:10.1016/j.jaad.2005.09.023

7. Bermas BL. Safety of rheumatic disease medication use during pregnancy and lactation. UptoDate website. Updated March 24, 2021. Accessed December 16, 2021. https://www.uptodate.com/contents/safety-of-rheumatic-disease-medication-use-during-pregnancy-and-lactation#H11

8. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149-153. doi:10.1046/j.1523-1747.2000.00061.x

References

1. Struck MF, Illert T, Liss Y, et al. Toxic epidermal necrolysis in pregnancy: case report and review of the literature. J Burn Care Res. 2010;31:816-821. doi:10.1097/BCR.0b013e3181eed441

2. Canavan TN, Mathes EF, Frieden I, et al. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015;72:239-245.e4. doi:10.1016/j.jaad.2014.06.026

3. Knight L, Todd G, Muloiwa R, et al. Stevens Johnson syndrome and toxic epidermal necrolysis: maternal and foetal outcomes in twenty-two consecutive pregnant HIV infected women. PLoS One. 2015;10:1-11. doi:10.1371/journal.pone.0135501

4. Velter C, Hotz C, Ingen-Housz-Oro S. Stevens-Johnson syndrome during pregnancy: case report of a newborn treated with the culprit drug. JAMA Dermatol. 2018;154:224-225. doi:10.1001/jamadermatol.2017.4607

5. El Daief SG, Das S, Ekekwe G, et al. A successful pregnancy outcome after Stevens-Johnson syndrome. J Obstet Gynaecol (Lahore). 2014;34:445-446. doi:10.3109/01443615.2014.914897

6. Rodriguez G, Trent JT, Mirzabeigi M. Toxic epidermal necrolysis in a mother and fetus. J Am Acad Dermatol. 2006;55(5 suppl):96-98. doi:10.1016/j.jaad.2005.09.023

7. Bermas BL. Safety of rheumatic disease medication use during pregnancy and lactation. UptoDate website. Updated March 24, 2021. Accessed December 16, 2021. https://www.uptodate.com/contents/safety-of-rheumatic-disease-medication-use-during-pregnancy-and-lactation#H11

8. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149-153. doi:10.1046/j.1523-1747.2000.00061.x

Issue
Cutis - 108(6)
Issue
Cutis - 108(6)
Page Number
E20-E22
Page Number
E20-E22
Publications
Publications
Topics
Article Type
Sections
Inside the Article

 

Practice Points

  • Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) represent a spectrum of severe mucocutaneous reactions commonly presenting as drug eruptions.
  • Pregnant patients affected by SJS/TEN represent a special patient population that requires a multidisciplinary approach for management and treatment.
  • The rates of adverse outcomes for pregnant patients with SJS/TEN are low with timely diagnosis, removal of the offending agent, and supportive care as mainstays of treatment.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Vegetative Plaques on the Face

Article Type
Changed
Tue, 03/01/2022 - 11:45

THE DIAGNOSIS: Vegetative Majocchi Granuloma

A biopsy and tissue culture showed acute dermal inflammation with granulomatous features and numerous fungal hyphae within the stratum corneum (Figure 1A), which were confirmed on GrocottGomori methenamine-silver staining (Figure 1B). Gram and Fite stains were negative for bacteria. A tissue culture speciated Trichophyton rubrum, which led to a diagnosis of deep dermatophyte infection (Majocchi granuloma) with a highly unusual clinical presentation of vegetative plaques. Predisposing factors included treatment with topical corticosteroids and possibly poor health and nutritional status at baseline. Our patient was treated with fluconazole 200 mg daily for 6 weeks, with near resolution of lesions at 3-week follow-up (Figure 2).

FIGURE 1. A, Biopsy results showed fungal hyphae in the stratum corneum and acute dermal inflammation with granulomatous features (H&E, original magnification ×20). B, Grocott-Gomori methenaminesilver stain highlighted numerous fungal hyphae in the stratum corneum (original magnification ×20).

FIGURE 2. Resolution of vegetative Majocchi granuloma on the face 3 weeks after treatment with oral fluconazole.

Dermatophytes are a common cause of superficial skin infections. The classic morphology consists of an annular scaly plaque; however, a wide variety of presentations have been observed (eg, verrucous, vesicular, pustular, granulomatous). Therefore, dermatophyte infections often mimic other dermatologic conditions, including atopic dermatitis, rosacea, psoriasis, bacterial abscess, erythema gyratum repens, lupus, granuloma annulare, cutaneous lymphoma, Hailey-Hailey disease, scarring alopecia, and syphilis.1

Notably, when dermatophytes grow downward along hair follicles causing deeper infection, disruption of the follicular wall can lead to an excessive inflammatory response with granulomatous features.2 Risk factors include cutaneous trauma, long-standing infection, immunocompromise, and treatment with topical corticosteroids.3 This disease evolution clinically appears as a nodule or infiltrated plaque, often without scale. The most well-known example is a kerion on the scalp. Elsewhere on the body, lesions often are termed Majocchi granulomas.2

Vegetative plaques, as seen in our patient, are a highly unusual morphology for deep tinea infection. Guanziroli et al4 reported a case of vegetative lesions on the forearm of a 67-year-old immunocompromised man that were successfully treated with a 3-month course of oral terbinafine after Trichophyton verrucosum was isolated. Skorepova et al5 reported a case of pyoderma vegetans triggered by recurrent Trichophyton mentagrophytes on the dorsal hands of a 64-year-old man with immunoglobulin deficiency of unknown etiology. The lesions were successfully treated with a prolonged course of doxycycline, topical triamcinolone, and intravenous immunoglobulin following 2 initial courses of terbinafine.

The differential diagnosis for vegetative lesions includes pemphigus vegetans, a vegetative variant of pyoderma gangrenosum; halogenoderma; and a variety of infections, including dimorphic fungi (histoplasmosis, blastomycosis), blastomycosislike pyoderma (bacterial), and candidiasis.6 These conditions usually can be distinguished based on histopathology. Clinically, pemphigus vegetans presents with pustules and vegetative lesions, as in our patient, but usually is more diffuse and favors the intertriginous areas. Histology likely would reveal foci of acantholysis and eosinophils. Vegetative pyoderma gangrenosum favors the trunk, particularly in sites of surgical trauma. In our patient, no lesions were present near the abdominal surgical sites, and there was no antecedent cribriform ulceration. Halogenoderma was a strong initial consideration given the localization, presence of large pustules, and history of numerous contrast computed tomography studies; however, our patient’s iodine levels were normal. Infectious etiologies including dimorphic fungi and blastomycosislike pyoderma generally are not restricted to the head and neck, and tissue culture helps exclude them. Vegetative lesions may occur in the setting of other infections, and tissue culture may be necessary to differentiate them if histopathology is not suggestive.

Deep dermatophyte infections require treatment with oral antifungals, as topicals do not penetrate adequately into the hair follicles. Exact regimens vary, but generally oral terbinafine or an oral azole (except ketoconazole) is administered for 2 to 6 weeks, with immunocompromise necessitating longer courses.

We present a rare case of vegetative Majocchi granuloma secondary to T rubrum infection. A dermatophyte infection should be included in the differential for vegetative lesions, especially in dense hair-bearing areas such as the beard. Treatment generally is straightforward with oral antifungals.

References
  1. Atzori L, Pau M, Aste N, et al. Dermatophyte infections mimicking other skin diseases: a 154-person case survey of tinea atypica in the district of Cagliari (Italy). Int J Dermatol. 2012;51:410-415.
  2. Ilkit M, Durdu M, Karakas M. Majocchi’s granuloma: a symptom complex caused by fungal pathogens. Med Mycol. 2012;50:449-457.
  3. Jevremovic L, Ilijin I, Kostic K, et al. Pyoderma vegetans—a case report. Serbian J Dermatol Venereol. 2017;9:22-28.
  4. Guanziroli E, Pavia G, Guttadauro A, et al. Deep dermatophytosis caused by Trichophyton verrucosum in an immunosuppressed patient: successful outcome with terbinafine. Mycopathologia. 2019;184:543-545.
  5. Skorepová M, Stuchlík D. Chronic pyoderma vegetans triggered by Trichophyton mentagrophytes. Mycoses. 2006;49:143-144.
  6. Reinholz M, Hermans C, Dietrich A, et al. A case of cutaneous vegetating candidiasis in a patient with keratitis-ichthyosis-deafness syndrome. J Eur Acad Dermatol Venereol. 2016;30:537-539.
Article PDF
Author and Disclosure Information

From the Department of Dermatology, University of Virginia, Charlottesville.

The authors report no conflict of interest.

Correspondence: Jack Lee, MD, Box 800718, Department of Dermatology, University of Virginia, Charlottesville, VA 22908-0718 (JL4EG@virginia.edu).

Issue
Cutis - 108(6)
Publications
Topics
Page Number
E9, E11
Sections
Author and Disclosure Information

From the Department of Dermatology, University of Virginia, Charlottesville.

The authors report no conflict of interest.

Correspondence: Jack Lee, MD, Box 800718, Department of Dermatology, University of Virginia, Charlottesville, VA 22908-0718 (JL4EG@virginia.edu).

Author and Disclosure Information

From the Department of Dermatology, University of Virginia, Charlottesville.

The authors report no conflict of interest.

Correspondence: Jack Lee, MD, Box 800718, Department of Dermatology, University of Virginia, Charlottesville, VA 22908-0718 (JL4EG@virginia.edu).

Article PDF
Article PDF

THE DIAGNOSIS: Vegetative Majocchi Granuloma

A biopsy and tissue culture showed acute dermal inflammation with granulomatous features and numerous fungal hyphae within the stratum corneum (Figure 1A), which were confirmed on GrocottGomori methenamine-silver staining (Figure 1B). Gram and Fite stains were negative for bacteria. A tissue culture speciated Trichophyton rubrum, which led to a diagnosis of deep dermatophyte infection (Majocchi granuloma) with a highly unusual clinical presentation of vegetative plaques. Predisposing factors included treatment with topical corticosteroids and possibly poor health and nutritional status at baseline. Our patient was treated with fluconazole 200 mg daily for 6 weeks, with near resolution of lesions at 3-week follow-up (Figure 2).

FIGURE 1. A, Biopsy results showed fungal hyphae in the stratum corneum and acute dermal inflammation with granulomatous features (H&E, original magnification ×20). B, Grocott-Gomori methenaminesilver stain highlighted numerous fungal hyphae in the stratum corneum (original magnification ×20).

FIGURE 2. Resolution of vegetative Majocchi granuloma on the face 3 weeks after treatment with oral fluconazole.

Dermatophytes are a common cause of superficial skin infections. The classic morphology consists of an annular scaly plaque; however, a wide variety of presentations have been observed (eg, verrucous, vesicular, pustular, granulomatous). Therefore, dermatophyte infections often mimic other dermatologic conditions, including atopic dermatitis, rosacea, psoriasis, bacterial abscess, erythema gyratum repens, lupus, granuloma annulare, cutaneous lymphoma, Hailey-Hailey disease, scarring alopecia, and syphilis.1

Notably, when dermatophytes grow downward along hair follicles causing deeper infection, disruption of the follicular wall can lead to an excessive inflammatory response with granulomatous features.2 Risk factors include cutaneous trauma, long-standing infection, immunocompromise, and treatment with topical corticosteroids.3 This disease evolution clinically appears as a nodule or infiltrated plaque, often without scale. The most well-known example is a kerion on the scalp. Elsewhere on the body, lesions often are termed Majocchi granulomas.2

Vegetative plaques, as seen in our patient, are a highly unusual morphology for deep tinea infection. Guanziroli et al4 reported a case of vegetative lesions on the forearm of a 67-year-old immunocompromised man that were successfully treated with a 3-month course of oral terbinafine after Trichophyton verrucosum was isolated. Skorepova et al5 reported a case of pyoderma vegetans triggered by recurrent Trichophyton mentagrophytes on the dorsal hands of a 64-year-old man with immunoglobulin deficiency of unknown etiology. The lesions were successfully treated with a prolonged course of doxycycline, topical triamcinolone, and intravenous immunoglobulin following 2 initial courses of terbinafine.

The differential diagnosis for vegetative lesions includes pemphigus vegetans, a vegetative variant of pyoderma gangrenosum; halogenoderma; and a variety of infections, including dimorphic fungi (histoplasmosis, blastomycosis), blastomycosislike pyoderma (bacterial), and candidiasis.6 These conditions usually can be distinguished based on histopathology. Clinically, pemphigus vegetans presents with pustules and vegetative lesions, as in our patient, but usually is more diffuse and favors the intertriginous areas. Histology likely would reveal foci of acantholysis and eosinophils. Vegetative pyoderma gangrenosum favors the trunk, particularly in sites of surgical trauma. In our patient, no lesions were present near the abdominal surgical sites, and there was no antecedent cribriform ulceration. Halogenoderma was a strong initial consideration given the localization, presence of large pustules, and history of numerous contrast computed tomography studies; however, our patient’s iodine levels were normal. Infectious etiologies including dimorphic fungi and blastomycosislike pyoderma generally are not restricted to the head and neck, and tissue culture helps exclude them. Vegetative lesions may occur in the setting of other infections, and tissue culture may be necessary to differentiate them if histopathology is not suggestive.

Deep dermatophyte infections require treatment with oral antifungals, as topicals do not penetrate adequately into the hair follicles. Exact regimens vary, but generally oral terbinafine or an oral azole (except ketoconazole) is administered for 2 to 6 weeks, with immunocompromise necessitating longer courses.

We present a rare case of vegetative Majocchi granuloma secondary to T rubrum infection. A dermatophyte infection should be included in the differential for vegetative lesions, especially in dense hair-bearing areas such as the beard. Treatment generally is straightforward with oral antifungals.

THE DIAGNOSIS: Vegetative Majocchi Granuloma

A biopsy and tissue culture showed acute dermal inflammation with granulomatous features and numerous fungal hyphae within the stratum corneum (Figure 1A), which were confirmed on GrocottGomori methenamine-silver staining (Figure 1B). Gram and Fite stains were negative for bacteria. A tissue culture speciated Trichophyton rubrum, which led to a diagnosis of deep dermatophyte infection (Majocchi granuloma) with a highly unusual clinical presentation of vegetative plaques. Predisposing factors included treatment with topical corticosteroids and possibly poor health and nutritional status at baseline. Our patient was treated with fluconazole 200 mg daily for 6 weeks, with near resolution of lesions at 3-week follow-up (Figure 2).

FIGURE 1. A, Biopsy results showed fungal hyphae in the stratum corneum and acute dermal inflammation with granulomatous features (H&E, original magnification ×20). B, Grocott-Gomori methenaminesilver stain highlighted numerous fungal hyphae in the stratum corneum (original magnification ×20).

FIGURE 2. Resolution of vegetative Majocchi granuloma on the face 3 weeks after treatment with oral fluconazole.

Dermatophytes are a common cause of superficial skin infections. The classic morphology consists of an annular scaly plaque; however, a wide variety of presentations have been observed (eg, verrucous, vesicular, pustular, granulomatous). Therefore, dermatophyte infections often mimic other dermatologic conditions, including atopic dermatitis, rosacea, psoriasis, bacterial abscess, erythema gyratum repens, lupus, granuloma annulare, cutaneous lymphoma, Hailey-Hailey disease, scarring alopecia, and syphilis.1

Notably, when dermatophytes grow downward along hair follicles causing deeper infection, disruption of the follicular wall can lead to an excessive inflammatory response with granulomatous features.2 Risk factors include cutaneous trauma, long-standing infection, immunocompromise, and treatment with topical corticosteroids.3 This disease evolution clinically appears as a nodule or infiltrated plaque, often without scale. The most well-known example is a kerion on the scalp. Elsewhere on the body, lesions often are termed Majocchi granulomas.2

Vegetative plaques, as seen in our patient, are a highly unusual morphology for deep tinea infection. Guanziroli et al4 reported a case of vegetative lesions on the forearm of a 67-year-old immunocompromised man that were successfully treated with a 3-month course of oral terbinafine after Trichophyton verrucosum was isolated. Skorepova et al5 reported a case of pyoderma vegetans triggered by recurrent Trichophyton mentagrophytes on the dorsal hands of a 64-year-old man with immunoglobulin deficiency of unknown etiology. The lesions were successfully treated with a prolonged course of doxycycline, topical triamcinolone, and intravenous immunoglobulin following 2 initial courses of terbinafine.

The differential diagnosis for vegetative lesions includes pemphigus vegetans, a vegetative variant of pyoderma gangrenosum; halogenoderma; and a variety of infections, including dimorphic fungi (histoplasmosis, blastomycosis), blastomycosislike pyoderma (bacterial), and candidiasis.6 These conditions usually can be distinguished based on histopathology. Clinically, pemphigus vegetans presents with pustules and vegetative lesions, as in our patient, but usually is more diffuse and favors the intertriginous areas. Histology likely would reveal foci of acantholysis and eosinophils. Vegetative pyoderma gangrenosum favors the trunk, particularly in sites of surgical trauma. In our patient, no lesions were present near the abdominal surgical sites, and there was no antecedent cribriform ulceration. Halogenoderma was a strong initial consideration given the localization, presence of large pustules, and history of numerous contrast computed tomography studies; however, our patient’s iodine levels were normal. Infectious etiologies including dimorphic fungi and blastomycosislike pyoderma generally are not restricted to the head and neck, and tissue culture helps exclude them. Vegetative lesions may occur in the setting of other infections, and tissue culture may be necessary to differentiate them if histopathology is not suggestive.

Deep dermatophyte infections require treatment with oral antifungals, as topicals do not penetrate adequately into the hair follicles. Exact regimens vary, but generally oral terbinafine or an oral azole (except ketoconazole) is administered for 2 to 6 weeks, with immunocompromise necessitating longer courses.

We present a rare case of vegetative Majocchi granuloma secondary to T rubrum infection. A dermatophyte infection should be included in the differential for vegetative lesions, especially in dense hair-bearing areas such as the beard. Treatment generally is straightforward with oral antifungals.

References
  1. Atzori L, Pau M, Aste N, et al. Dermatophyte infections mimicking other skin diseases: a 154-person case survey of tinea atypica in the district of Cagliari (Italy). Int J Dermatol. 2012;51:410-415.
  2. Ilkit M, Durdu M, Karakas M. Majocchi’s granuloma: a symptom complex caused by fungal pathogens. Med Mycol. 2012;50:449-457.
  3. Jevremovic L, Ilijin I, Kostic K, et al. Pyoderma vegetans—a case report. Serbian J Dermatol Venereol. 2017;9:22-28.
  4. Guanziroli E, Pavia G, Guttadauro A, et al. Deep dermatophytosis caused by Trichophyton verrucosum in an immunosuppressed patient: successful outcome with terbinafine. Mycopathologia. 2019;184:543-545.
  5. Skorepová M, Stuchlík D. Chronic pyoderma vegetans triggered by Trichophyton mentagrophytes. Mycoses. 2006;49:143-144.
  6. Reinholz M, Hermans C, Dietrich A, et al. A case of cutaneous vegetating candidiasis in a patient with keratitis-ichthyosis-deafness syndrome. J Eur Acad Dermatol Venereol. 2016;30:537-539.
References
  1. Atzori L, Pau M, Aste N, et al. Dermatophyte infections mimicking other skin diseases: a 154-person case survey of tinea atypica in the district of Cagliari (Italy). Int J Dermatol. 2012;51:410-415.
  2. Ilkit M, Durdu M, Karakas M. Majocchi’s granuloma: a symptom complex caused by fungal pathogens. Med Mycol. 2012;50:449-457.
  3. Jevremovic L, Ilijin I, Kostic K, et al. Pyoderma vegetans—a case report. Serbian J Dermatol Venereol. 2017;9:22-28.
  4. Guanziroli E, Pavia G, Guttadauro A, et al. Deep dermatophytosis caused by Trichophyton verrucosum in an immunosuppressed patient: successful outcome with terbinafine. Mycopathologia. 2019;184:543-545.
  5. Skorepová M, Stuchlík D. Chronic pyoderma vegetans triggered by Trichophyton mentagrophytes. Mycoses. 2006;49:143-144.
  6. Reinholz M, Hermans C, Dietrich A, et al. A case of cutaneous vegetating candidiasis in a patient with keratitis-ichthyosis-deafness syndrome. J Eur Acad Dermatol Venereol. 2016;30:537-539.
Issue
Cutis - 108(6)
Issue
Cutis - 108(6)
Page Number
E9, E11
Page Number
E9, E11
Publications
Publications
Topics
Article Type
Sections
Questionnaire Body

An 86-year-old man was admitted to the hospital for sigmoid colon perforation secondary to ischemic colitis. His medical history consisted of sequelae from atherosclerotic vascular disease. He had no known personal or family history of skin disease. His bowel perforation was surgically repaired, and his clinical status was stabilized, enabling transfer to a transitional care hospital. His course was complicated by delayed healing of the midline abdominal surgical wounds, leading to multiple computed tomography studies with iodinated contrast. One week following arrival at the transitional care hospital, he was noted to have a pustular rash on the face. He was empirically treated with topical steroids, mupirocin, and sulfacetamide. The rash did not improve, and the appearance changed, at which point dermatology was consulted. On evaluation, the patient was afebrile with a normal white blood cell count. Physical examination revealed gray-brown, moist, vegetative plaques on the cheeks with a few large pustules as well as similar-appearing lesions on the neck and upper chest. Attempted removal of a portion of the plaque left an erosion.

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 12/14/2021 - 11:00
Un-Gate On Date
Tue, 12/14/2021 - 11:00
Use ProPublica
CFC Schedule Remove Status
Tue, 12/14/2021 - 11:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Widespread Necrotizing Purpura and Lucio Phenomenon as the First Diagnostic Presentation of Diffuse Nonnodular Lepromatous Leprosy

Article Type
Changed
Wed, 12/15/2021 - 12:43

 

Case Report

A 70-year-old man living in Esna, Luxor, Egypt presented to the Department of Rheumatology and Rehabilitation with widespread gangrenous skin lesions associated with ulcers of 2 weeks’ duration. One year prior, the patient had an insidious onset of nocturnal fever, bilateral leg edema, and numbness and a tingling sensation in both hands. He presented some laboratory and radiologic investigations that were performed at another hospital prior to the current presentation, which revealed thrombocytopenia, mild splenomegaly, and generalized lymphadenopathy. An excisional left axillary lymph node biopsy was performed at another hospital prior to the current presentation, and the pathology report provided by the patient described a reactive, foamy, histiocyte-rich lesion, suggesting a diagnosis of hemophagocytic lymphohistiocytosis. The patient had no diabetes or hypertension and no history of deep vein thrombosis, stroke, or unintentional weight loss. No medications were taken prior to the onset of the skin lesions, and his family history was irrelevant.

General examination at the current presentation revealed a fever (temperature, 101.3 °F [38.5 °C]), a normal heart rate (90 beats per minute), normal blood pressure (120/80 mmHg), normal respiratory rate (14 breaths per minute), accentuated heart sounds, and normal vesicular breathing without adventitious sounds. He had saddle nose, loss of the outer third of the eyebrows, and marked reduction in the density of the eyelashes (madarosis). Bilateral pitting edema of the legs also was present. Neurologic examination revealed hypoesthesia in a glove-and-stocking pattern, thickened peripheral nerves, and trophic changes over both hands; however, he had normal muscle power and deep reflexes. Joint examination revealed no abnormalities. Skin examination revealed widespread, reticulated, necrotizing, purpuric lesions on the arms, legs, abdomen, and ears, some associated with gangrenous ulcerations and hemorrhagic blisters. Scattered vasculitic ulcers and gangrenous patches were seen on the fingers. A gangrenous ulcer mimicking Fournier gangrene was seen involving the scrotal skin in addition to a gangrenous lesion on the glans penis (Figure 1–3). Unaffected skin appeared smooth, shiny, and edematous and showed no nodular lesions. Peripheral pulsations were intact.

FIGURE 1. Necrotizing purpuric/gangrenous skin lesions involving the legs.

FIGURE 2. Necrotizing purpuric/gangrenous lesion involving the ear.

FIGURE 3. Founier gangrene–like scrotal lesion and penile gangrene.



Positive findings from a wide panel of laboratory investigations included an elevated erythrocyte sedimentation rate (103 mm for the first hour [reference range, 0–22 mm]), high C-reactive protein (50.7 mg/L [reference range, up to 6 mg/L]), anemia (hemoglobin count, 7.3 g/dL [reference range, 13.5–17.5 g/dL]), thrombocytopenia (45×103/mm3 [reference range, 150×103/mm3), low serum albumin (2.3 g/dL [reference range, 3.4–5.4 g/dL]), elevated IgG and IgM anticardiolipin antibodies (IgG, 21.4 IgG phospholipid [GPL] units [reference range, <10 IgG phospholipid (GPL) units]; IgM, 59.4 IgM phospholipid (MPL) units [reference range, <7 IgM phospholipid (MPL) units]), positive lupus anticoagulant panel test, elevated anti-β2 glycoprotein antibodies (IgG, 17.5 µ/mL [reference range, <8 µ/mL]; IgM, 124.8 µ/mL [reference range, <8 µ/mL]), and low complement C3 (78 IU [reference range, 90–180 IU]). White blood cell count, liver and kidney functions, triglycerides, serum ferritin, and complement C4 all were normal. Hepatitis B surface antigen, hepatitis C viral antibody, HIV, antinuclear antibodies (ANA), antineutrophil cytoplasmic antibodies C and P (ANCA-C&P), and venereal disease research laboratory tests all were negative.

Nerve conduction velocity showed axonal sensory polyneuropathy. Motor nerve conduction studies for median and ulnar nerves were within normal range. Lower-limb nerves assessment was limited by the ulcerated areas and marked edema. Echocardiography was unremarkable. Arterial Doppler studies were only available for the upper limbs and were unremarkable.

A punch biopsy was taken from one of the necrotizing purpuric lesions on the legs, and histopathologic examination revealed foci of epidermal necrosis and subepidermal separation and superficial and deep perivascular and periadnexal infiltrates extending into the fat lobules. The infiltrates were mainly made up of foamy macrophages, and some contained globi (lepra cells), in addition to lymphocytes and many neutrophils with nuclear dust. Blood vessels in the superficial and deep dermis and in the subcutaneous fat showed fibrinoid necrosis in their walls with neutrophils infiltrating the walls and thrombi in the lumens (Figure 4). Modified Ziehl-Neelsen staining revealed clumps of acid-fast lepra bacilli inside vascular lumina and endothelial cell lining and within the foamy macrophages (Figure 5). Slit-skin smear examination was performed twice and yielded negative results. The slide and paraffin block of the already performed lymph node biopsy were retrieved. Examination revealed aggregates of foamy histiocytes surrounded by lymphocytes and plasma cells replacing normal lymphoid follicles. Modified Ziehl-Neelsen stain was performed, and clusters of acid-fast bacilli were detected within the foamy histiocytic infiltrate (Figure 6).

FIGURE 4. Photomicrograph depicting histopathologic changes of the skin biopsy taken from one of the necrotizing purpuric lesions on the legs in the form of dense collections of foamy histiocytes (lepra cells) in the subcutaneous fat with large vessel vasculitis and thrombosis (black arrow)(H&E, original magnification ×100).

FIGURE 5. Photomicrograph depicting acid-fast bacilli within the lumen of a blood vessel and within endothelial cells in the skin biopsy taken from one of the necrotizing purpuric lesions in the legs (modified Ziehl-Neelsen, original magnification ×1000, oil immersion).

FIGURE 6. Photomicrograph depicting acid-fast bacilli in the lymph node biopsy (modified Ziehl-Neelsen, original magnification ×1000, oil immersion).


According to the results of the skin biopsy, the revised result of the lymph node biopsy, and the pattern of neurologic deficit together with clinical and laboratory correlation, the patient was diagnosed with diffuse nonnodular lepromatous leprosy presenting with Lucio phenomenon (Lucio leprosy) and associated with lepromatous lymphadenitis.

The patient received the following treatment: methylprednisolone 500 mg (intravenous pulse therapy) followed by daily oral administration of prednisolone 10 mg, rifampicin 300 mg, dapsone 100 mg, clofazimine 100 mg, acetylsalicylic acid 150 mg, and enoxaparin sodium 80 mg. In addition, the scrotal Fournier gangrene–like lesion was treated by surgical debridement followed by vacuum therapy. By the second week after treatment, the gangrenous lesions of the fingers developed a line of demarcation, and the skin infarctions started to recede.

 

 

Comment

Despite a decrease in its prevalence through a World Health Organization (WHO)–empowered eradication program, leprosy still represents a health problem in endemic areas.1,2 It is characterized by a wide range of immune responses to Mycobacterium leprae, displaying a spectrum of clinical and histopathologic manifestations that vary from the tuberculoid or paucibacillary pole with a strong cell-mediated immune response and fewer organisms to the lepromatous or multibacillary pole with weaker cell-mediated immune response and higher loads of organisms.3 In addition to its well-known cutaneous and neurologic manifestations, leprosy can present with a variety of manifestations, including constitutional symptoms, musculoskeletal manifestations, and serologic abnormalities; thus, leprosy can mimic rheumatoid arthritis, spondyloarthritis, and vasculitis—a pitfall that may result in misdiagnosis as a rheumatologic disorder.3-7

The chronic course of leprosy can be disrupted by acute, immunologically mediated reactions known as lepra reactions, of which there are 3 types.8 Type I lepra reactions are cell mediated and occur mainly in patients with borderline disease, often representing an upgrade toward the tuberculoid pole; less often they represent a downgrade reaction. Nerves become painful and swollen with possible loss of function, and skin lesions become edematous and tender; sometimes arthritis develops.9 Type II lepra reactions, also known as erythema nodosum leprosum (ENL), occur in borderline lepromatous and lepromatous patients with a high bacillary load. They are characterized by fever, body aches, tender cutaneous/subcutaneous nodules that may ulcerate, possible bullous lesions, painful nerve swellings, swollen joints, iritis, lymphadenitis, glomerulonephritis, epididymo-orchitis, and hepatic affection. Both immune-complex and delayed hypersensitivity reactions play a role in ENL.8,10 The third reaction is a rare aggressive type known as Lucio phenomenon or Lucio leprosy, which presents with irregular-shaped, angulated, or stellar necrotizing purpuric lesions (hemorrhagic infacrtions) developing mainly on the extremities. The lesions evolve into ulcers that heal with atrophic scarring.2,11 Lucio phenomenon develops as a result of thrombotic vascular occlusion secondary to massive invasion of vascular endothelial cells by lepra bacilli.2,11-14 Involvement of the scrotal skin, such as in our patient, is rare.

Lucio phenomenon mainly is seen in Mexico and Central America, and few cases have been documented in Cuba, South America, the United States, India, Polynesia, South Africa, and Southeast Asia.15-17 It specifically occurs in patients with untreated, diffuse, nonnodular lepromatous leprosy (pure and primitive diffuse lepromatous leprosy (DLL)/diffuse leprosy of Lucio and Latapí). This type of leprosy was first described by Lucio and Alvarado18 in 1852 as a distinct form of lepromatous leprosy characterized by widespread and dense infiltration of the whole skin by lepra bacilli without the typical nodular lesions of leprosy, rendering its diagnosis challenging, especially in sporadic cases. Other manifestations of DLL include complete alopecia of the eyebrows and eyelashes, destructive rhinitis, and areas of anhidrosis and dyesthesia.2

Latapí and Chévez-Zomora19 defined Lucio phenomenon in 1948 as a form of histopathologic vasculitis restricted to patients with DLL. Histopathologically, in addition to the infiltration of the skin with acid-fast bacilli–laden foamy histiocytes, lesions of Lucio phenomenon show features of necrotizing (leukocytoclastic) vasculitis with fibrinoid necrosis20 or vascular thrombi with minimal perivascular lymphocytic infiltrate and no evidence of vasculitis.11 Medium to large vessels in the deep dermis and subcutaneous tissue show infiltration of their walls with a large number of macrophages laden with acid-fast bacilli.11 Cases with histopathologic features mimicking antiphospholipid syndrome with endothelial cell proliferation, thrombosis, and mild mononuclear cell infiltrate also may be seen.20 In all cases, ischemic epidermal necrosis is seen, as well as acid-fast bacilli, both singly and in clusters (globi) within endothelial cells and inside blood vessel lumina.

Although Lucio phenomenon initially was thought to be immune-complex mediated like ENL, it has been suggested that the main trigger is thrombotic vascular occlusion secondary to massive invasion of the vascular endothelial cells by the lepra bacilli, resulting in necrosis.14 Bacterial lipopolysaccharides promote the release of IL-1 and tumor necrosis factor α, which in turn stimulate the production of prostaglandins, IL-6, and coagulation factor III, leading to vascular thrombosis and tissue necrosis.21,22 Moreover, antiphospholipid antibodies, which have been found to be induced in response to certain infectious agents in genetically predisposed individuals,23 have been reported in patients with leprosy, mainly in association with lepromatous leprosy. The reported prevalence of anticardiolipin antibodies ranged from 37% to 98%, whereas anti-β2-glycoprotein I antibodies ranged from 3% to 19%, and antiprothrombin antibodies ranged from 6% to 45%.24,25 Antiphospholipid antibodies have been reported to play a role in the pathogenesis of Lucio phenomenon.11,13,15,26 Our case supports this hypothesis with positive anticardiolipin antibodies, anti-β2 glycoprotein antibodies, and positive lupus anticoagulant.

In accordance with Curi et al,2 who reported 5 cases of DLL with Lucio phenomenon, our patient showed a similar presentation with positive inflammatory markers in association with a negative autoimmune profile (ANA, ANCA-C&P) and negative venereal disease research laboratory test. It is important to mention that a positive autoimmune profile (ANA, ANCA-C&P) can be present in leprotic patients, causing possible diagnostic confusion with collagen diseases.27,28

An interesting finding in our case was the negative slit-skin smear results. Although the specificity of slit-skin smear is 100%, as it directly demonstrates the presence of acid-fast bacilli,29 its sensitivity is low and varies from 10% to 50%.30 The detection of acid-fast bacilli in tissue sections is reported to be a better method for confirming the diagnosis of leprosy.31

The provisional impression of hemophagocytic lymphohistiocytosis in the lymph node biopsy in our patient was excluded upon detection of acid-fast bacilli in the foamy histiocytes infiltrating the lymph node; moreover, the normal serum lipids and serum ferritin argued against this diagnosis.32 Leprosy tends to involve the lymph nodes, particularly in borderline, borderline lepromatous, and lepromatous forms.33 The incidence of lymph node involvement accompanied by skin lesions with the presence of acid-fast bacilli in the lymph nodes is 92.2%.34

Our patient showed an excellent response to antileprotic treatment, which was administered according to the WHO multidrug therapy guidelines for multibacillary leprosy,35 combined with low-dose prednisolone, acetylsalicylic acid, and anticoagulant treatment. Thalidomide and high-dose prednisolone (60 mg/d) combined with antileprotic treatment also have been reported to be successful in managing recurrent infarctions in leprosy.36 The Fournier-like gangrenous ulcer of the scrotum was managed by surgical debridement and vacuum therapy.

It is noteworthy that the WHO elimination goal for leprosy was to reduce the prevalence to less than 1 case per 10,000 population. Egypt is among the first countries in North Africa and the Middle East regions to achieve this target supervised by the National Leprosy Control Program as early as 1994; this was further reduced to 0.33 cases per 10,000 population in 2004, and reduced again in 2009; however, certain foci showed a prevalence rate more than the elimination target, particularly in the cities of Qena (1.12) and Sohag (2.47).37 Esna, where our patient is from, is an endemic area in Egypt.38

Conclusion

Leprosy is a great mimicker of many connective tissue diseases, including vasculitis. Antiphospholipid antibodies are involved in Lucio phenomenon. Recognition of Lucio phenomenon is important to initiate prompt treatment and avoid morbidity and mortality. We report a rare case of diffuse nonnodular lepromatous leprosy in Egypt in which Lucio phenomenon was the first diagnostic presentation. Scrotal involvement with Lucio phenomenon was not previously reported in any case of Lucio leprosy.

References

1. World Health Organization. World Health Statistics: 2011. World Health Organization; 2011. https://www.who.int/gho/publications/world_health_statistics/EN_WHS2011_Full.pdf

2. Curi PF, Villaroel JS, Migliore N, et al. Lucio’s phenomenon: report of five cases. Clin Rheumatol. 2016;35:1397-1401.

3. Shrestha B, Li YQ, Fu P. Leprosy mimics adult onset Still’s disease in a Chinese patient. Egypt Rheumatol. 2018;40:217-220.

4. Prasad S, Misra R, Aggarwal A, et al. Leprosy revealed in a rheumatology clinic: a case series. Int J Rheum Dis. 2013;16:129-133.

5. Chao G, Fang L, Lu C. Leprosy with ANA positive mistaken for connective tissue disease. Clin Rheumatol. 2013;32:645-648.

6. Chauhan S, Wakhlu A, Agarwal V. Arthritis in leprosy. Rheumatology. 2010;49:2237-2242.

7. Rath D, Bhargava S, Kundu BK. Leprosy mimicking common rheumatologic entities: a trial for the clinician in the era of biologics. Case Rep Rheumatol. 2014;2014:429698.

8. Cuevas J, Rodríguez-Peralto JL, Carrillo R, et al. Erythema nodosum leprosum: reactional leprosy. Semin Cutan Med Surg. 2007;26:126-130.

9. Henriques CC, Lopéz B, Mestre T, et al. Leprosy and rheumatoid arthritis: consequence or association? BMJ Case Rep. 2012;13:1-4.

10. Vázquez-Botet M, Sánchez JL. Erythema nodosum leprosum. Int J Dermatol. 1987;26:436-437.

11. Nunzie E, Ortega Cabrera LV, Macanchi Moncayo FM, et al. Lucio leprosy with Lucio’s phenomenon, digital gangrene and anticardiolipin antibodies. Lepr Rev. 2014;85:194-200.

12. Salvi S, Chopra A. Leprosy in a rheumatology setting: a challenging mimic to expose. Clin Rheumatol. 2013;32:1557-1563.

13. Azulay-Abulafia L, Pereira SL, Hardmann D, et al. Lucio phenomenon. vasculitis or occlusive vasculopathy? Hautarzt. 2006;57:1101-1105.

14. Benard G, Sakai-Valente NY, Bianconcini Trindade MA. Concomittant Lucio phenomenon and erythema nodosum in a leprosy patient: clues for their distinct pathogenesis. Am J Dermatopathol. 2009;31:288-292.

15. Rocha RH, Emerich PS, Diniz LM, et al. Lucio’s phenomenon: exuberant case report and review of Brazilian cases. An Bras Dermatol. 2016;91(suppl 5):S60-S63.

16. Costa IM, Kawano LB, Pereira CP, et al. Lucio’s phenomenon: a case report and review of the literature. Int J Dermatol. 2005;44:566-571.

17. Kumari R, Thappa DM, Basu D. A fatal case of Lucio phenomenon from India. Dermatol Online J. 2008;14:10.

18. Lucio R, Alvarado I. Opúsculo Sobre el Mal de San Lázaro o Elefantiasis de los Griegos. M. Murguía; 1852.

19. Latapí F, Chévez-Zamora A. The “spotted” leprosy of Lucio: an introduction to its clinical and histological study. Int J Lepr. 1948;16:421-437.

20. Vargas OF. Diffuse leprosy of Lucio and Latapí: a histologic study. Lepr Rev. 2007;78:248-260.

21. Latapí FR, Chevez-Zamora A. La lepra manchada de Lucio. Rev Dermatol Mex. 1978;22:102-107.

22. Monteiro R, Abreu MA, Tiezzi MG, et al. Fenômeno de Lúcio: mais um caso relatado no Brasil. An Bras Dermatol. 2012;87:296-300.

23. Gharavi EE, Chaimovich H, Cucucrull E, et al. Induction of antiphospholipid antibodies by immunization with synthetic bacterial & viral peptides. Lupus. 1999;8:449-455.

24. de Larrañaga GF, Forastiero RR, Martinuzzo ME, et al. High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity. Lupus. 2000;9:594-600.

25. Loizou S, Singh S, Wypkema E, et al. Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease. Ann Rheum Dis. 2003;62:1106-1111.

26. Akerkar SM, Bichile LS. Leprosy & gangrene: a rare association; role of antiphospholipid antibodies. BMC Infect Dis. 2005,5:74.

27. Horta-Baas G, Hernández-Cabrera MF, Barile-Fabris LA, et al. Multibacillary leprosy mimicking systemic lupus erythematosus: case report and literature review. Lupus. 2015;24:1095-1102.

28. Pradhan V, Badakere SS, Shankar KU. Increased incidence of cytoplasmic ANCA (cANCA) and other auto antibodies in leprosy patients from western India. Lepr Rev. 2004;75:50-56.

29. Oskam L. Diagnosis and classification of leprosy. Lepr Rev. 2002;73:17-26.

30. Rao PN. Recent advances in the control programs and therapy of leprosy. Indian J Dermatol Venereol Leprol. 2004;70:269-276.

31. Rao PN, Pratap D, Ramana Reddy AV, et al. Evaluation of leprosy patients with 1 to 5 skin lesions with relevance to their grouping into paucibacillary or multibacillary disease. Indian J Dermatol Venereol Leprol. 2006;72:207-210.

32. Rosado FGN, Kim AS. Hemophagocytic lymphohistiocytosis. an update on diagnosis and pathogenesis. Am J Clin Pathol. 2013;139:713-727.

33. Kar HK, Mohanty HC, Mohanty GN, et al. Clinicopathological study of lymph node involvement in leprosy. Lepr India. 1983;55:725-738.

34. Gupta JC, Panda PK, Shrivastava KK, et al. A histopathologic study of lymph nodes in 43 cases of leprosy. Lepr India. 1978;50:196-203.

35. WHO Expert Committee on Leprosy. Seventh Report. World Health Organization; 1998. https://apps.who.int/iris/bitstream/handle/10665/42060/WHO_TRS_874.pdf?sequence=1&isAllowed=y

36. Misra DP, Parida JR, Chowdhury AC, et al. Lepra reaction with Lucio phenomenon mimicking cutaneous vasculitis. Case Rep Immunol. 2014;2014:641989.

37. Amer A, Mansour A. Epidemiological study of leprosy in Egypt: 2005-2009. Egypt J Dermatol Venereol. 2014;34:70-73.

38. World Health Organization. Screening campaign aims to eliminate leprosy in Egypt. Published May 9, 2018. Accessed September 8, 2021. http://www.emro.who.int/egy/egypt-events/last-miless-activities-on-eliminating-leprosy-from-egypt.html

Article PDF
Author and Disclosure Information

 

Drs. Shahin, Yousef, Niazy, Attia, Elmasry, Shalaby, Abdelkader, and Abdel-Halim as well as Ms. Teleb, Ms. Elbendary, Mr. Mourad, and Mr. Hamed are from the Kasr Al Aini Hospital, Faculty of Medicine, Cairo University, Egypt. Drs. Shahin, Niazy, and Attia as well as Ms. Teleb and Mr. Hamed are from the Department of Rheumatology and Rehabilitation. Drs. Yousef, Elmasry, Shalaby, Abdelkader, and Abdel-Halim as well as Ms. Elbendary and Mr. Mourad are from the Department of Dermatology. Dr. Hussein is from Al Kalaa Leprosarium Hospital, Cairo. Ms. Bahgat is from Al Omrania Leprosarium Hospital, Giza, Egypt.

The authors report no conflict of interest.

Correspondence: Mona R.E. Abdel-Halim, MD, Kasr Al Aini Hospital, Faculty of Medicine, Cairo University, Kasr Al Aini St, Cairo, Egypt 11562 (abdelhalimmona@gmail.com).
 

Issue
Cutis - 108(6)
Publications
Topics
Page Number
E4-E8
Sections
Author and Disclosure Information

 

Drs. Shahin, Yousef, Niazy, Attia, Elmasry, Shalaby, Abdelkader, and Abdel-Halim as well as Ms. Teleb, Ms. Elbendary, Mr. Mourad, and Mr. Hamed are from the Kasr Al Aini Hospital, Faculty of Medicine, Cairo University, Egypt. Drs. Shahin, Niazy, and Attia as well as Ms. Teleb and Mr. Hamed are from the Department of Rheumatology and Rehabilitation. Drs. Yousef, Elmasry, Shalaby, Abdelkader, and Abdel-Halim as well as Ms. Elbendary and Mr. Mourad are from the Department of Dermatology. Dr. Hussein is from Al Kalaa Leprosarium Hospital, Cairo. Ms. Bahgat is from Al Omrania Leprosarium Hospital, Giza, Egypt.

The authors report no conflict of interest.

Correspondence: Mona R.E. Abdel-Halim, MD, Kasr Al Aini Hospital, Faculty of Medicine, Cairo University, Kasr Al Aini St, Cairo, Egypt 11562 (abdelhalimmona@gmail.com).
 

Author and Disclosure Information

 

Drs. Shahin, Yousef, Niazy, Attia, Elmasry, Shalaby, Abdelkader, and Abdel-Halim as well as Ms. Teleb, Ms. Elbendary, Mr. Mourad, and Mr. Hamed are from the Kasr Al Aini Hospital, Faculty of Medicine, Cairo University, Egypt. Drs. Shahin, Niazy, and Attia as well as Ms. Teleb and Mr. Hamed are from the Department of Rheumatology and Rehabilitation. Drs. Yousef, Elmasry, Shalaby, Abdelkader, and Abdel-Halim as well as Ms. Elbendary and Mr. Mourad are from the Department of Dermatology. Dr. Hussein is from Al Kalaa Leprosarium Hospital, Cairo. Ms. Bahgat is from Al Omrania Leprosarium Hospital, Giza, Egypt.

The authors report no conflict of interest.

Correspondence: Mona R.E. Abdel-Halim, MD, Kasr Al Aini Hospital, Faculty of Medicine, Cairo University, Kasr Al Aini St, Cairo, Egypt 11562 (abdelhalimmona@gmail.com).
 

Article PDF
Article PDF

 

Case Report

A 70-year-old man living in Esna, Luxor, Egypt presented to the Department of Rheumatology and Rehabilitation with widespread gangrenous skin lesions associated with ulcers of 2 weeks’ duration. One year prior, the patient had an insidious onset of nocturnal fever, bilateral leg edema, and numbness and a tingling sensation in both hands. He presented some laboratory and radiologic investigations that were performed at another hospital prior to the current presentation, which revealed thrombocytopenia, mild splenomegaly, and generalized lymphadenopathy. An excisional left axillary lymph node biopsy was performed at another hospital prior to the current presentation, and the pathology report provided by the patient described a reactive, foamy, histiocyte-rich lesion, suggesting a diagnosis of hemophagocytic lymphohistiocytosis. The patient had no diabetes or hypertension and no history of deep vein thrombosis, stroke, or unintentional weight loss. No medications were taken prior to the onset of the skin lesions, and his family history was irrelevant.

General examination at the current presentation revealed a fever (temperature, 101.3 °F [38.5 °C]), a normal heart rate (90 beats per minute), normal blood pressure (120/80 mmHg), normal respiratory rate (14 breaths per minute), accentuated heart sounds, and normal vesicular breathing without adventitious sounds. He had saddle nose, loss of the outer third of the eyebrows, and marked reduction in the density of the eyelashes (madarosis). Bilateral pitting edema of the legs also was present. Neurologic examination revealed hypoesthesia in a glove-and-stocking pattern, thickened peripheral nerves, and trophic changes over both hands; however, he had normal muscle power and deep reflexes. Joint examination revealed no abnormalities. Skin examination revealed widespread, reticulated, necrotizing, purpuric lesions on the arms, legs, abdomen, and ears, some associated with gangrenous ulcerations and hemorrhagic blisters. Scattered vasculitic ulcers and gangrenous patches were seen on the fingers. A gangrenous ulcer mimicking Fournier gangrene was seen involving the scrotal skin in addition to a gangrenous lesion on the glans penis (Figure 1–3). Unaffected skin appeared smooth, shiny, and edematous and showed no nodular lesions. Peripheral pulsations were intact.

FIGURE 1. Necrotizing purpuric/gangrenous skin lesions involving the legs.

FIGURE 2. Necrotizing purpuric/gangrenous lesion involving the ear.

FIGURE 3. Founier gangrene–like scrotal lesion and penile gangrene.



Positive findings from a wide panel of laboratory investigations included an elevated erythrocyte sedimentation rate (103 mm for the first hour [reference range, 0–22 mm]), high C-reactive protein (50.7 mg/L [reference range, up to 6 mg/L]), anemia (hemoglobin count, 7.3 g/dL [reference range, 13.5–17.5 g/dL]), thrombocytopenia (45×103/mm3 [reference range, 150×103/mm3), low serum albumin (2.3 g/dL [reference range, 3.4–5.4 g/dL]), elevated IgG and IgM anticardiolipin antibodies (IgG, 21.4 IgG phospholipid [GPL] units [reference range, <10 IgG phospholipid (GPL) units]; IgM, 59.4 IgM phospholipid (MPL) units [reference range, <7 IgM phospholipid (MPL) units]), positive lupus anticoagulant panel test, elevated anti-β2 glycoprotein antibodies (IgG, 17.5 µ/mL [reference range, <8 µ/mL]; IgM, 124.8 µ/mL [reference range, <8 µ/mL]), and low complement C3 (78 IU [reference range, 90–180 IU]). White blood cell count, liver and kidney functions, triglycerides, serum ferritin, and complement C4 all were normal. Hepatitis B surface antigen, hepatitis C viral antibody, HIV, antinuclear antibodies (ANA), antineutrophil cytoplasmic antibodies C and P (ANCA-C&P), and venereal disease research laboratory tests all were negative.

Nerve conduction velocity showed axonal sensory polyneuropathy. Motor nerve conduction studies for median and ulnar nerves were within normal range. Lower-limb nerves assessment was limited by the ulcerated areas and marked edema. Echocardiography was unremarkable. Arterial Doppler studies were only available for the upper limbs and were unremarkable.

A punch biopsy was taken from one of the necrotizing purpuric lesions on the legs, and histopathologic examination revealed foci of epidermal necrosis and subepidermal separation and superficial and deep perivascular and periadnexal infiltrates extending into the fat lobules. The infiltrates were mainly made up of foamy macrophages, and some contained globi (lepra cells), in addition to lymphocytes and many neutrophils with nuclear dust. Blood vessels in the superficial and deep dermis and in the subcutaneous fat showed fibrinoid necrosis in their walls with neutrophils infiltrating the walls and thrombi in the lumens (Figure 4). Modified Ziehl-Neelsen staining revealed clumps of acid-fast lepra bacilli inside vascular lumina and endothelial cell lining and within the foamy macrophages (Figure 5). Slit-skin smear examination was performed twice and yielded negative results. The slide and paraffin block of the already performed lymph node biopsy were retrieved. Examination revealed aggregates of foamy histiocytes surrounded by lymphocytes and plasma cells replacing normal lymphoid follicles. Modified Ziehl-Neelsen stain was performed, and clusters of acid-fast bacilli were detected within the foamy histiocytic infiltrate (Figure 6).

FIGURE 4. Photomicrograph depicting histopathologic changes of the skin biopsy taken from one of the necrotizing purpuric lesions on the legs in the form of dense collections of foamy histiocytes (lepra cells) in the subcutaneous fat with large vessel vasculitis and thrombosis (black arrow)(H&E, original magnification ×100).

FIGURE 5. Photomicrograph depicting acid-fast bacilli within the lumen of a blood vessel and within endothelial cells in the skin biopsy taken from one of the necrotizing purpuric lesions in the legs (modified Ziehl-Neelsen, original magnification ×1000, oil immersion).

FIGURE 6. Photomicrograph depicting acid-fast bacilli in the lymph node biopsy (modified Ziehl-Neelsen, original magnification ×1000, oil immersion).


According to the results of the skin biopsy, the revised result of the lymph node biopsy, and the pattern of neurologic deficit together with clinical and laboratory correlation, the patient was diagnosed with diffuse nonnodular lepromatous leprosy presenting with Lucio phenomenon (Lucio leprosy) and associated with lepromatous lymphadenitis.

The patient received the following treatment: methylprednisolone 500 mg (intravenous pulse therapy) followed by daily oral administration of prednisolone 10 mg, rifampicin 300 mg, dapsone 100 mg, clofazimine 100 mg, acetylsalicylic acid 150 mg, and enoxaparin sodium 80 mg. In addition, the scrotal Fournier gangrene–like lesion was treated by surgical debridement followed by vacuum therapy. By the second week after treatment, the gangrenous lesions of the fingers developed a line of demarcation, and the skin infarctions started to recede.

 

 

Comment

Despite a decrease in its prevalence through a World Health Organization (WHO)–empowered eradication program, leprosy still represents a health problem in endemic areas.1,2 It is characterized by a wide range of immune responses to Mycobacterium leprae, displaying a spectrum of clinical and histopathologic manifestations that vary from the tuberculoid or paucibacillary pole with a strong cell-mediated immune response and fewer organisms to the lepromatous or multibacillary pole with weaker cell-mediated immune response and higher loads of organisms.3 In addition to its well-known cutaneous and neurologic manifestations, leprosy can present with a variety of manifestations, including constitutional symptoms, musculoskeletal manifestations, and serologic abnormalities; thus, leprosy can mimic rheumatoid arthritis, spondyloarthritis, and vasculitis—a pitfall that may result in misdiagnosis as a rheumatologic disorder.3-7

The chronic course of leprosy can be disrupted by acute, immunologically mediated reactions known as lepra reactions, of which there are 3 types.8 Type I lepra reactions are cell mediated and occur mainly in patients with borderline disease, often representing an upgrade toward the tuberculoid pole; less often they represent a downgrade reaction. Nerves become painful and swollen with possible loss of function, and skin lesions become edematous and tender; sometimes arthritis develops.9 Type II lepra reactions, also known as erythema nodosum leprosum (ENL), occur in borderline lepromatous and lepromatous patients with a high bacillary load. They are characterized by fever, body aches, tender cutaneous/subcutaneous nodules that may ulcerate, possible bullous lesions, painful nerve swellings, swollen joints, iritis, lymphadenitis, glomerulonephritis, epididymo-orchitis, and hepatic affection. Both immune-complex and delayed hypersensitivity reactions play a role in ENL.8,10 The third reaction is a rare aggressive type known as Lucio phenomenon or Lucio leprosy, which presents with irregular-shaped, angulated, or stellar necrotizing purpuric lesions (hemorrhagic infacrtions) developing mainly on the extremities. The lesions evolve into ulcers that heal with atrophic scarring.2,11 Lucio phenomenon develops as a result of thrombotic vascular occlusion secondary to massive invasion of vascular endothelial cells by lepra bacilli.2,11-14 Involvement of the scrotal skin, such as in our patient, is rare.

Lucio phenomenon mainly is seen in Mexico and Central America, and few cases have been documented in Cuba, South America, the United States, India, Polynesia, South Africa, and Southeast Asia.15-17 It specifically occurs in patients with untreated, diffuse, nonnodular lepromatous leprosy (pure and primitive diffuse lepromatous leprosy (DLL)/diffuse leprosy of Lucio and Latapí). This type of leprosy was first described by Lucio and Alvarado18 in 1852 as a distinct form of lepromatous leprosy characterized by widespread and dense infiltration of the whole skin by lepra bacilli without the typical nodular lesions of leprosy, rendering its diagnosis challenging, especially in sporadic cases. Other manifestations of DLL include complete alopecia of the eyebrows and eyelashes, destructive rhinitis, and areas of anhidrosis and dyesthesia.2

Latapí and Chévez-Zomora19 defined Lucio phenomenon in 1948 as a form of histopathologic vasculitis restricted to patients with DLL. Histopathologically, in addition to the infiltration of the skin with acid-fast bacilli–laden foamy histiocytes, lesions of Lucio phenomenon show features of necrotizing (leukocytoclastic) vasculitis with fibrinoid necrosis20 or vascular thrombi with minimal perivascular lymphocytic infiltrate and no evidence of vasculitis.11 Medium to large vessels in the deep dermis and subcutaneous tissue show infiltration of their walls with a large number of macrophages laden with acid-fast bacilli.11 Cases with histopathologic features mimicking antiphospholipid syndrome with endothelial cell proliferation, thrombosis, and mild mononuclear cell infiltrate also may be seen.20 In all cases, ischemic epidermal necrosis is seen, as well as acid-fast bacilli, both singly and in clusters (globi) within endothelial cells and inside blood vessel lumina.

Although Lucio phenomenon initially was thought to be immune-complex mediated like ENL, it has been suggested that the main trigger is thrombotic vascular occlusion secondary to massive invasion of the vascular endothelial cells by the lepra bacilli, resulting in necrosis.14 Bacterial lipopolysaccharides promote the release of IL-1 and tumor necrosis factor α, which in turn stimulate the production of prostaglandins, IL-6, and coagulation factor III, leading to vascular thrombosis and tissue necrosis.21,22 Moreover, antiphospholipid antibodies, which have been found to be induced in response to certain infectious agents in genetically predisposed individuals,23 have been reported in patients with leprosy, mainly in association with lepromatous leprosy. The reported prevalence of anticardiolipin antibodies ranged from 37% to 98%, whereas anti-β2-glycoprotein I antibodies ranged from 3% to 19%, and antiprothrombin antibodies ranged from 6% to 45%.24,25 Antiphospholipid antibodies have been reported to play a role in the pathogenesis of Lucio phenomenon.11,13,15,26 Our case supports this hypothesis with positive anticardiolipin antibodies, anti-β2 glycoprotein antibodies, and positive lupus anticoagulant.

In accordance with Curi et al,2 who reported 5 cases of DLL with Lucio phenomenon, our patient showed a similar presentation with positive inflammatory markers in association with a negative autoimmune profile (ANA, ANCA-C&P) and negative venereal disease research laboratory test. It is important to mention that a positive autoimmune profile (ANA, ANCA-C&P) can be present in leprotic patients, causing possible diagnostic confusion with collagen diseases.27,28

An interesting finding in our case was the negative slit-skin smear results. Although the specificity of slit-skin smear is 100%, as it directly demonstrates the presence of acid-fast bacilli,29 its sensitivity is low and varies from 10% to 50%.30 The detection of acid-fast bacilli in tissue sections is reported to be a better method for confirming the diagnosis of leprosy.31

The provisional impression of hemophagocytic lymphohistiocytosis in the lymph node biopsy in our patient was excluded upon detection of acid-fast bacilli in the foamy histiocytes infiltrating the lymph node; moreover, the normal serum lipids and serum ferritin argued against this diagnosis.32 Leprosy tends to involve the lymph nodes, particularly in borderline, borderline lepromatous, and lepromatous forms.33 The incidence of lymph node involvement accompanied by skin lesions with the presence of acid-fast bacilli in the lymph nodes is 92.2%.34

Our patient showed an excellent response to antileprotic treatment, which was administered according to the WHO multidrug therapy guidelines for multibacillary leprosy,35 combined with low-dose prednisolone, acetylsalicylic acid, and anticoagulant treatment. Thalidomide and high-dose prednisolone (60 mg/d) combined with antileprotic treatment also have been reported to be successful in managing recurrent infarctions in leprosy.36 The Fournier-like gangrenous ulcer of the scrotum was managed by surgical debridement and vacuum therapy.

It is noteworthy that the WHO elimination goal for leprosy was to reduce the prevalence to less than 1 case per 10,000 population. Egypt is among the first countries in North Africa and the Middle East regions to achieve this target supervised by the National Leprosy Control Program as early as 1994; this was further reduced to 0.33 cases per 10,000 population in 2004, and reduced again in 2009; however, certain foci showed a prevalence rate more than the elimination target, particularly in the cities of Qena (1.12) and Sohag (2.47).37 Esna, where our patient is from, is an endemic area in Egypt.38

Conclusion

Leprosy is a great mimicker of many connective tissue diseases, including vasculitis. Antiphospholipid antibodies are involved in Lucio phenomenon. Recognition of Lucio phenomenon is important to initiate prompt treatment and avoid morbidity and mortality. We report a rare case of diffuse nonnodular lepromatous leprosy in Egypt in which Lucio phenomenon was the first diagnostic presentation. Scrotal involvement with Lucio phenomenon was not previously reported in any case of Lucio leprosy.

 

Case Report

A 70-year-old man living in Esna, Luxor, Egypt presented to the Department of Rheumatology and Rehabilitation with widespread gangrenous skin lesions associated with ulcers of 2 weeks’ duration. One year prior, the patient had an insidious onset of nocturnal fever, bilateral leg edema, and numbness and a tingling sensation in both hands. He presented some laboratory and radiologic investigations that were performed at another hospital prior to the current presentation, which revealed thrombocytopenia, mild splenomegaly, and generalized lymphadenopathy. An excisional left axillary lymph node biopsy was performed at another hospital prior to the current presentation, and the pathology report provided by the patient described a reactive, foamy, histiocyte-rich lesion, suggesting a diagnosis of hemophagocytic lymphohistiocytosis. The patient had no diabetes or hypertension and no history of deep vein thrombosis, stroke, or unintentional weight loss. No medications were taken prior to the onset of the skin lesions, and his family history was irrelevant.

General examination at the current presentation revealed a fever (temperature, 101.3 °F [38.5 °C]), a normal heart rate (90 beats per minute), normal blood pressure (120/80 mmHg), normal respiratory rate (14 breaths per minute), accentuated heart sounds, and normal vesicular breathing without adventitious sounds. He had saddle nose, loss of the outer third of the eyebrows, and marked reduction in the density of the eyelashes (madarosis). Bilateral pitting edema of the legs also was present. Neurologic examination revealed hypoesthesia in a glove-and-stocking pattern, thickened peripheral nerves, and trophic changes over both hands; however, he had normal muscle power and deep reflexes. Joint examination revealed no abnormalities. Skin examination revealed widespread, reticulated, necrotizing, purpuric lesions on the arms, legs, abdomen, and ears, some associated with gangrenous ulcerations and hemorrhagic blisters. Scattered vasculitic ulcers and gangrenous patches were seen on the fingers. A gangrenous ulcer mimicking Fournier gangrene was seen involving the scrotal skin in addition to a gangrenous lesion on the glans penis (Figure 1–3). Unaffected skin appeared smooth, shiny, and edematous and showed no nodular lesions. Peripheral pulsations were intact.

FIGURE 1. Necrotizing purpuric/gangrenous skin lesions involving the legs.

FIGURE 2. Necrotizing purpuric/gangrenous lesion involving the ear.

FIGURE 3. Founier gangrene–like scrotal lesion and penile gangrene.



Positive findings from a wide panel of laboratory investigations included an elevated erythrocyte sedimentation rate (103 mm for the first hour [reference range, 0–22 mm]), high C-reactive protein (50.7 mg/L [reference range, up to 6 mg/L]), anemia (hemoglobin count, 7.3 g/dL [reference range, 13.5–17.5 g/dL]), thrombocytopenia (45×103/mm3 [reference range, 150×103/mm3), low serum albumin (2.3 g/dL [reference range, 3.4–5.4 g/dL]), elevated IgG and IgM anticardiolipin antibodies (IgG, 21.4 IgG phospholipid [GPL] units [reference range, <10 IgG phospholipid (GPL) units]; IgM, 59.4 IgM phospholipid (MPL) units [reference range, <7 IgM phospholipid (MPL) units]), positive lupus anticoagulant panel test, elevated anti-β2 glycoprotein antibodies (IgG, 17.5 µ/mL [reference range, <8 µ/mL]; IgM, 124.8 µ/mL [reference range, <8 µ/mL]), and low complement C3 (78 IU [reference range, 90–180 IU]). White blood cell count, liver and kidney functions, triglycerides, serum ferritin, and complement C4 all were normal. Hepatitis B surface antigen, hepatitis C viral antibody, HIV, antinuclear antibodies (ANA), antineutrophil cytoplasmic antibodies C and P (ANCA-C&P), and venereal disease research laboratory tests all were negative.

Nerve conduction velocity showed axonal sensory polyneuropathy. Motor nerve conduction studies for median and ulnar nerves were within normal range. Lower-limb nerves assessment was limited by the ulcerated areas and marked edema. Echocardiography was unremarkable. Arterial Doppler studies were only available for the upper limbs and were unremarkable.

A punch biopsy was taken from one of the necrotizing purpuric lesions on the legs, and histopathologic examination revealed foci of epidermal necrosis and subepidermal separation and superficial and deep perivascular and periadnexal infiltrates extending into the fat lobules. The infiltrates were mainly made up of foamy macrophages, and some contained globi (lepra cells), in addition to lymphocytes and many neutrophils with nuclear dust. Blood vessels in the superficial and deep dermis and in the subcutaneous fat showed fibrinoid necrosis in their walls with neutrophils infiltrating the walls and thrombi in the lumens (Figure 4). Modified Ziehl-Neelsen staining revealed clumps of acid-fast lepra bacilli inside vascular lumina and endothelial cell lining and within the foamy macrophages (Figure 5). Slit-skin smear examination was performed twice and yielded negative results. The slide and paraffin block of the already performed lymph node biopsy were retrieved. Examination revealed aggregates of foamy histiocytes surrounded by lymphocytes and plasma cells replacing normal lymphoid follicles. Modified Ziehl-Neelsen stain was performed, and clusters of acid-fast bacilli were detected within the foamy histiocytic infiltrate (Figure 6).

FIGURE 4. Photomicrograph depicting histopathologic changes of the skin biopsy taken from one of the necrotizing purpuric lesions on the legs in the form of dense collections of foamy histiocytes (lepra cells) in the subcutaneous fat with large vessel vasculitis and thrombosis (black arrow)(H&E, original magnification ×100).

FIGURE 5. Photomicrograph depicting acid-fast bacilli within the lumen of a blood vessel and within endothelial cells in the skin biopsy taken from one of the necrotizing purpuric lesions in the legs (modified Ziehl-Neelsen, original magnification ×1000, oil immersion).

FIGURE 6. Photomicrograph depicting acid-fast bacilli in the lymph node biopsy (modified Ziehl-Neelsen, original magnification ×1000, oil immersion).


According to the results of the skin biopsy, the revised result of the lymph node biopsy, and the pattern of neurologic deficit together with clinical and laboratory correlation, the patient was diagnosed with diffuse nonnodular lepromatous leprosy presenting with Lucio phenomenon (Lucio leprosy) and associated with lepromatous lymphadenitis.

The patient received the following treatment: methylprednisolone 500 mg (intravenous pulse therapy) followed by daily oral administration of prednisolone 10 mg, rifampicin 300 mg, dapsone 100 mg, clofazimine 100 mg, acetylsalicylic acid 150 mg, and enoxaparin sodium 80 mg. In addition, the scrotal Fournier gangrene–like lesion was treated by surgical debridement followed by vacuum therapy. By the second week after treatment, the gangrenous lesions of the fingers developed a line of demarcation, and the skin infarctions started to recede.

 

 

Comment

Despite a decrease in its prevalence through a World Health Organization (WHO)–empowered eradication program, leprosy still represents a health problem in endemic areas.1,2 It is characterized by a wide range of immune responses to Mycobacterium leprae, displaying a spectrum of clinical and histopathologic manifestations that vary from the tuberculoid or paucibacillary pole with a strong cell-mediated immune response and fewer organisms to the lepromatous or multibacillary pole with weaker cell-mediated immune response and higher loads of organisms.3 In addition to its well-known cutaneous and neurologic manifestations, leprosy can present with a variety of manifestations, including constitutional symptoms, musculoskeletal manifestations, and serologic abnormalities; thus, leprosy can mimic rheumatoid arthritis, spondyloarthritis, and vasculitis—a pitfall that may result in misdiagnosis as a rheumatologic disorder.3-7

The chronic course of leprosy can be disrupted by acute, immunologically mediated reactions known as lepra reactions, of which there are 3 types.8 Type I lepra reactions are cell mediated and occur mainly in patients with borderline disease, often representing an upgrade toward the tuberculoid pole; less often they represent a downgrade reaction. Nerves become painful and swollen with possible loss of function, and skin lesions become edematous and tender; sometimes arthritis develops.9 Type II lepra reactions, also known as erythema nodosum leprosum (ENL), occur in borderline lepromatous and lepromatous patients with a high bacillary load. They are characterized by fever, body aches, tender cutaneous/subcutaneous nodules that may ulcerate, possible bullous lesions, painful nerve swellings, swollen joints, iritis, lymphadenitis, glomerulonephritis, epididymo-orchitis, and hepatic affection. Both immune-complex and delayed hypersensitivity reactions play a role in ENL.8,10 The third reaction is a rare aggressive type known as Lucio phenomenon or Lucio leprosy, which presents with irregular-shaped, angulated, or stellar necrotizing purpuric lesions (hemorrhagic infacrtions) developing mainly on the extremities. The lesions evolve into ulcers that heal with atrophic scarring.2,11 Lucio phenomenon develops as a result of thrombotic vascular occlusion secondary to massive invasion of vascular endothelial cells by lepra bacilli.2,11-14 Involvement of the scrotal skin, such as in our patient, is rare.

Lucio phenomenon mainly is seen in Mexico and Central America, and few cases have been documented in Cuba, South America, the United States, India, Polynesia, South Africa, and Southeast Asia.15-17 It specifically occurs in patients with untreated, diffuse, nonnodular lepromatous leprosy (pure and primitive diffuse lepromatous leprosy (DLL)/diffuse leprosy of Lucio and Latapí). This type of leprosy was first described by Lucio and Alvarado18 in 1852 as a distinct form of lepromatous leprosy characterized by widespread and dense infiltration of the whole skin by lepra bacilli without the typical nodular lesions of leprosy, rendering its diagnosis challenging, especially in sporadic cases. Other manifestations of DLL include complete alopecia of the eyebrows and eyelashes, destructive rhinitis, and areas of anhidrosis and dyesthesia.2

Latapí and Chévez-Zomora19 defined Lucio phenomenon in 1948 as a form of histopathologic vasculitis restricted to patients with DLL. Histopathologically, in addition to the infiltration of the skin with acid-fast bacilli–laden foamy histiocytes, lesions of Lucio phenomenon show features of necrotizing (leukocytoclastic) vasculitis with fibrinoid necrosis20 or vascular thrombi with minimal perivascular lymphocytic infiltrate and no evidence of vasculitis.11 Medium to large vessels in the deep dermis and subcutaneous tissue show infiltration of their walls with a large number of macrophages laden with acid-fast bacilli.11 Cases with histopathologic features mimicking antiphospholipid syndrome with endothelial cell proliferation, thrombosis, and mild mononuclear cell infiltrate also may be seen.20 In all cases, ischemic epidermal necrosis is seen, as well as acid-fast bacilli, both singly and in clusters (globi) within endothelial cells and inside blood vessel lumina.

Although Lucio phenomenon initially was thought to be immune-complex mediated like ENL, it has been suggested that the main trigger is thrombotic vascular occlusion secondary to massive invasion of the vascular endothelial cells by the lepra bacilli, resulting in necrosis.14 Bacterial lipopolysaccharides promote the release of IL-1 and tumor necrosis factor α, which in turn stimulate the production of prostaglandins, IL-6, and coagulation factor III, leading to vascular thrombosis and tissue necrosis.21,22 Moreover, antiphospholipid antibodies, which have been found to be induced in response to certain infectious agents in genetically predisposed individuals,23 have been reported in patients with leprosy, mainly in association with lepromatous leprosy. The reported prevalence of anticardiolipin antibodies ranged from 37% to 98%, whereas anti-β2-glycoprotein I antibodies ranged from 3% to 19%, and antiprothrombin antibodies ranged from 6% to 45%.24,25 Antiphospholipid antibodies have been reported to play a role in the pathogenesis of Lucio phenomenon.11,13,15,26 Our case supports this hypothesis with positive anticardiolipin antibodies, anti-β2 glycoprotein antibodies, and positive lupus anticoagulant.

In accordance with Curi et al,2 who reported 5 cases of DLL with Lucio phenomenon, our patient showed a similar presentation with positive inflammatory markers in association with a negative autoimmune profile (ANA, ANCA-C&P) and negative venereal disease research laboratory test. It is important to mention that a positive autoimmune profile (ANA, ANCA-C&P) can be present in leprotic patients, causing possible diagnostic confusion with collagen diseases.27,28

An interesting finding in our case was the negative slit-skin smear results. Although the specificity of slit-skin smear is 100%, as it directly demonstrates the presence of acid-fast bacilli,29 its sensitivity is low and varies from 10% to 50%.30 The detection of acid-fast bacilli in tissue sections is reported to be a better method for confirming the diagnosis of leprosy.31

The provisional impression of hemophagocytic lymphohistiocytosis in the lymph node biopsy in our patient was excluded upon detection of acid-fast bacilli in the foamy histiocytes infiltrating the lymph node; moreover, the normal serum lipids and serum ferritin argued against this diagnosis.32 Leprosy tends to involve the lymph nodes, particularly in borderline, borderline lepromatous, and lepromatous forms.33 The incidence of lymph node involvement accompanied by skin lesions with the presence of acid-fast bacilli in the lymph nodes is 92.2%.34

Our patient showed an excellent response to antileprotic treatment, which was administered according to the WHO multidrug therapy guidelines for multibacillary leprosy,35 combined with low-dose prednisolone, acetylsalicylic acid, and anticoagulant treatment. Thalidomide and high-dose prednisolone (60 mg/d) combined with antileprotic treatment also have been reported to be successful in managing recurrent infarctions in leprosy.36 The Fournier-like gangrenous ulcer of the scrotum was managed by surgical debridement and vacuum therapy.

It is noteworthy that the WHO elimination goal for leprosy was to reduce the prevalence to less than 1 case per 10,000 population. Egypt is among the first countries in North Africa and the Middle East regions to achieve this target supervised by the National Leprosy Control Program as early as 1994; this was further reduced to 0.33 cases per 10,000 population in 2004, and reduced again in 2009; however, certain foci showed a prevalence rate more than the elimination target, particularly in the cities of Qena (1.12) and Sohag (2.47).37 Esna, where our patient is from, is an endemic area in Egypt.38

Conclusion

Leprosy is a great mimicker of many connective tissue diseases, including vasculitis. Antiphospholipid antibodies are involved in Lucio phenomenon. Recognition of Lucio phenomenon is important to initiate prompt treatment and avoid morbidity and mortality. We report a rare case of diffuse nonnodular lepromatous leprosy in Egypt in which Lucio phenomenon was the first diagnostic presentation. Scrotal involvement with Lucio phenomenon was not previously reported in any case of Lucio leprosy.

References

1. World Health Organization. World Health Statistics: 2011. World Health Organization; 2011. https://www.who.int/gho/publications/world_health_statistics/EN_WHS2011_Full.pdf

2. Curi PF, Villaroel JS, Migliore N, et al. Lucio’s phenomenon: report of five cases. Clin Rheumatol. 2016;35:1397-1401.

3. Shrestha B, Li YQ, Fu P. Leprosy mimics adult onset Still’s disease in a Chinese patient. Egypt Rheumatol. 2018;40:217-220.

4. Prasad S, Misra R, Aggarwal A, et al. Leprosy revealed in a rheumatology clinic: a case series. Int J Rheum Dis. 2013;16:129-133.

5. Chao G, Fang L, Lu C. Leprosy with ANA positive mistaken for connective tissue disease. Clin Rheumatol. 2013;32:645-648.

6. Chauhan S, Wakhlu A, Agarwal V. Arthritis in leprosy. Rheumatology. 2010;49:2237-2242.

7. Rath D, Bhargava S, Kundu BK. Leprosy mimicking common rheumatologic entities: a trial for the clinician in the era of biologics. Case Rep Rheumatol. 2014;2014:429698.

8. Cuevas J, Rodríguez-Peralto JL, Carrillo R, et al. Erythema nodosum leprosum: reactional leprosy. Semin Cutan Med Surg. 2007;26:126-130.

9. Henriques CC, Lopéz B, Mestre T, et al. Leprosy and rheumatoid arthritis: consequence or association? BMJ Case Rep. 2012;13:1-4.

10. Vázquez-Botet M, Sánchez JL. Erythema nodosum leprosum. Int J Dermatol. 1987;26:436-437.

11. Nunzie E, Ortega Cabrera LV, Macanchi Moncayo FM, et al. Lucio leprosy with Lucio’s phenomenon, digital gangrene and anticardiolipin antibodies. Lepr Rev. 2014;85:194-200.

12. Salvi S, Chopra A. Leprosy in a rheumatology setting: a challenging mimic to expose. Clin Rheumatol. 2013;32:1557-1563.

13. Azulay-Abulafia L, Pereira SL, Hardmann D, et al. Lucio phenomenon. vasculitis or occlusive vasculopathy? Hautarzt. 2006;57:1101-1105.

14. Benard G, Sakai-Valente NY, Bianconcini Trindade MA. Concomittant Lucio phenomenon and erythema nodosum in a leprosy patient: clues for their distinct pathogenesis. Am J Dermatopathol. 2009;31:288-292.

15. Rocha RH, Emerich PS, Diniz LM, et al. Lucio’s phenomenon: exuberant case report and review of Brazilian cases. An Bras Dermatol. 2016;91(suppl 5):S60-S63.

16. Costa IM, Kawano LB, Pereira CP, et al. Lucio’s phenomenon: a case report and review of the literature. Int J Dermatol. 2005;44:566-571.

17. Kumari R, Thappa DM, Basu D. A fatal case of Lucio phenomenon from India. Dermatol Online J. 2008;14:10.

18. Lucio R, Alvarado I. Opúsculo Sobre el Mal de San Lázaro o Elefantiasis de los Griegos. M. Murguía; 1852.

19. Latapí F, Chévez-Zamora A. The “spotted” leprosy of Lucio: an introduction to its clinical and histological study. Int J Lepr. 1948;16:421-437.

20. Vargas OF. Diffuse leprosy of Lucio and Latapí: a histologic study. Lepr Rev. 2007;78:248-260.

21. Latapí FR, Chevez-Zamora A. La lepra manchada de Lucio. Rev Dermatol Mex. 1978;22:102-107.

22. Monteiro R, Abreu MA, Tiezzi MG, et al. Fenômeno de Lúcio: mais um caso relatado no Brasil. An Bras Dermatol. 2012;87:296-300.

23. Gharavi EE, Chaimovich H, Cucucrull E, et al. Induction of antiphospholipid antibodies by immunization with synthetic bacterial & viral peptides. Lupus. 1999;8:449-455.

24. de Larrañaga GF, Forastiero RR, Martinuzzo ME, et al. High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity. Lupus. 2000;9:594-600.

25. Loizou S, Singh S, Wypkema E, et al. Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease. Ann Rheum Dis. 2003;62:1106-1111.

26. Akerkar SM, Bichile LS. Leprosy & gangrene: a rare association; role of antiphospholipid antibodies. BMC Infect Dis. 2005,5:74.

27. Horta-Baas G, Hernández-Cabrera MF, Barile-Fabris LA, et al. Multibacillary leprosy mimicking systemic lupus erythematosus: case report and literature review. Lupus. 2015;24:1095-1102.

28. Pradhan V, Badakere SS, Shankar KU. Increased incidence of cytoplasmic ANCA (cANCA) and other auto antibodies in leprosy patients from western India. Lepr Rev. 2004;75:50-56.

29. Oskam L. Diagnosis and classification of leprosy. Lepr Rev. 2002;73:17-26.

30. Rao PN. Recent advances in the control programs and therapy of leprosy. Indian J Dermatol Venereol Leprol. 2004;70:269-276.

31. Rao PN, Pratap D, Ramana Reddy AV, et al. Evaluation of leprosy patients with 1 to 5 skin lesions with relevance to their grouping into paucibacillary or multibacillary disease. Indian J Dermatol Venereol Leprol. 2006;72:207-210.

32. Rosado FGN, Kim AS. Hemophagocytic lymphohistiocytosis. an update on diagnosis and pathogenesis. Am J Clin Pathol. 2013;139:713-727.

33. Kar HK, Mohanty HC, Mohanty GN, et al. Clinicopathological study of lymph node involvement in leprosy. Lepr India. 1983;55:725-738.

34. Gupta JC, Panda PK, Shrivastava KK, et al. A histopathologic study of lymph nodes in 43 cases of leprosy. Lepr India. 1978;50:196-203.

35. WHO Expert Committee on Leprosy. Seventh Report. World Health Organization; 1998. https://apps.who.int/iris/bitstream/handle/10665/42060/WHO_TRS_874.pdf?sequence=1&isAllowed=y

36. Misra DP, Parida JR, Chowdhury AC, et al. Lepra reaction with Lucio phenomenon mimicking cutaneous vasculitis. Case Rep Immunol. 2014;2014:641989.

37. Amer A, Mansour A. Epidemiological study of leprosy in Egypt: 2005-2009. Egypt J Dermatol Venereol. 2014;34:70-73.

38. World Health Organization. Screening campaign aims to eliminate leprosy in Egypt. Published May 9, 2018. Accessed September 8, 2021. http://www.emro.who.int/egy/egypt-events/last-miless-activities-on-eliminating-leprosy-from-egypt.html

References

1. World Health Organization. World Health Statistics: 2011. World Health Organization; 2011. https://www.who.int/gho/publications/world_health_statistics/EN_WHS2011_Full.pdf

2. Curi PF, Villaroel JS, Migliore N, et al. Lucio’s phenomenon: report of five cases. Clin Rheumatol. 2016;35:1397-1401.

3. Shrestha B, Li YQ, Fu P. Leprosy mimics adult onset Still’s disease in a Chinese patient. Egypt Rheumatol. 2018;40:217-220.

4. Prasad S, Misra R, Aggarwal A, et al. Leprosy revealed in a rheumatology clinic: a case series. Int J Rheum Dis. 2013;16:129-133.

5. Chao G, Fang L, Lu C. Leprosy with ANA positive mistaken for connective tissue disease. Clin Rheumatol. 2013;32:645-648.

6. Chauhan S, Wakhlu A, Agarwal V. Arthritis in leprosy. Rheumatology. 2010;49:2237-2242.

7. Rath D, Bhargava S, Kundu BK. Leprosy mimicking common rheumatologic entities: a trial for the clinician in the era of biologics. Case Rep Rheumatol. 2014;2014:429698.

8. Cuevas J, Rodríguez-Peralto JL, Carrillo R, et al. Erythema nodosum leprosum: reactional leprosy. Semin Cutan Med Surg. 2007;26:126-130.

9. Henriques CC, Lopéz B, Mestre T, et al. Leprosy and rheumatoid arthritis: consequence or association? BMJ Case Rep. 2012;13:1-4.

10. Vázquez-Botet M, Sánchez JL. Erythema nodosum leprosum. Int J Dermatol. 1987;26:436-437.

11. Nunzie E, Ortega Cabrera LV, Macanchi Moncayo FM, et al. Lucio leprosy with Lucio’s phenomenon, digital gangrene and anticardiolipin antibodies. Lepr Rev. 2014;85:194-200.

12. Salvi S, Chopra A. Leprosy in a rheumatology setting: a challenging mimic to expose. Clin Rheumatol. 2013;32:1557-1563.

13. Azulay-Abulafia L, Pereira SL, Hardmann D, et al. Lucio phenomenon. vasculitis or occlusive vasculopathy? Hautarzt. 2006;57:1101-1105.

14. Benard G, Sakai-Valente NY, Bianconcini Trindade MA. Concomittant Lucio phenomenon and erythema nodosum in a leprosy patient: clues for their distinct pathogenesis. Am J Dermatopathol. 2009;31:288-292.

15. Rocha RH, Emerich PS, Diniz LM, et al. Lucio’s phenomenon: exuberant case report and review of Brazilian cases. An Bras Dermatol. 2016;91(suppl 5):S60-S63.

16. Costa IM, Kawano LB, Pereira CP, et al. Lucio’s phenomenon: a case report and review of the literature. Int J Dermatol. 2005;44:566-571.

17. Kumari R, Thappa DM, Basu D. A fatal case of Lucio phenomenon from India. Dermatol Online J. 2008;14:10.

18. Lucio R, Alvarado I. Opúsculo Sobre el Mal de San Lázaro o Elefantiasis de los Griegos. M. Murguía; 1852.

19. Latapí F, Chévez-Zamora A. The “spotted” leprosy of Lucio: an introduction to its clinical and histological study. Int J Lepr. 1948;16:421-437.

20. Vargas OF. Diffuse leprosy of Lucio and Latapí: a histologic study. Lepr Rev. 2007;78:248-260.

21. Latapí FR, Chevez-Zamora A. La lepra manchada de Lucio. Rev Dermatol Mex. 1978;22:102-107.

22. Monteiro R, Abreu MA, Tiezzi MG, et al. Fenômeno de Lúcio: mais um caso relatado no Brasil. An Bras Dermatol. 2012;87:296-300.

23. Gharavi EE, Chaimovich H, Cucucrull E, et al. Induction of antiphospholipid antibodies by immunization with synthetic bacterial & viral peptides. Lupus. 1999;8:449-455.

24. de Larrañaga GF, Forastiero RR, Martinuzzo ME, et al. High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity. Lupus. 2000;9:594-600.

25. Loizou S, Singh S, Wypkema E, et al. Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease. Ann Rheum Dis. 2003;62:1106-1111.

26. Akerkar SM, Bichile LS. Leprosy & gangrene: a rare association; role of antiphospholipid antibodies. BMC Infect Dis. 2005,5:74.

27. Horta-Baas G, Hernández-Cabrera MF, Barile-Fabris LA, et al. Multibacillary leprosy mimicking systemic lupus erythematosus: case report and literature review. Lupus. 2015;24:1095-1102.

28. Pradhan V, Badakere SS, Shankar KU. Increased incidence of cytoplasmic ANCA (cANCA) and other auto antibodies in leprosy patients from western India. Lepr Rev. 2004;75:50-56.

29. Oskam L. Diagnosis and classification of leprosy. Lepr Rev. 2002;73:17-26.

30. Rao PN. Recent advances in the control programs and therapy of leprosy. Indian J Dermatol Venereol Leprol. 2004;70:269-276.

31. Rao PN, Pratap D, Ramana Reddy AV, et al. Evaluation of leprosy patients with 1 to 5 skin lesions with relevance to their grouping into paucibacillary or multibacillary disease. Indian J Dermatol Venereol Leprol. 2006;72:207-210.

32. Rosado FGN, Kim AS. Hemophagocytic lymphohistiocytosis. an update on diagnosis and pathogenesis. Am J Clin Pathol. 2013;139:713-727.

33. Kar HK, Mohanty HC, Mohanty GN, et al. Clinicopathological study of lymph node involvement in leprosy. Lepr India. 1983;55:725-738.

34. Gupta JC, Panda PK, Shrivastava KK, et al. A histopathologic study of lymph nodes in 43 cases of leprosy. Lepr India. 1978;50:196-203.

35. WHO Expert Committee on Leprosy. Seventh Report. World Health Organization; 1998. https://apps.who.int/iris/bitstream/handle/10665/42060/WHO_TRS_874.pdf?sequence=1&isAllowed=y

36. Misra DP, Parida JR, Chowdhury AC, et al. Lepra reaction with Lucio phenomenon mimicking cutaneous vasculitis. Case Rep Immunol. 2014;2014:641989.

37. Amer A, Mansour A. Epidemiological study of leprosy in Egypt: 2005-2009. Egypt J Dermatol Venereol. 2014;34:70-73.

38. World Health Organization. Screening campaign aims to eliminate leprosy in Egypt. Published May 9, 2018. Accessed September 8, 2021. http://www.emro.who.int/egy/egypt-events/last-miless-activities-on-eliminating-leprosy-from-egypt.html

Issue
Cutis - 108(6)
Issue
Cutis - 108(6)
Page Number
E4-E8
Page Number
E4-E8
Publications
Publications
Topics
Article Type
Sections
Inside the Article

 

Practice Points

  • Leprosy is a great mimicker of many connective tissue diseases, including vasculitis.
  • Antiphospholipid antibodies are involved in Lucio phenomenon.
  • Prompt treatment is important in Lucio phenomenon to avoid morbidity and mortality.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

A Fatal Case of Hemophagocytic Lymphohistiocytosis Secondary to Anti-MDA5–Positive Dermatomyositis

Article Type
Changed
Tue, 12/14/2021 - 15:40

 

To the Editor:

Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by bilateral, symmetrical, proximal muscle weakness and classic cutaneous manifestations.1 Patients with antibodies directed against melanoma differentiation–associated gene 5, MDA5, have a distinct presentation due to vasculopathy with more severe cutaneous ulcerations, palmar papules, alopecia, and an elevated risk of rapidly progressive interstitial lung disease.2 A ferritin level greater than 1600 ng/mL portends an increased risk for pulmonary disease and therefore can be of prognostic value.3 Further, patients with anti-MDA5 DM are at a lower risk of malignancy and are more likely to test negative for antinuclear antibodies in comparison to other patients with DM.2,4

Hemophagocytic lymphohistiocytosis (HLH), also known as hemophagocytic syndrome, is a potentially lethal condition whereby uncontrolled activation of histiocytes in the reticuloendothelial system causes hemophagocytosis and a hyperinflammatory state. Patients present with fever, splenomegaly, cytopenia, and hyperferritinemia.5 Autoimmune‐associated hemophagocytic syndrome (AAHS) describes HLH that develops in association with autoimmune conditions, most commonly systemic lupus erythematosus and adult-onset Still disease. Cases reported in association with DM exist but are few in number, and there is no standard-of-care treatment.6 We report a case of a woman with anti-MDA5 DM complicated by HLH and DM-associated liver injury.



A 50-year-old woman presented as a direct admit from the rheumatology clinic for diffuse muscle weakness of 8 months’ duration, 40-pound unintentional weight loss, pruritic rash, bilateral joint pains, dry eyes, dry mouth, and altered mental status. Four months prior, she presented to an outside hospital and was given a diagnosis of probable Sjögren syndrome and autoimmune hepatitis vs drug-induced liver injury. At that time, a workup was notable for antibodies against Sjögren syndrome–related antigen A, anti–smooth muscle antibodies, and transaminitis. Ultrasonography of the right upper quadrant revealed hepatic steatosis. The patient was started on oral prednisone and pilocarpine but had been off all medications for 1 month when she presented to our hospital.

On hospital admission, physical examination revealed a violaceous heliotrope rash; a v-sign on the chest; shawl sign; palmar papules with pits at the fingertips; and periungual erythema and ulcerations along the metacarpophalangeal joints, elbows, lateral feet, and upper eyelids (Figure 1). Laboratory workup showed the following results: white blood cell count, 4100/μL (reference range, 4000–11,000/μL); hemoglobin, 11.6 g/dL (reference range, 12–16 g/dL); platelet count, 100,000/μL (reference range, 150,000–450,000/μL); lactate dehydrogenase, 510 U/L (reference range, 80–225 U/L); alkaline phosphatase (ALP), 766 U/L (reference range, 30–120 U/L); alanine aminotransferase (ALT), 88 U/L (reference range, 10–40 U/L); aspartate aminotransferase (AST), 544 U/L (reference range, 10–40 U/L); total bilirubin, 4.2 mg/dL (reference range, 0.3–1.0 mg/dL); direct bilirubin, 3.7 mg/dL (reference range, 0.1–0.3 mg/dL); aldolase, 20.2 U/L (reference range, 1–7.5 U/L), creatine kinase, 180 U/L (reference range, 30–135 U/L); γ-glutamyltransferase (GGT), 2743 U/L (reference range, 8–40 U/L); high sensitivity C-reactive protein, 122.9 mg/L (low-risk reference range, <1.0 mg/L); triglycerides, 534 mg/dL (reference range, <150 mg/dL); ferritin, 3784 ng/mL (reference range, 24–307 ng/mL); antinuclear antibody, negative titer; antimitochondrial antibody, negative titer; soluble IL-2 receptor (CD25), 7000 U/mL (reference range, 189–846 U/mL); anti-Sjögren syndrome–related antigen A antibody, positive.

FIGURE 1. A–C, At first hospital admission, physical examination revealed ulcerations along the metacarpophalangeal joints, painful palmar papules, and ulcerations on the buttocks, respectively.

Magnetic resonance imaging of the shoulders showed diffuse soft-tissue edema. Computed tomography (CT) of the chest demonstrated parabronchial thickening and parenchymal bands suggestive of DM. An age-appropriate malignancy workup was negative, and results from a liver biopsy showed diffuse steatosis with no histologic evidence of autoimmune hepatitis. Punch biopsy results from a plaque on the left knee revealed vacuolar interface dermatitis with increased dermal mucin on colloidal iron staining, indicative of connective tissue disease (Figure 2). The patient was treated with intravenous (IV) methylprednisolone 250 mg twice daily for 2 days followed by oral prednisone 50 mg daily with IV immunoglobulin (IVIG) 0.4 mg/kg daily for 5 days. The patient’s symptoms improved, and she was discharged on oral prednisone 50 mg and mycophenolate mofetil 1000 mg twice daily with a plan for outpatient IVIG.

FIGURE 2. A, Histopathology revealed vacuolar interface dermatitis (arrows)(H&E, original magnification ×40). B, Colloidal iron staining showed increased dermal mucin (arrows), consistent with connective tissue disease. Reference bars indicate 50 µm.


Two days after discharge, the patient was re-admitted for worsening muscle weakness; recalcitrant rash; new-onset hypophonia, dysphagia, and odynophagia; and intermittent fevers. Myositis panel results were positive for MDA5. Additionally, workup for HLH, which was initiated during the first hospital admission, revealed that she met 6 of 8 diagnostic criteria: intermittent fevers (maximum temperature, 38.2 °C), splenomegaly (12.6 cm on CT scan of abdomen), cytopenia in 2 cell lines (anemia, thrombocytopenia), hypertriglyceridemia, hyperferritinemia, and elevated IL-2 receptor (CD25). Based on these findings, the patient was diagnosed with anti-MDA5 DM associated with HLH.

The patient was started on IV methylprednisolone 1000 mg daily and received 1 rituximab infusion. Two days later, she experienced worsening fever with tachycardia, and a chest radiograph showed bibasilar infiltrates concerning for aspiration pneumonia, with sputum cultures growing Staphylococcus aureus. Due to the infection, the dosage of methylprednisolone was decreased to 16 mg 3 times daily and rituximab was stopped. The hematology department was consulted for the patient’s HLH, and due to her profound weakness and sepsis, the decision was made to hold initiation of etoposide, which, in addition to glucocorticoids, is considered first-line therapy for HLH. She subsequently experienced worsening hypoxia requiring intubation and received a second course of IVIG. Two days later, CT of the chest revealed progressive ground-glass opacities in the lower lobes of the lungs. The patient was then started on plasmapheresis every other day, hydroxychloroquine 200 mg daily, and IV methylprednisolone 1000 mg daily. Over the subsequent 6 days, she developed worsening renal failure, liver dysfunction, profound thrombocytopenia (13/μL), and acidemia. After extensive discussion with her family, the patient was transitioned to comfort care, and she died 33 days after the initial admission to our hospital.

Our case is a collection of several rare presentations: anti-MDA5 DM, with HLH and AAHS as complications of anti-MDA5 DM, and DM-associated liver injury. Anti-MDA5 DM is frequently refractory to conventional therapy, including high-dose glucocorticoids, cyclophosphamide, oral tacrolimus, and cyclosporine, and there currently is no single treatment algorithm.2 Lake and colleagues7 highlighted the importance of personalizing treatment of anti-MDA5 DM, as it can be one of the most aggressive rheumatologic diseases. We initially chose to treat our patient with high-dose methylprednisolone, IVIG, and rituximab. Kampylafka et al8 performed a retrospective analysis of the use of IVIG for DM as compared to standard therapy and demonstrated improved muscle and cutaneous involvement from a collection of 50 patients. Case reports have specifically revealed efficacy for the use of IVIG in patients with anti-MDA5 DM.9,10 Additionally, rituximab—an anti–B lymphocyte therapy—has been shown to be an effective supplemental therapy for cases of aggressive anti-MDA5 DM with associated interstitial lung disease, especially when conventional therapy has failed.11,12 Our patient’s sepsis secondary to S aureus pneumonia limited her to only receiving 1 dose of rituximab.

One promising treatment approach for anti-MDA5 DM recently published by Tsuji et al13 involves the use of combination therapy. In this prospective multicenter trial, patients were initially treated with a combination of high-dose glucocorticoids, oral tacrolimus, and IV cyclophosphamide. Plasmapheresis was then started for patients without symptomatic improvement. This method was compared to the more traditional step-up approach of high-dose steroids followed by another immunosuppressant. At 1-year follow-up, the combination therapy group demonstrated an 85% survival rate compared to 33% of historical controls.13

We suspect that our patient developed HLH and AAHS secondary to her underlying anti-MDA5 DM. Kumakura and Murakawa6 reported that among 116 cases of AAHS, 6.9% of cases were associated with DM, most commonly anti-Jo-1 DM. Hemophagocytic lymphohistiocytosis associated with anti-MDA5 DM has been described in only a few cases.14-16 The diagnosis of HLH is critical, as the treatments for HLH and DM differ. Both diseases manifest with hyperferritinemia—greater than 500 ng/mL in the case of HLH and 3784 ng/mL in our patient. Therefore, HLH can be easily overlooked. It is possible the rates of HLH associated with anti-MDA5 DM are higher than reported given their similar presentations.

Analogous to our case, Fujita et al15 reported a case of HLH associated with anti-MDA5 DM successfully treated with IV cyclophosphamide pulse therapy and plasmapheresis. The rationale for using plasmapheresis in anti-MDA5 DM is based on its success in patients with other antibody-mediated conditions such as Goodpasture syndrome and granulomatosis with polyangiitis.7 It is thought to expedite response to traditional treatment, and in the case described by Fujita et al,15 the patient received plasmapheresis 6 times total over the course of 9 days. The patient’s clinical symptoms, as well as platelet levels, liver enzymes, and ferritin value, improved.15 Our patient received 3 days of plasmapheresis with no improvement when the decision was made to discontinue plasmapheresis given her worsening clinical state.

Additionally, our patient had elevated hepatic enzymes (ALT, AST, ALP, GGT), and results of a liver biopsy demonstrated diffuse steatosis. We speculate her transaminitis was a complication of anti-MDA5 DM. Hepatocellular damage accompanying DM has been investigated in multiple studies and is most often defined as an elevated ALT.17-20 Improvement in ALT levels has been seen with DM treatment. However, investigators note that creatine kinase (CK) values often do not correlate with the resolution of the transaminitis, suggesting that CK denotes muscle damage whereas ALT represents separate liver damage.18-21

Nagashima et al22 highlighted that among 50 patients with DM without malignancy, only 20% presented with a transaminitis or elevated bilirubin. However, among those with liver injury, all were positive for antibodies against MDA5.22 The patients with anti-MDA5 DM liver dysfunction had higher ALT, ALP, and GGT levels compared to those without liver dysfunction. Similarly, in a retrospective review of 14 patients with anti-MDA5 DM, Gono and colleagues3 found elevated GGT levels and lower CK levels in comparison to patients with anti-aminoacyl-transfer RNA synthetase DM. Although liver enzymes can be elevated in patients with DM secondary to muscle damage, the authors argue that the specificity of GGT to the liver suggests intrinsic liver damage.3

The mechanism behind liver disease in anti-MDA5 DM is unclear, but it is hypothesized to be similar to nonalcoholic steatohepatitis.22 Other studies have revealed drug-induced hepatitis, hepatic congestion, nonspecific reactive hepatitis, metastatic liver tumor, primary biliary cholangitis, and autoimmune hepatitis as the etiology behind liver disease in their patients with DM.17-19 Liver biopsy results from patients with anti-MDA5 DM most commonly reveal hepatic steatosis, as seen in our patient, as well as hepatocyte ballooning and increased pigmented macrophages.22

We presented a case of anti-MDA5 DM complicated by HLH. Our patient had a fatal outcome despite aggressive treatment with high-dose methylprednisolone, IVIG, rituximab, and plasmapheresis. It is accepted that anti-MDA5 DM affects the lungs and skin, and our patient’s presentation also suggests liver involvement. In our case, onset of symptoms to fatality was approximately 1 year. It is essential to consider the diagnosis of HLH in all cases of anti-MDA5 DM given clinical disease overlap. Our patient could have benefited from earlier disease recognition and thus earlier aggressive therapy.

 

References

1. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344-347.

2. Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018;78:776-785.

3. Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49:1713-1719.

4. Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65:25-34.

5. Sepulveda FE, de Saint Basile G. Hemophagocytic syndrome: primary forms and predisposing conditions. Curr Opin Immunol. 2017;49:20-26.

6. Kumakura S, Murakawa Y. Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheum. 2014;66:2297-2307.

7. Lake M, George G, Summer R. Time to personalize the treatment of anti-MDA-5 associated lung disease. Ann Rheum Dis. 2019;78:E52.

8. Kampylafka EI, Kosmidis ML, Panagiotakos DB, et al. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study. Clin Exp Rheumatol. 2012;30:397-401.

9. Koguchi-Yoshioka H, Okiyama N, Iwamoto K, et al. Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules/papules. Br J Dermatol. 2017;177:1442-1446.

10. Hamada-Ode K, Taniguchi Y, Kimata T, et al. High-dose intravenous immunoglobulin therapy for rapidly progressive interstitial pneumonitis accompanied by anti-melanoma differentiation-associated gene 5 antibody-positive amyopathic dermatomyositis. Eur J Rheumatol. 2015;2:83-85.

11. So H, Wong VTL, Lao VWN, et al. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clin Rheumatol. 2018;37:1983-1989.

12. Koichi Y, Aya Y, Megumi U, et al. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol. 2017;27:536-540.

13. Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020;72:488-498.

14. Honda M, Moriyama M, Kondo M, et al. Three cases of autoimmune-associated haemophagocytic syndrome in dermatomyositis with anti-MDA5 autoantibody. Scand J Rheumatol. 2020;49:244-246.

15. Fujita Y, Fukui S, Suzuki T, et al. Anti-MDA5 antibody-positive dermatomyositis complicated by autoimmune-associated hemophagocytic syndrome that was successfully treated with immunosuppressive therapy and plasmapheresis. Intern Med. 2018;57:3473-3478.

16. Gono T, Miyake K, Kawaguchi Y, et al. Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM. Rheumatology (Oxford). 2012;51:1336-1338.

17. Wada T, Abe G, Kudou, T, et al. Liver damage in patients with polymyositis and dermatomyositis. Kitasato Med Journal. 2016;46:40-46.

18. Takahashi A, Abe K, Yokokawa J, et al. Clinical features of liver dysfunction in collagen diseases. Hepatol Res. 2010;40:1092-1097.

19. Matsumoto T, Kobayashi S, Shimizu H, et al. The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver. 2000;20:366-373.

20. Shi Q, Niu J, Huang X, et al. Do muscle enzyme changes forecast liver injury in polymyositis/dermatomyositis patients treated with methylprednisolone and methotrexate? Ann Clin Lab Sci. 2016;46:266-269.

21. Noda S, Asano Y, Tamaki Z, et al. A case of dermatomyositis with “liver disease associated with rheumatoid diseases” positive for anti-liver-kidney microsome-1 antibody. Clin Rheumatol. 2010;29:941-943.

22. Nagashima T, Kamata Y, Iwamoto M, et al. Liver dysfunction in anti-melanoma differentiation-associated gene 5 antibody-positive patients with dermatomyositis. Rheumatol Int. 2019;39:901-909.

Article PDF
Author and Disclosure Information

Dr. Riopelle is from the Department of Dermatology, Boston Medical Center, Massachusetts.

Drs. Zikry, Rabi, Crew, and Worswick are from the Department of Dermatology, University of Southern California Keck School of Medicine, Los Angeles.

The authors report no conflict of interest.

Correspondence: Alexandria Riopelle, MD, 609 Albany St, Boston, MA 02118 (LexiRiopelle@gmail.com).

Issue
Cutis - 108(5)
Publications
Topics
Page Number
E35-E38
Sections
Author and Disclosure Information

Dr. Riopelle is from the Department of Dermatology, Boston Medical Center, Massachusetts.

Drs. Zikry, Rabi, Crew, and Worswick are from the Department of Dermatology, University of Southern California Keck School of Medicine, Los Angeles.

The authors report no conflict of interest.

Correspondence: Alexandria Riopelle, MD, 609 Albany St, Boston, MA 02118 (LexiRiopelle@gmail.com).

Author and Disclosure Information

Dr. Riopelle is from the Department of Dermatology, Boston Medical Center, Massachusetts.

Drs. Zikry, Rabi, Crew, and Worswick are from the Department of Dermatology, University of Southern California Keck School of Medicine, Los Angeles.

The authors report no conflict of interest.

Correspondence: Alexandria Riopelle, MD, 609 Albany St, Boston, MA 02118 (LexiRiopelle@gmail.com).

Article PDF
Article PDF

 

To the Editor:

Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by bilateral, symmetrical, proximal muscle weakness and classic cutaneous manifestations.1 Patients with antibodies directed against melanoma differentiation–associated gene 5, MDA5, have a distinct presentation due to vasculopathy with more severe cutaneous ulcerations, palmar papules, alopecia, and an elevated risk of rapidly progressive interstitial lung disease.2 A ferritin level greater than 1600 ng/mL portends an increased risk for pulmonary disease and therefore can be of prognostic value.3 Further, patients with anti-MDA5 DM are at a lower risk of malignancy and are more likely to test negative for antinuclear antibodies in comparison to other patients with DM.2,4

Hemophagocytic lymphohistiocytosis (HLH), also known as hemophagocytic syndrome, is a potentially lethal condition whereby uncontrolled activation of histiocytes in the reticuloendothelial system causes hemophagocytosis and a hyperinflammatory state. Patients present with fever, splenomegaly, cytopenia, and hyperferritinemia.5 Autoimmune‐associated hemophagocytic syndrome (AAHS) describes HLH that develops in association with autoimmune conditions, most commonly systemic lupus erythematosus and adult-onset Still disease. Cases reported in association with DM exist but are few in number, and there is no standard-of-care treatment.6 We report a case of a woman with anti-MDA5 DM complicated by HLH and DM-associated liver injury.



A 50-year-old woman presented as a direct admit from the rheumatology clinic for diffuse muscle weakness of 8 months’ duration, 40-pound unintentional weight loss, pruritic rash, bilateral joint pains, dry eyes, dry mouth, and altered mental status. Four months prior, she presented to an outside hospital and was given a diagnosis of probable Sjögren syndrome and autoimmune hepatitis vs drug-induced liver injury. At that time, a workup was notable for antibodies against Sjögren syndrome–related antigen A, anti–smooth muscle antibodies, and transaminitis. Ultrasonography of the right upper quadrant revealed hepatic steatosis. The patient was started on oral prednisone and pilocarpine but had been off all medications for 1 month when she presented to our hospital.

On hospital admission, physical examination revealed a violaceous heliotrope rash; a v-sign on the chest; shawl sign; palmar papules with pits at the fingertips; and periungual erythema and ulcerations along the metacarpophalangeal joints, elbows, lateral feet, and upper eyelids (Figure 1). Laboratory workup showed the following results: white blood cell count, 4100/μL (reference range, 4000–11,000/μL); hemoglobin, 11.6 g/dL (reference range, 12–16 g/dL); platelet count, 100,000/μL (reference range, 150,000–450,000/μL); lactate dehydrogenase, 510 U/L (reference range, 80–225 U/L); alkaline phosphatase (ALP), 766 U/L (reference range, 30–120 U/L); alanine aminotransferase (ALT), 88 U/L (reference range, 10–40 U/L); aspartate aminotransferase (AST), 544 U/L (reference range, 10–40 U/L); total bilirubin, 4.2 mg/dL (reference range, 0.3–1.0 mg/dL); direct bilirubin, 3.7 mg/dL (reference range, 0.1–0.3 mg/dL); aldolase, 20.2 U/L (reference range, 1–7.5 U/L), creatine kinase, 180 U/L (reference range, 30–135 U/L); γ-glutamyltransferase (GGT), 2743 U/L (reference range, 8–40 U/L); high sensitivity C-reactive protein, 122.9 mg/L (low-risk reference range, <1.0 mg/L); triglycerides, 534 mg/dL (reference range, <150 mg/dL); ferritin, 3784 ng/mL (reference range, 24–307 ng/mL); antinuclear antibody, negative titer; antimitochondrial antibody, negative titer; soluble IL-2 receptor (CD25), 7000 U/mL (reference range, 189–846 U/mL); anti-Sjögren syndrome–related antigen A antibody, positive.

FIGURE 1. A–C, At first hospital admission, physical examination revealed ulcerations along the metacarpophalangeal joints, painful palmar papules, and ulcerations on the buttocks, respectively.

Magnetic resonance imaging of the shoulders showed diffuse soft-tissue edema. Computed tomography (CT) of the chest demonstrated parabronchial thickening and parenchymal bands suggestive of DM. An age-appropriate malignancy workup was negative, and results from a liver biopsy showed diffuse steatosis with no histologic evidence of autoimmune hepatitis. Punch biopsy results from a plaque on the left knee revealed vacuolar interface dermatitis with increased dermal mucin on colloidal iron staining, indicative of connective tissue disease (Figure 2). The patient was treated with intravenous (IV) methylprednisolone 250 mg twice daily for 2 days followed by oral prednisone 50 mg daily with IV immunoglobulin (IVIG) 0.4 mg/kg daily for 5 days. The patient’s symptoms improved, and she was discharged on oral prednisone 50 mg and mycophenolate mofetil 1000 mg twice daily with a plan for outpatient IVIG.

FIGURE 2. A, Histopathology revealed vacuolar interface dermatitis (arrows)(H&E, original magnification ×40). B, Colloidal iron staining showed increased dermal mucin (arrows), consistent with connective tissue disease. Reference bars indicate 50 µm.


Two days after discharge, the patient was re-admitted for worsening muscle weakness; recalcitrant rash; new-onset hypophonia, dysphagia, and odynophagia; and intermittent fevers. Myositis panel results were positive for MDA5. Additionally, workup for HLH, which was initiated during the first hospital admission, revealed that she met 6 of 8 diagnostic criteria: intermittent fevers (maximum temperature, 38.2 °C), splenomegaly (12.6 cm on CT scan of abdomen), cytopenia in 2 cell lines (anemia, thrombocytopenia), hypertriglyceridemia, hyperferritinemia, and elevated IL-2 receptor (CD25). Based on these findings, the patient was diagnosed with anti-MDA5 DM associated with HLH.

The patient was started on IV methylprednisolone 1000 mg daily and received 1 rituximab infusion. Two days later, she experienced worsening fever with tachycardia, and a chest radiograph showed bibasilar infiltrates concerning for aspiration pneumonia, with sputum cultures growing Staphylococcus aureus. Due to the infection, the dosage of methylprednisolone was decreased to 16 mg 3 times daily and rituximab was stopped. The hematology department was consulted for the patient’s HLH, and due to her profound weakness and sepsis, the decision was made to hold initiation of etoposide, which, in addition to glucocorticoids, is considered first-line therapy for HLH. She subsequently experienced worsening hypoxia requiring intubation and received a second course of IVIG. Two days later, CT of the chest revealed progressive ground-glass opacities in the lower lobes of the lungs. The patient was then started on plasmapheresis every other day, hydroxychloroquine 200 mg daily, and IV methylprednisolone 1000 mg daily. Over the subsequent 6 days, she developed worsening renal failure, liver dysfunction, profound thrombocytopenia (13/μL), and acidemia. After extensive discussion with her family, the patient was transitioned to comfort care, and she died 33 days after the initial admission to our hospital.

Our case is a collection of several rare presentations: anti-MDA5 DM, with HLH and AAHS as complications of anti-MDA5 DM, and DM-associated liver injury. Anti-MDA5 DM is frequently refractory to conventional therapy, including high-dose glucocorticoids, cyclophosphamide, oral tacrolimus, and cyclosporine, and there currently is no single treatment algorithm.2 Lake and colleagues7 highlighted the importance of personalizing treatment of anti-MDA5 DM, as it can be one of the most aggressive rheumatologic diseases. We initially chose to treat our patient with high-dose methylprednisolone, IVIG, and rituximab. Kampylafka et al8 performed a retrospective analysis of the use of IVIG for DM as compared to standard therapy and demonstrated improved muscle and cutaneous involvement from a collection of 50 patients. Case reports have specifically revealed efficacy for the use of IVIG in patients with anti-MDA5 DM.9,10 Additionally, rituximab—an anti–B lymphocyte therapy—has been shown to be an effective supplemental therapy for cases of aggressive anti-MDA5 DM with associated interstitial lung disease, especially when conventional therapy has failed.11,12 Our patient’s sepsis secondary to S aureus pneumonia limited her to only receiving 1 dose of rituximab.

One promising treatment approach for anti-MDA5 DM recently published by Tsuji et al13 involves the use of combination therapy. In this prospective multicenter trial, patients were initially treated with a combination of high-dose glucocorticoids, oral tacrolimus, and IV cyclophosphamide. Plasmapheresis was then started for patients without symptomatic improvement. This method was compared to the more traditional step-up approach of high-dose steroids followed by another immunosuppressant. At 1-year follow-up, the combination therapy group demonstrated an 85% survival rate compared to 33% of historical controls.13

We suspect that our patient developed HLH and AAHS secondary to her underlying anti-MDA5 DM. Kumakura and Murakawa6 reported that among 116 cases of AAHS, 6.9% of cases were associated with DM, most commonly anti-Jo-1 DM. Hemophagocytic lymphohistiocytosis associated with anti-MDA5 DM has been described in only a few cases.14-16 The diagnosis of HLH is critical, as the treatments for HLH and DM differ. Both diseases manifest with hyperferritinemia—greater than 500 ng/mL in the case of HLH and 3784 ng/mL in our patient. Therefore, HLH can be easily overlooked. It is possible the rates of HLH associated with anti-MDA5 DM are higher than reported given their similar presentations.

Analogous to our case, Fujita et al15 reported a case of HLH associated with anti-MDA5 DM successfully treated with IV cyclophosphamide pulse therapy and plasmapheresis. The rationale for using plasmapheresis in anti-MDA5 DM is based on its success in patients with other antibody-mediated conditions such as Goodpasture syndrome and granulomatosis with polyangiitis.7 It is thought to expedite response to traditional treatment, and in the case described by Fujita et al,15 the patient received plasmapheresis 6 times total over the course of 9 days. The patient’s clinical symptoms, as well as platelet levels, liver enzymes, and ferritin value, improved.15 Our patient received 3 days of plasmapheresis with no improvement when the decision was made to discontinue plasmapheresis given her worsening clinical state.

Additionally, our patient had elevated hepatic enzymes (ALT, AST, ALP, GGT), and results of a liver biopsy demonstrated diffuse steatosis. We speculate her transaminitis was a complication of anti-MDA5 DM. Hepatocellular damage accompanying DM has been investigated in multiple studies and is most often defined as an elevated ALT.17-20 Improvement in ALT levels has been seen with DM treatment. However, investigators note that creatine kinase (CK) values often do not correlate with the resolution of the transaminitis, suggesting that CK denotes muscle damage whereas ALT represents separate liver damage.18-21

Nagashima et al22 highlighted that among 50 patients with DM without malignancy, only 20% presented with a transaminitis or elevated bilirubin. However, among those with liver injury, all were positive for antibodies against MDA5.22 The patients with anti-MDA5 DM liver dysfunction had higher ALT, ALP, and GGT levels compared to those without liver dysfunction. Similarly, in a retrospective review of 14 patients with anti-MDA5 DM, Gono and colleagues3 found elevated GGT levels and lower CK levels in comparison to patients with anti-aminoacyl-transfer RNA synthetase DM. Although liver enzymes can be elevated in patients with DM secondary to muscle damage, the authors argue that the specificity of GGT to the liver suggests intrinsic liver damage.3

The mechanism behind liver disease in anti-MDA5 DM is unclear, but it is hypothesized to be similar to nonalcoholic steatohepatitis.22 Other studies have revealed drug-induced hepatitis, hepatic congestion, nonspecific reactive hepatitis, metastatic liver tumor, primary biliary cholangitis, and autoimmune hepatitis as the etiology behind liver disease in their patients with DM.17-19 Liver biopsy results from patients with anti-MDA5 DM most commonly reveal hepatic steatosis, as seen in our patient, as well as hepatocyte ballooning and increased pigmented macrophages.22

We presented a case of anti-MDA5 DM complicated by HLH. Our patient had a fatal outcome despite aggressive treatment with high-dose methylprednisolone, IVIG, rituximab, and plasmapheresis. It is accepted that anti-MDA5 DM affects the lungs and skin, and our patient’s presentation also suggests liver involvement. In our case, onset of symptoms to fatality was approximately 1 year. It is essential to consider the diagnosis of HLH in all cases of anti-MDA5 DM given clinical disease overlap. Our patient could have benefited from earlier disease recognition and thus earlier aggressive therapy.

 

 

To the Editor:

Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by bilateral, symmetrical, proximal muscle weakness and classic cutaneous manifestations.1 Patients with antibodies directed against melanoma differentiation–associated gene 5, MDA5, have a distinct presentation due to vasculopathy with more severe cutaneous ulcerations, palmar papules, alopecia, and an elevated risk of rapidly progressive interstitial lung disease.2 A ferritin level greater than 1600 ng/mL portends an increased risk for pulmonary disease and therefore can be of prognostic value.3 Further, patients with anti-MDA5 DM are at a lower risk of malignancy and are more likely to test negative for antinuclear antibodies in comparison to other patients with DM.2,4

Hemophagocytic lymphohistiocytosis (HLH), also known as hemophagocytic syndrome, is a potentially lethal condition whereby uncontrolled activation of histiocytes in the reticuloendothelial system causes hemophagocytosis and a hyperinflammatory state. Patients present with fever, splenomegaly, cytopenia, and hyperferritinemia.5 Autoimmune‐associated hemophagocytic syndrome (AAHS) describes HLH that develops in association with autoimmune conditions, most commonly systemic lupus erythematosus and adult-onset Still disease. Cases reported in association with DM exist but are few in number, and there is no standard-of-care treatment.6 We report a case of a woman with anti-MDA5 DM complicated by HLH and DM-associated liver injury.



A 50-year-old woman presented as a direct admit from the rheumatology clinic for diffuse muscle weakness of 8 months’ duration, 40-pound unintentional weight loss, pruritic rash, bilateral joint pains, dry eyes, dry mouth, and altered mental status. Four months prior, she presented to an outside hospital and was given a diagnosis of probable Sjögren syndrome and autoimmune hepatitis vs drug-induced liver injury. At that time, a workup was notable for antibodies against Sjögren syndrome–related antigen A, anti–smooth muscle antibodies, and transaminitis. Ultrasonography of the right upper quadrant revealed hepatic steatosis. The patient was started on oral prednisone and pilocarpine but had been off all medications for 1 month when she presented to our hospital.

On hospital admission, physical examination revealed a violaceous heliotrope rash; a v-sign on the chest; shawl sign; palmar papules with pits at the fingertips; and periungual erythema and ulcerations along the metacarpophalangeal joints, elbows, lateral feet, and upper eyelids (Figure 1). Laboratory workup showed the following results: white blood cell count, 4100/μL (reference range, 4000–11,000/μL); hemoglobin, 11.6 g/dL (reference range, 12–16 g/dL); platelet count, 100,000/μL (reference range, 150,000–450,000/μL); lactate dehydrogenase, 510 U/L (reference range, 80–225 U/L); alkaline phosphatase (ALP), 766 U/L (reference range, 30–120 U/L); alanine aminotransferase (ALT), 88 U/L (reference range, 10–40 U/L); aspartate aminotransferase (AST), 544 U/L (reference range, 10–40 U/L); total bilirubin, 4.2 mg/dL (reference range, 0.3–1.0 mg/dL); direct bilirubin, 3.7 mg/dL (reference range, 0.1–0.3 mg/dL); aldolase, 20.2 U/L (reference range, 1–7.5 U/L), creatine kinase, 180 U/L (reference range, 30–135 U/L); γ-glutamyltransferase (GGT), 2743 U/L (reference range, 8–40 U/L); high sensitivity C-reactive protein, 122.9 mg/L (low-risk reference range, <1.0 mg/L); triglycerides, 534 mg/dL (reference range, <150 mg/dL); ferritin, 3784 ng/mL (reference range, 24–307 ng/mL); antinuclear antibody, negative titer; antimitochondrial antibody, negative titer; soluble IL-2 receptor (CD25), 7000 U/mL (reference range, 189–846 U/mL); anti-Sjögren syndrome–related antigen A antibody, positive.

FIGURE 1. A–C, At first hospital admission, physical examination revealed ulcerations along the metacarpophalangeal joints, painful palmar papules, and ulcerations on the buttocks, respectively.

Magnetic resonance imaging of the shoulders showed diffuse soft-tissue edema. Computed tomography (CT) of the chest demonstrated parabronchial thickening and parenchymal bands suggestive of DM. An age-appropriate malignancy workup was negative, and results from a liver biopsy showed diffuse steatosis with no histologic evidence of autoimmune hepatitis. Punch biopsy results from a plaque on the left knee revealed vacuolar interface dermatitis with increased dermal mucin on colloidal iron staining, indicative of connective tissue disease (Figure 2). The patient was treated with intravenous (IV) methylprednisolone 250 mg twice daily for 2 days followed by oral prednisone 50 mg daily with IV immunoglobulin (IVIG) 0.4 mg/kg daily for 5 days. The patient’s symptoms improved, and she was discharged on oral prednisone 50 mg and mycophenolate mofetil 1000 mg twice daily with a plan for outpatient IVIG.

FIGURE 2. A, Histopathology revealed vacuolar interface dermatitis (arrows)(H&E, original magnification ×40). B, Colloidal iron staining showed increased dermal mucin (arrows), consistent with connective tissue disease. Reference bars indicate 50 µm.


Two days after discharge, the patient was re-admitted for worsening muscle weakness; recalcitrant rash; new-onset hypophonia, dysphagia, and odynophagia; and intermittent fevers. Myositis panel results were positive for MDA5. Additionally, workup for HLH, which was initiated during the first hospital admission, revealed that she met 6 of 8 diagnostic criteria: intermittent fevers (maximum temperature, 38.2 °C), splenomegaly (12.6 cm on CT scan of abdomen), cytopenia in 2 cell lines (anemia, thrombocytopenia), hypertriglyceridemia, hyperferritinemia, and elevated IL-2 receptor (CD25). Based on these findings, the patient was diagnosed with anti-MDA5 DM associated with HLH.

The patient was started on IV methylprednisolone 1000 mg daily and received 1 rituximab infusion. Two days later, she experienced worsening fever with tachycardia, and a chest radiograph showed bibasilar infiltrates concerning for aspiration pneumonia, with sputum cultures growing Staphylococcus aureus. Due to the infection, the dosage of methylprednisolone was decreased to 16 mg 3 times daily and rituximab was stopped. The hematology department was consulted for the patient’s HLH, and due to her profound weakness and sepsis, the decision was made to hold initiation of etoposide, which, in addition to glucocorticoids, is considered first-line therapy for HLH. She subsequently experienced worsening hypoxia requiring intubation and received a second course of IVIG. Two days later, CT of the chest revealed progressive ground-glass opacities in the lower lobes of the lungs. The patient was then started on plasmapheresis every other day, hydroxychloroquine 200 mg daily, and IV methylprednisolone 1000 mg daily. Over the subsequent 6 days, she developed worsening renal failure, liver dysfunction, profound thrombocytopenia (13/μL), and acidemia. After extensive discussion with her family, the patient was transitioned to comfort care, and she died 33 days after the initial admission to our hospital.

Our case is a collection of several rare presentations: anti-MDA5 DM, with HLH and AAHS as complications of anti-MDA5 DM, and DM-associated liver injury. Anti-MDA5 DM is frequently refractory to conventional therapy, including high-dose glucocorticoids, cyclophosphamide, oral tacrolimus, and cyclosporine, and there currently is no single treatment algorithm.2 Lake and colleagues7 highlighted the importance of personalizing treatment of anti-MDA5 DM, as it can be one of the most aggressive rheumatologic diseases. We initially chose to treat our patient with high-dose methylprednisolone, IVIG, and rituximab. Kampylafka et al8 performed a retrospective analysis of the use of IVIG for DM as compared to standard therapy and demonstrated improved muscle and cutaneous involvement from a collection of 50 patients. Case reports have specifically revealed efficacy for the use of IVIG in patients with anti-MDA5 DM.9,10 Additionally, rituximab—an anti–B lymphocyte therapy—has been shown to be an effective supplemental therapy for cases of aggressive anti-MDA5 DM with associated interstitial lung disease, especially when conventional therapy has failed.11,12 Our patient’s sepsis secondary to S aureus pneumonia limited her to only receiving 1 dose of rituximab.

One promising treatment approach for anti-MDA5 DM recently published by Tsuji et al13 involves the use of combination therapy. In this prospective multicenter trial, patients were initially treated with a combination of high-dose glucocorticoids, oral tacrolimus, and IV cyclophosphamide. Plasmapheresis was then started for patients without symptomatic improvement. This method was compared to the more traditional step-up approach of high-dose steroids followed by another immunosuppressant. At 1-year follow-up, the combination therapy group demonstrated an 85% survival rate compared to 33% of historical controls.13

We suspect that our patient developed HLH and AAHS secondary to her underlying anti-MDA5 DM. Kumakura and Murakawa6 reported that among 116 cases of AAHS, 6.9% of cases were associated with DM, most commonly anti-Jo-1 DM. Hemophagocytic lymphohistiocytosis associated with anti-MDA5 DM has been described in only a few cases.14-16 The diagnosis of HLH is critical, as the treatments for HLH and DM differ. Both diseases manifest with hyperferritinemia—greater than 500 ng/mL in the case of HLH and 3784 ng/mL in our patient. Therefore, HLH can be easily overlooked. It is possible the rates of HLH associated with anti-MDA5 DM are higher than reported given their similar presentations.

Analogous to our case, Fujita et al15 reported a case of HLH associated with anti-MDA5 DM successfully treated with IV cyclophosphamide pulse therapy and plasmapheresis. The rationale for using plasmapheresis in anti-MDA5 DM is based on its success in patients with other antibody-mediated conditions such as Goodpasture syndrome and granulomatosis with polyangiitis.7 It is thought to expedite response to traditional treatment, and in the case described by Fujita et al,15 the patient received plasmapheresis 6 times total over the course of 9 days. The patient’s clinical symptoms, as well as platelet levels, liver enzymes, and ferritin value, improved.15 Our patient received 3 days of plasmapheresis with no improvement when the decision was made to discontinue plasmapheresis given her worsening clinical state.

Additionally, our patient had elevated hepatic enzymes (ALT, AST, ALP, GGT), and results of a liver biopsy demonstrated diffuse steatosis. We speculate her transaminitis was a complication of anti-MDA5 DM. Hepatocellular damage accompanying DM has been investigated in multiple studies and is most often defined as an elevated ALT.17-20 Improvement in ALT levels has been seen with DM treatment. However, investigators note that creatine kinase (CK) values often do not correlate with the resolution of the transaminitis, suggesting that CK denotes muscle damage whereas ALT represents separate liver damage.18-21

Nagashima et al22 highlighted that among 50 patients with DM without malignancy, only 20% presented with a transaminitis or elevated bilirubin. However, among those with liver injury, all were positive for antibodies against MDA5.22 The patients with anti-MDA5 DM liver dysfunction had higher ALT, ALP, and GGT levels compared to those without liver dysfunction. Similarly, in a retrospective review of 14 patients with anti-MDA5 DM, Gono and colleagues3 found elevated GGT levels and lower CK levels in comparison to patients with anti-aminoacyl-transfer RNA synthetase DM. Although liver enzymes can be elevated in patients with DM secondary to muscle damage, the authors argue that the specificity of GGT to the liver suggests intrinsic liver damage.3

The mechanism behind liver disease in anti-MDA5 DM is unclear, but it is hypothesized to be similar to nonalcoholic steatohepatitis.22 Other studies have revealed drug-induced hepatitis, hepatic congestion, nonspecific reactive hepatitis, metastatic liver tumor, primary biliary cholangitis, and autoimmune hepatitis as the etiology behind liver disease in their patients with DM.17-19 Liver biopsy results from patients with anti-MDA5 DM most commonly reveal hepatic steatosis, as seen in our patient, as well as hepatocyte ballooning and increased pigmented macrophages.22

We presented a case of anti-MDA5 DM complicated by HLH. Our patient had a fatal outcome despite aggressive treatment with high-dose methylprednisolone, IVIG, rituximab, and plasmapheresis. It is accepted that anti-MDA5 DM affects the lungs and skin, and our patient’s presentation also suggests liver involvement. In our case, onset of symptoms to fatality was approximately 1 year. It is essential to consider the diagnosis of HLH in all cases of anti-MDA5 DM given clinical disease overlap. Our patient could have benefited from earlier disease recognition and thus earlier aggressive therapy.

 

References

1. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344-347.

2. Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018;78:776-785.

3. Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49:1713-1719.

4. Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65:25-34.

5. Sepulveda FE, de Saint Basile G. Hemophagocytic syndrome: primary forms and predisposing conditions. Curr Opin Immunol. 2017;49:20-26.

6. Kumakura S, Murakawa Y. Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheum. 2014;66:2297-2307.

7. Lake M, George G, Summer R. Time to personalize the treatment of anti-MDA-5 associated lung disease. Ann Rheum Dis. 2019;78:E52.

8. Kampylafka EI, Kosmidis ML, Panagiotakos DB, et al. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study. Clin Exp Rheumatol. 2012;30:397-401.

9. Koguchi-Yoshioka H, Okiyama N, Iwamoto K, et al. Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules/papules. Br J Dermatol. 2017;177:1442-1446.

10. Hamada-Ode K, Taniguchi Y, Kimata T, et al. High-dose intravenous immunoglobulin therapy for rapidly progressive interstitial pneumonitis accompanied by anti-melanoma differentiation-associated gene 5 antibody-positive amyopathic dermatomyositis. Eur J Rheumatol. 2015;2:83-85.

11. So H, Wong VTL, Lao VWN, et al. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clin Rheumatol. 2018;37:1983-1989.

12. Koichi Y, Aya Y, Megumi U, et al. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol. 2017;27:536-540.

13. Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020;72:488-498.

14. Honda M, Moriyama M, Kondo M, et al. Three cases of autoimmune-associated haemophagocytic syndrome in dermatomyositis with anti-MDA5 autoantibody. Scand J Rheumatol. 2020;49:244-246.

15. Fujita Y, Fukui S, Suzuki T, et al. Anti-MDA5 antibody-positive dermatomyositis complicated by autoimmune-associated hemophagocytic syndrome that was successfully treated with immunosuppressive therapy and plasmapheresis. Intern Med. 2018;57:3473-3478.

16. Gono T, Miyake K, Kawaguchi Y, et al. Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM. Rheumatology (Oxford). 2012;51:1336-1338.

17. Wada T, Abe G, Kudou, T, et al. Liver damage in patients with polymyositis and dermatomyositis. Kitasato Med Journal. 2016;46:40-46.

18. Takahashi A, Abe K, Yokokawa J, et al. Clinical features of liver dysfunction in collagen diseases. Hepatol Res. 2010;40:1092-1097.

19. Matsumoto T, Kobayashi S, Shimizu H, et al. The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver. 2000;20:366-373.

20. Shi Q, Niu J, Huang X, et al. Do muscle enzyme changes forecast liver injury in polymyositis/dermatomyositis patients treated with methylprednisolone and methotrexate? Ann Clin Lab Sci. 2016;46:266-269.

21. Noda S, Asano Y, Tamaki Z, et al. A case of dermatomyositis with “liver disease associated with rheumatoid diseases” positive for anti-liver-kidney microsome-1 antibody. Clin Rheumatol. 2010;29:941-943.

22. Nagashima T, Kamata Y, Iwamoto M, et al. Liver dysfunction in anti-melanoma differentiation-associated gene 5 antibody-positive patients with dermatomyositis. Rheumatol Int. 2019;39:901-909.

References

1. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344-347.

2. Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018;78:776-785.

3. Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49:1713-1719.

4. Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65:25-34.

5. Sepulveda FE, de Saint Basile G. Hemophagocytic syndrome: primary forms and predisposing conditions. Curr Opin Immunol. 2017;49:20-26.

6. Kumakura S, Murakawa Y. Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheum. 2014;66:2297-2307.

7. Lake M, George G, Summer R. Time to personalize the treatment of anti-MDA-5 associated lung disease. Ann Rheum Dis. 2019;78:E52.

8. Kampylafka EI, Kosmidis ML, Panagiotakos DB, et al. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study. Clin Exp Rheumatol. 2012;30:397-401.

9. Koguchi-Yoshioka H, Okiyama N, Iwamoto K, et al. Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules/papules. Br J Dermatol. 2017;177:1442-1446.

10. Hamada-Ode K, Taniguchi Y, Kimata T, et al. High-dose intravenous immunoglobulin therapy for rapidly progressive interstitial pneumonitis accompanied by anti-melanoma differentiation-associated gene 5 antibody-positive amyopathic dermatomyositis. Eur J Rheumatol. 2015;2:83-85.

11. So H, Wong VTL, Lao VWN, et al. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clin Rheumatol. 2018;37:1983-1989.

12. Koichi Y, Aya Y, Megumi U, et al. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol. 2017;27:536-540.

13. Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020;72:488-498.

14. Honda M, Moriyama M, Kondo M, et al. Three cases of autoimmune-associated haemophagocytic syndrome in dermatomyositis with anti-MDA5 autoantibody. Scand J Rheumatol. 2020;49:244-246.

15. Fujita Y, Fukui S, Suzuki T, et al. Anti-MDA5 antibody-positive dermatomyositis complicated by autoimmune-associated hemophagocytic syndrome that was successfully treated with immunosuppressive therapy and plasmapheresis. Intern Med. 2018;57:3473-3478.

16. Gono T, Miyake K, Kawaguchi Y, et al. Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM. Rheumatology (Oxford). 2012;51:1336-1338.

17. Wada T, Abe G, Kudou, T, et al. Liver damage in patients with polymyositis and dermatomyositis. Kitasato Med Journal. 2016;46:40-46.

18. Takahashi A, Abe K, Yokokawa J, et al. Clinical features of liver dysfunction in collagen diseases. Hepatol Res. 2010;40:1092-1097.

19. Matsumoto T, Kobayashi S, Shimizu H, et al. The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver. 2000;20:366-373.

20. Shi Q, Niu J, Huang X, et al. Do muscle enzyme changes forecast liver injury in polymyositis/dermatomyositis patients treated with methylprednisolone and methotrexate? Ann Clin Lab Sci. 2016;46:266-269.

21. Noda S, Asano Y, Tamaki Z, et al. A case of dermatomyositis with “liver disease associated with rheumatoid diseases” positive for anti-liver-kidney microsome-1 antibody. Clin Rheumatol. 2010;29:941-943.

22. Nagashima T, Kamata Y, Iwamoto M, et al. Liver dysfunction in anti-melanoma differentiation-associated gene 5 antibody-positive patients with dermatomyositis. Rheumatol Int. 2019;39:901-909.

Issue
Cutis - 108(5)
Issue
Cutis - 108(5)
Page Number
E35-E38
Page Number
E35-E38
Publications
Publications
Topics
Article Type
Sections
Inside the Article

PRACTICE POINTS

  • Anti-MDA5 (melanoma differentiation–associated gene 5 antibody)–positive dermatomyositis associated with hemophagocytic lymphohistiocytosis is a rare and aggressive condition associated with a poor prognosis, and there is no standard treatment.
  • Dermatomyositis-associated liver injury is not well defined.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media